WO2017013210A1 - Treatment and prevention of viral diseases with 2,3-dihydrobenzofuran-5-yl compounds - Google Patents
Treatment and prevention of viral diseases with 2,3-dihydrobenzofuran-5-yl compounds Download PDFInfo
- Publication number
- WO2017013210A1 WO2017013210A1 PCT/EP2016/067417 EP2016067417W WO2017013210A1 WO 2017013210 A1 WO2017013210 A1 WO 2017013210A1 EP 2016067417 W EP2016067417 W EP 2016067417W WO 2017013210 A1 WO2017013210 A1 WO 2017013210A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- conh
- group
- methyl
- coo
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 30
- 230000002265 prevention Effects 0.000 title claims abstract description 23
- 201000010099 disease Diseases 0.000 title claims abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 19
- -1 2,3-dihydrobenzofuran-5-yl compounds Chemical class 0.000 title claims description 151
- 230000003612 virological effect Effects 0.000 title description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 164
- 150000003839 salts Chemical class 0.000 claims abstract description 78
- 125000006413 ring segment Chemical group 0.000 claims abstract description 64
- 239000012453 solvate Substances 0.000 claims abstract description 46
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 30
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 26
- 208000036142 Viral infection Diseases 0.000 claims abstract description 22
- 125000002950 monocyclic group Chemical group 0.000 claims abstract description 22
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 22
- 230000009385 viral infection Effects 0.000 claims abstract description 22
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 21
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 20
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical group C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 claims abstract description 17
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 94
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 58
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 57
- 125000000217 alkyl group Chemical group 0.000 claims description 56
- 229910052731 fluorine Inorganic materials 0.000 claims description 52
- 229910052736 halogen Inorganic materials 0.000 claims description 48
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 48
- 150000002367 halogens Chemical class 0.000 claims description 45
- 229910052801 chlorine Inorganic materials 0.000 claims description 44
- 125000003118 aryl group Chemical group 0.000 claims description 43
- 239000000460 chlorine Substances 0.000 claims description 42
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 42
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 41
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 41
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 40
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 39
- 239000011737 fluorine Substances 0.000 claims description 39
- 125000001072 heteroaryl group Chemical group 0.000 claims description 39
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 37
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims description 32
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 32
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 31
- 125000001424 substituent group Chemical group 0.000 claims description 31
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 29
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 27
- 125000001188 haloalkyl group Chemical group 0.000 claims description 26
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 26
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 25
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 23
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 22
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 21
- 125000003545 alkoxy group Chemical group 0.000 claims description 21
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 21
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 21
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 20
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 20
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 19
- 241000700605 Viruses Species 0.000 claims description 18
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims description 15
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 15
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 12
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 11
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 11
- 229910052794 bromium Inorganic materials 0.000 claims description 11
- 125000005843 halogen group Chemical group 0.000 claims description 11
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 11
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 10
- CPRRHERYRRXBRZ-SRVKXCTJSA-N methyl n-[(2s)-1-[[(2s)-1-hydroxy-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound COC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)C[C@@H]1CCNC1=O CPRRHERYRRXBRZ-SRVKXCTJSA-N 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 10
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 9
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims description 8
- 241000700584 Simplexvirus Species 0.000 claims description 8
- 125000002541 furyl group Chemical group 0.000 claims description 8
- 229910052740 iodine Inorganic materials 0.000 claims description 8
- 125000002757 morpholinyl group Chemical group 0.000 claims description 8
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 7
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 7
- 125000004434 sulfur atom Chemical group 0.000 claims description 7
- 150000003852 triazoles Chemical class 0.000 claims description 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 6
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 6
- 125000004515 1,2,4-thiadiazol-3-yl group Chemical group S1N=C(N=C1)* 0.000 claims description 5
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 5
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims description 5
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 4
- 229920001577 copolymer Chemical class 0.000 claims description 4
- 125000001207 fluorophenyl group Chemical group 0.000 claims description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 3
- 241000700586 Herpesviridae Species 0.000 claims description 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 241001387976 Pera Species 0.000 claims 1
- 241000534944 Thia Species 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 46
- 239000000203 mixture Substances 0.000 description 22
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 16
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 229960004150 aciclovir Drugs 0.000 description 14
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 14
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 13
- 150000002430 hydrocarbons Chemical group 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 125000001624 naphthyl group Chemical group 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 10
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 10
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 10
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 9
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 8
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 125000001544 thienyl group Chemical group 0.000 description 7
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- 125000003367 polycyclic group Chemical group 0.000 description 6
- 125000003226 pyrazolyl group Chemical group 0.000 description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- BGVLELSCIHASRV-QPEQYQDCSA-N (1z)-1-(3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene)propan-2-one Chemical compound C1=C(OC)C=C2N(CC)\C(=C\C(C)=O)SC2=C1 BGVLELSCIHASRV-QPEQYQDCSA-N 0.000 description 5
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 5
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 5
- 239000001828 Gelatine Substances 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 229940125898 compound 5 Drugs 0.000 description 5
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 125000004193 piperazinyl group Chemical group 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 5
- 125000000335 thiazolyl group Chemical group 0.000 description 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 125000002971 oxazolyl group Chemical group 0.000 description 4
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- 125000001425 triazolyl group Chemical group 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 125000004521 1,3,4-thiadiazol-2-yl group Chemical group S1C(=NN=C1)* 0.000 description 3
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 3
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 0 C*1=NC(C(N(*)C(CCCCCCC(*)(*)S)=N)=C)=C(*)*1 Chemical compound C*1=NC(C(N(*)C(CCCCCCC(*)(*)S)=N)=C)=C(*)*1 0.000 description 3
- 108010040648 Dyrk kinase Proteins 0.000 description 3
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 229960002963 ganciclovir Drugs 0.000 description 3
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 125000005059 halophenyl group Chemical group 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 230000007721 medicinal effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 125000005936 piperidyl group Chemical group 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 3
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 229960000329 ribavirin Drugs 0.000 description 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 2
- 125000004516 1,2,4-thiadiazol-5-yl group Chemical group S1N=CN=C1* 0.000 description 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 230000010530 Virus Neutralization Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 125000000597 dioxinyl group Chemical group 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229960001179 penciclovir Drugs 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000004258 purin-2-yl group Chemical group [H]N1C2=NC(*)=NC([H])=C2N([H])C1([H])[H] 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 2
- 229960001028 zanamivir Drugs 0.000 description 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 1
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 description 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 1
- 125000004507 1,2,5-oxadiazol-3-yl group Chemical group O1N=C(C=N1)* 0.000 description 1
- 125000004518 1,2,5-thiadiazol-3-yl group Chemical group S1N=C(C=N1)* 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 description 1
- 125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- BGVLELSCIHASRV-UHFFFAOYSA-N 1-(3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene)propan-2-one Chemical compound C1=C(OC)C=C2N(CC)C(=CC(C)=O)SC2=C1 BGVLELSCIHASRV-UHFFFAOYSA-N 0.000 description 1
- DSPHFASHOJAOKN-UHFFFAOYSA-N 1-[(7-oxobenzo[a]phenalen-2-yl)amino]anthracene-9,10-dione Chemical class C1=CC2=CC(NC3=C4C(=O)C5=CC=CC=C5C(C4=CC=C3)=O)=CC(C=3C(=CC=CC=3)C3=O)=C2C3=C1 DSPHFASHOJAOKN-UHFFFAOYSA-N 0.000 description 1
- 125000004134 1-norbornyl group Chemical group [H]C1([H])C([H])([H])C2(*)C([H])([H])C([H])([H])C1([H])C2([H])[H] 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical group N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 description 1
- FNZUBLMCAXMLQC-UHFFFAOYSA-N 2-(2,3-dihydro-1-benzofuran-5-yl)-n-(3-piperazin-1-ylpyridin-2-yl)-1,3-thiazole-4-carboxamide Chemical compound C=1SC(C=2C=C3CCOC3=CC=2)=NC=1C(=O)NC1=NC=CC=C1N1CCNCC1 FNZUBLMCAXMLQC-UHFFFAOYSA-N 0.000 description 1
- KUNNUNBSGQSGDY-UHFFFAOYSA-N 2-butyl-6-methylphenol Chemical compound CCCCC1=CC=CC(C)=C1O KUNNUNBSGQSGDY-UHFFFAOYSA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 1
- GUUULVAMQJLDSY-UHFFFAOYSA-N 4,5-dihydro-1,2-thiazole Chemical compound C1CC=NS1 GUUULVAMQJLDSY-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004136 7-norbornyl group Chemical group [H]C1([H])C([H])([H])C2([H])C([H])([H])C([H])([H])C1([H])C2([H])* 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 125000006519 CCH3 Chemical group 0.000 description 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 102100040862 Dual specificity protein kinase CLK1 Human genes 0.000 description 1
- 102100028554 Dual specificity tyrosine-phosphorylation-regulated kinase 1A Human genes 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001481828 Glyptocephalus cynoglossus Species 0.000 description 1
- 244000060234 Gmelina philippensis Species 0.000 description 1
- 241000288140 Gruiformes Species 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- 101000749294 Homo sapiens Dual specificity protein kinase CLK1 Proteins 0.000 description 1
- 101000838016 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1A Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000282910 Tayassuidae Species 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- WPVFJKSGQUFQAP-GKAPJAKFSA-N Valcyte Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 WPVFJKSGQUFQAP-GKAPJAKFSA-N 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000003670 adamantan-2-yl group Chemical group [H]C1([H])C(C2([H])[H])([H])C([H])([H])C3([H])C([*])([H])C1([H])C([H])([H])C2([H])C3([H])[H] 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960001997 adefovir Drugs 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000002832 anti-viral assay Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229950007936 apricitabine Drugs 0.000 description 1
- RYMCFYKJDVMSIR-RNFRBKRXSA-N apricitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1S[C@H](CO)OC1 RYMCFYKJDVMSIR-RNFRBKRXSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- AXLOCHLTNQDFFS-BESJYZOMSA-N azastene Chemical compound C([C@H]1[C@@H]2CC[C@@]([C@]2(CC[C@@H]1[C@@]1(C)C2)C)(O)C)C=C1C(C)(C)C1=C2C=NO1 AXLOCHLTNQDFFS-BESJYZOMSA-N 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 150000001556 benzimidazoles Chemical group 0.000 description 1
- 125000004190 benzothiazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)SC2=C1[H] 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical class OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Chemical class 0.000 description 1
- 229960001169 brivudine Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 229960000724 cidofovir Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- TXKMVPPZCYKFAC-UHFFFAOYSA-N disulfur monoxide Inorganic materials O=S=S TXKMVPPZCYKFAC-UHFFFAOYSA-N 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- 229960000366 emtricitabine Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229960000980 entecavir Drugs 0.000 description 1
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 238000005558 fluorometry Methods 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical class OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- ODZBBRURCPAEIQ-PIXDULNESA-N helpin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 ODZBBRURCPAEIQ-PIXDULNESA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 208000024697 human cytomegalovirus infection Diseases 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008011 inorganic excipient Substances 0.000 description 1
- 230000034184 interaction with host Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001793 isothiazol-3-yl group Chemical group [H]C1=C([H])C(*)=NS1 0.000 description 1
- 125000004500 isothiazol-4-yl group Chemical group S1N=CC(=C1)* 0.000 description 1
- 125000004501 isothiazol-5-yl group Chemical group S1N=CC=C1* 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 description 1
- 125000004498 isoxazol-4-yl group Chemical group O1N=CC(=C1)* 0.000 description 1
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 238000011328 necessary treatment Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000008012 organic excipient Substances 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- NENPYTRHICXVCS-YNEHKIRRSA-N oseltamivir acid Chemical compound CCC(CC)O[C@@H]1C=C(C(O)=O)C[C@H](N)[C@H]1NC(C)=O NENPYTRHICXVCS-YNEHKIRRSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001828 phenalenyl group Chemical group C1(C=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 238000002962 plaque-reduction assay Methods 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 125000004542 purin-6-yl group Chemical group N1=CN=C2N=CNC2=C1* 0.000 description 1
- 125000004544 purin-8-yl group Chemical group N1=CN=C2N=C(NC2=C1)* 0.000 description 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 125000004159 quinolin-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C([H])C(*)=NC2=C1[H] 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000002911 sialidase inhibitor Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical compound S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 description 1
- 229960004556 tenofovir Drugs 0.000 description 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 1
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 description 1
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- WHLUQAYNVOGZST-UHFFFAOYSA-N tifenamil Chemical compound C=1C=CC=CC=1C(C(=O)SCCN(CC)CC)C1=CC=CC=C1 WHLUQAYNVOGZST-UHFFFAOYSA-N 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 229960002149 valganciclovir Drugs 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Definitions
- Viral infections are usually treated with substances targeting viral proteins.
- influenza is treated with M2-membrane protein inhibitors (adamantin and rimantadin) or neuraminidase inhibitors (oseltamivir and zanamivir).
- HIV is treated with HIV protease inhibitors, reverse transcriptase inhibitors (nucleoside and non-nuc!eoside analoga), fusion inhibitors (blocking the viral transmembrane protein gp41 ) or cell entry inhibitors.
- HCV is usually treated by a combination of ribavirin and interferone alpha, where ribavirin as a nucleoside analogue inhibits the viral polymerase and interferone alpha activates the host immune system; also viral protease inhibitors and viral RNA polymerase inhibitors have been recently approved for treatment.
- HBV is treated with pegylated interferone alpha and/or nucleoside or nucleotide analoga.
- Herpes and human cytomegalovirus infections are treated with ganciclovir or structurally related substances like acyclovir and penciclovir, respectively, which also are analogs of the nuclein base guanine.
- targets constitutes the small molecule CLK inhibitor TG003 ((Z)-l -(3-Ethyl-5-methoxy-2,3- dihydrobenzothiazol-2-ylidene)propan-2-one).
- TG003 has been tested against influenza viruses i in vitro assays and its activity was attributed to its interference with the splicing of viral M2 messanger RNA (Karlas A et al. (2010) Nature 463, 818-822). In this way, the cellular machinery required for production of virus progeny is inhibited and thus can be exploited to suppress the replication of certain viruses.
- WO 2014/202638 Al describes certain compounds of the present Formula. (I) and that they interact with DYRK kinase, suggesting their applicability in prevention and/or therapy o medical conditions wherein the function o DYRK kinase plays a role.
- the present invention therefore provides methods for the treatment or prevention of medical conditions involving viral infections, the method comprising the administration of compounds of Formula (I), physiologically functional derivatives or salts thereof, to a subject in need thereof, as detailed further herein below.
- the present invention provides the use of compounds of Formula (I), physiologically functional derivatives or salts thereof, in the manufacture of a medicament for the treatment or prevention of medical conditions involving viral infections, as detailed further herein below.
- the present invention provides compounds of Formula (I), physiologically functional derivatives or salts thereof, for use in the treatment or prevention of medical conditions involving viral infections, as detailed further herein below.
- Said compounds are particularly advantageous for the treatment or prevention of diseases caused by viral infections, more particularly herpes viridae, even more particularly by one of the following viruses: Human Cytomegalo Virus (HCMV) and Herpes Simplex Virus (HSV).
- HCMV Human Cytomegalo Virus
- HSV Herpes Simplex Virus
- the present invention provides phannaceutical compositions comprising compounds of Formula (I), physiologically functional derivatives or salts thereof and one or more pharmaceutically acceptable excipients for the above medicinal purposes.
- Figure 1 shows the impact of DYRK. activity on HCMV replication.
- Compounds were analyzed by a GFP-based replication assay using HCMV AD169-GFP for the infection of HFFs (MOI of 0.01 , uninfected control, Mock).
- Antiviral compounds were added immediately post-infection at the concentrations indicated (reference drug ganciclovir - GCV, 20 ⁇ ).
- n is an integer from 0 to 2;
- n is an integer from 0 to 3;
- p is an integer from 0 to 4.
- R 1 is independently selected from the group comprising H, halogen, alkyl, aralkyl, haloalkyl, haloalkoxy, OH, alkoxy. -CN, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, -S-R-, -SO-R " , nitro, -NH 2 .
- R 2 is independently selected from the group comprising H, halogen, alkyl, aralkyl, haloalkyl, haloalkoxy, OH, alkoxy, -CN, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, -S-R ⁇ -SO-R-, nitro, -NH , -N(R') 2 , -NH(R'), -NHCO(R'), -CONH 2 , -CONH(R ) -CO(R'), -COH, -COO(R'), -COOH, -S0 2 NH 2 , -S0 2 NH(R " ). -S0 2 (R ' ). -NH-S0 2 (R') and -NHCOOR';
- R 3 is independently selected from the group comprising H. halogen, alkyl, aralkyl, haloalkyl haloalkoxy, OH, alkoxy, -CN, aryl, heteroaryl, cycloalkyl. heterocycloalkyl, -S-R ⁇ -SO-R', nitro. -N3 ⁇ 4, -N(R') 2 , -NH(R'), -NHCO(R'), -CONH 2 , -CONH(R'), -CO(R'), -COH, -COO(R'), -COOH, -S0 2 NH 2 , -S0 3 NH(R " ), -S0 2 (R ⁇ ). -NH-S0 2 (R " ) and -NHCOOR';
- R 4 is independently selected from the group comprising 11, alkyl, aralkyl, haloalkyl, haloalkoxy, OH, alkoxy, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, -CONH 2s -CONH(R'), -CO(R'), -COO(R'), and -S0 2 (R ⁇ ); 1 is independently selected from the group comprising NR", O or S;
- R n is independently selected from the group comprising H, alkyl, aralkyl, haloalkyl. haloalkoxy. OH, alkoxy, aryl, heteroaryl, cycloalkyl. heterocycloalkyl, -CONH 2 , -CONH(R'), -CO(R'), -COO(R'), and -S0 2 (R');
- A is a monocyclic or bi cyclic heteroaromatic ring system consisting of 5 to 10 ring atoms, at least one of which is an N atom, wherein optionally one to three further ring atoms are heteroatoms independently selected from the group comprising O, S and N and wherein the remaining ring atoms are carbon atoms;
- R A is independently selected from the group comprising H, halogen, CN, N0 2 , alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, -OR * . -CO-R * . -COO-R * . -CONH-R ' , -NHCO-R " , -CON(R') 2 , -NR'CO-R', -NR'-CONR * .
- R A is independently selected from the group comprising H, halogen.
- CN N0 2 , alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, -OR 5 , -CO-R', -COO-R " , -CONH-R', -NHCO-R', -CON(R ) 2 . -NR'CO-R', -NR'-CONR', -NR'-COOR', -S-R ⁇ -SO-R " . -S0 2 -R ⁇ -NHS0 2 -R " .
- R' is independently selected from the group comprising H. alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl;
- any of the aforementioned alkyl. aryl. heteroaryl, cycloalkyl and heterocycloalkyl may independently be substituted with one or more, particularly one to three, more particularly one or two substituents R", wherein R" independently selected from the group comprising Ci_4-alkyl halogen, Ci ⁇ -haloalkyl. OH, Ci -4 - alkoxy, C,. 4 -haloalkoxy, itro, -NH 2 , -N(C -alkyl) 2 , -NH(C
- R 1 is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, triiluoromethoxy, OH, methoxy, ethoxy, -CN, nitro, -NH 2 , -N(methyl) 2 , -NH-methyl, -NHCO-methyl.
- R 2 is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, triiluoromethoxy, OH, methoxy, ethoxy, -CN, nitro, -NH 2 , -N(methyl) 2 , -NH-methyl, -NHCO-methyl, -CO H 2 . -CONH-methyl, acetyl, -COO-methyl, and COOH.
- R 3 is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, -OCF 3 , OH, methoxy, ethoxy, -CN, nitro, -NH 2 , -N(methyi) 2 , -NH-methyl, -NHCO-methyl, -CONH 2 , -CONH-methyl, acetyl, -COO-methyl, and -COOH.
- R 4 is independently selected from the group comprising I I, Ci -3 -alkyl. Ci-4-haloalky], OIL -CONH 2 , -CONH-C ,. 3 -alkyi, -CO-C ⁇ -alkyl, and -COO-C 1-3 -alkyl.
- A is a monocyclic heteroaromatic ring system consisting o 5 or 6 ring atoms, or a bicyclic heteroaromatic ring system consisting of 9 ring atoms, wherein at least one of the ring atoms is an N atom, wherein optionally one or two further ring atoms are N atoms and wherein the remaining ring atoms are carbon atoms,
- A is a monocyclic heteroaromatic ring system consisting of 5 or 6 ring atoms, or a bicyclic heteroaromatic ring system consisting of 9 ring atoms, wherein at least one of the ring atoms is an N atom, wherein optionally one or two further ring atoms are N atoms,
- R A selected from the group comprising H, CN, NC1 ⁇ 2, halogen Oi l, alkoxy, haloalkyL alkyl, haloalkoxy, -COOH, -COO-alkyl, aralkyl, aryi, -CO-N(alkyl) 2 , -CONH-(alkyl), -CONH-alkyl- alkoxy, -CONH-cycloalkyl, -C NH-alk yl -heterocycl oalk yl , -CO-heterocycloalkyl- alkyl-heterocycloalkyl, -CO-heterocycloalkyl,
- -aryl-halogen -CO-N(alkyl) 2 , -CONH-(aikyl), -CONH-alkyl- alkoxy, -CONH-cycloalkyl, -CONH-alkyl-heteroeycloalkyl, -CO-heterocycloalkyl- alkyl-heteroeycloalkyl, -CO-heterocycloalkyl, -CO-heteroaryl, -CO-aryl, -CO- alkyl, -S0 2 -alkyl, -S-alkyl, -S-alkyl-COO-alkyl. and -S-aralkyl.
- A is a monocyclic or bicyclic heteroaromatic ring system selected from the group comprising thiazole, oxazole, pyrazole, pyrrole, benzoxazole, benzothiazole, benzimidazole, imidazole, triazole, pyrazine, triazine, pyiimidine and pyridine, or in an alternative embodiment of item 9,
- A is a monocyclic or bicyclic heteroaromatic ring system selected from the group comprising thiazole. oxazole, pyrazole, pyrrole, benzoxazole, benzothiazole, benzimidazole, imidazole, triazole.
- R A selected from the group comprising H, CN, F, CI, OH, C
- A is optionally substituted with a substituent R A selected from the group comprising H, CN, F, CI, Br, OH. Cj 2 -alkyl, C, . 2 -alkoxy. CF 3 , OCF 3 , -COOH, -COO-(Ci.
- A when A is benzoxazole, benzothiazole or benzimidazole, A may optionally further be substituted with a halogen atom, or in an alternative embodiment of item 9, when A is benzoxazole, benzothiazole or benzimidazole, A may optionally further be substituted with a halogen atom, and wherein, when A is thi azoic, A may optionally further be substituted with a methyl group.
- 1 is 0 or 1 ;
- n 0 or 1 ;
- X 1 is independently selected from the group comprising NR n , O or S;
- R" is independently selected from the group comprising I I, methyl, ethyl, OH, - CONH 2 , -CO H-methyl, and -COO-methyl;
- R' is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, tri iluoromethyl, trifluoromethoxy, OH, methoxy, cthoxy, -CN, nitro, -NH 2 , -N(methyl) 2 , -NH-methyl, -NHCO-methyl, -CONH 2 , -CONH-methyl, acetyl, -COO-methyl, and COOH;
- R 2 is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, triiluoromethyl. trifluoromethoxy, OH, methoxy, ethoxy, -CN. nitro, -NH2, -N(methyl) 2 , -NH-methyl, -NHC O-methyl, -CONH 2 .
- R 3 is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, OH, methoxy, ethoxy, -CN, nitro, -NH 2 , -N(methyl) 2 . -NH-methyl, -NHCO-methyl, -CONH 2 . -CONH-methyl, acetyl, -COO-methyl, and -COOH;
- R 4 is independently selected from the group comprising H, Ci-3-alkyl, Ci . 4 -haloalkyl, OH, -CONH 2 , -CO H-C i .3-alkyl, -CO-Ci -3 -alkyl, and -COO-d . 3 -alkyl;
- A is independently selected from the group comprising thiazole, oxazole, pyrazol c. pyrrole, benzoxazole, benzothiazole, benzimidazole. imidazole, triazole, pyrazine, triazine, pyrimidine and pyridine; or in an alternative embodiment of item 1 1 , A is independently selected from the group comprising thiazole, oxazole, pyrazol e. pyrrole, benzoxazole, benzothiazole, benzimidazole, imidazole, triazole, pyrazine.
- A is optionally substituted with a substituent R A selected from the group comprising H, CN, F, CI, Oi l, C
- R A selected from the group comprising H, CN, F, CI, Oi l, C
- A is optionally substituted with a substituent R A selected from the group comprising H, CN, F, CI, Br, OH, C
- A when A is benzoxazole, benzothiazole or benzimidazole, A may optionally further be substituted with a halogen atom, or in an alternative embodiment of item 1 1 , when A is benzoxazole, benzothiazole or benzimidazole, A may optionally further be substituted with a halogen atom, and wherein, when A is thiazole, A may optionally further be substituted with a methyl group.
- A is a monocyclic or bicyclic hetcroaromatic ring system selected from the group comprising lH-irnidazol-2-yl, 1 //- 1 ,2,4-triazol-5-yl, 1 H-benzo [c ] i midazol -2-yl and pyridin-2-yl; or in an alternative embodiment of item 12.
- A is a monocyclic or bicyclic hetcroaromatic ring system selected from the group comprising l//-imidazol-2-yl, 1 //- 1.2,4-triazol-5-yl, l/J-benzo[ «i]imidazol-2-yi, pyridin-2-yl, 1 ,3,4-thiadiazol-2-yl, 1 H- pyrazol-3-yl, l ,3-thiazol-2-yl, and 1 ,2,4-thiadiazol-3-yl; wherein A is optionally substituted with a substituent R A selected from the group comprising F, CL CN, -S0 2 -Me, O e.
- A is optionally substituted with a substituent R A selected from the group comprising F, CI, Br. CN, methyl, -S0 2 -Me, OMe.
- 2-yl, A may optionally further be substituted with a methyl group.
- n is an integer from 0 to 1. More particularly n is 0.
- m is an integer from 0 to 2, more particularly 0 to 1 , even more particularly 0.
- p is an integer from 0 to 3, more particularly 0 to 2, even more particularly 0 to 1 , yet even more particularly 1 ,
- R 1 is independently selected from the group comprising H, halogen, Ci-4-aIkyl, benzyl, C ⁇ 4 -haloalkyl, Ci-4-haloalkoxy, OH, C 1 .4-alko.xy, -CN, phenyl, naphthyl, pyridyl, pyrrolyl, furanyl, tliienyl, thiazolyl, oxazolyl, pyrazolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohcxyl, cycloheptyl. decalinyl, tetrahydrofuryl, tetrahydropyranyl. tetrahydrothienyl, piperidyl, piperazinyl, morpholinyl, pyrrolidinyl,
- R l is independently selected from the group comprising H, halogen, C ⁇ -alky!, benzyl, Ci -4 -haloalkyl, C i -4-haloalkoxy, OH, Ci-4-alkoxy, -CN, phenyl, cyclopropyl, cyclobutyl. cyclopentyl, cyclohexyl, -S-C i. 4 alkyl, -SO-C i-4 alkyl.
- R 1 is independently selected from the group comprising H, halogen, C
- R 1 is independently selected from the group comprising H, halogen, Ci -4 -alkyl, Ci -4 -haloalkyl, d-4-haloalkoxy, OH, C
- R 1 is independently selected from the group comprising 11, fluorine, chlorine, bromine, trifluoromethyl, difluoromethyl, trifluoromethoxy, OH, Ci. 3 -alkoxy. -CN, nitro, -NH 2 , -N(C, . 2 alkyl) 2 . -NH-C,. 2 alkyl, -NHCO-Ci 2 alkyl, -CONH 2 , -CONH-Ci 2 alkyl, -CO-C,_ 2 alkyl, -COO-C 1 2 alkyl and -COOH.
- P is independently selected from the group comprising 11, fluorine, chlorine, bromine, trifluoromethyl, difluoromethyl, trifluoromethoxy, OH, Ci. 3 -alkoxy. -CN, nitro, -NH 2 , -N(C, . 2 alkyl) 2 . -NH-C,. 2 alkyl, -NHCO-Ci 2 al
- 1 is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, OH, methoxy, ethoxy, -CN. nitro, -NH 2 . -N(methyl) 2 , -NH-methyl, -NHCO-methyl, -CONH 2 . -CONH-methyl, acetyl, -COO-methyl, and -COOH.
- R ! is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, OH, and methoxy.
- R 1 is independently selected from the group comprising H, fluorine, chlorine, metliyl, trifluoromethyl. trifluoromethoxy, OH, and methoxy.
- R l is independently H.
- R 2 is independently selected from the group comprising H, halogen, Ci-4-alkyl, benzyl, Q-4-haloalkyl, Ci -4 -haloalkoxy, OH, Ci -4 -alkoxy, -CN. phenyl, naphthyl, pyridyl, pyrrol yl. furanyl, thienyl, thiazolyl, oxa/olyl. pyrazolyl, cyclopropyl, cyclobutyl.
- cyclopentyl cyclohexyl, cycl heptyl, decalinyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothienyl, piperidyl, piperazinyL morpholinyl, pyrrolidinyl, -SO-C,. 4 alkyl, nitro, -NH 2 . -N(Ci. 4 alkyl) 2 , -NH-C 1-4 alkyl, -NHCO-Ci. 4 alkyl, -CONH2, -CONH-C
- R 2 is independently selected from the group comprising H, halogen, C 1-4 -alkyl, benzyl, C ! -4 -haloalkyl, Cj. 4 -haloalkoxy, OH, C )-4 -alkoxy, -CN, phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -S-Ci_ 4 alkyl, -SO-Ci.
- alkyl nitro, -NH 2 , -N(C 1-4 alkyl) 2 , -NH-C, -4 alkyl, -NHCO-C ⁇ alkyl, -CONH 2 , -CONIi-C alkyl, -CO-Ci -4 alkyl, -COO-C
- R 2 is independently selected from the group comprising H, halogen, d . -alkyl, C ] -4 -haloalkyl, Ci . 4 -haloalkoxy, OI L C
- R 2 is independently selected from the group comprising H, halogen, Ci -4 -alkyl, C
- R 2 is independently selected from the group comprising H, fluorine, chlorine, bromine, Chalky!, trifluoromethyl, dilluoromethyl, trifluoromethoxy, OH, C 1-3 -alkoxy, -CN, nitro, -NH 2 , -N(C ] -2 alkyl) 2 , -NH-C, -2 alkyl. -NHCO-C
- R 2 is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, Oi l. methoxy, ethoxy, -CN, nitro, -NH 2 , -N(methyl) 2 , -NH-methyl. -NHCO-methyl, -CONH 2 , -CONH-methyl, acetyl, -COO-methyl, and -COOH.
- R 2 is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, OH, and methoxy. In yet even more particular embodiments, R 2 is independently selected from the group comprising H, fluorine, chlorine, methyl, trifluoromcthyl, tri fl uorom ethox y, OH, and methoxy.
- R is independently 11.
- R 3 is independently selected from the group comprising H, halogen, Ci-4-alkyl, benzyl, C i -4 -haloalkyl, Ci_4-haloalkoxy, OH, C i - -alkoxy, -CN, phenyl, naphthyl, pyridyl, pyrro!yl, furanyl, thienyl, thiazolyl, oxazolyl, pyrazolyl, cyclopropyl, cyclobutyl, eyclopentyl, cyclohexyl, cycloheptyl.
- dccalinyl tetrahydrofuryl, tetrahydropyranyl, tetrahydro thienyl, piperidyi, piperazinyl, morpholinyl, pyrrolidinyl, ⁇ S-C,_ 4 alkyL -SO-C alkyl, nitro, -NH 2 . -N(C 1-4 alkyl) 2 , -NH-C 1-4 alkyl, -NHCO-C ! -4 alkyl. -CONH 2 . -CONH-C 1 -4 a!ky!, -CO-C;. 4 alkyL -COH, -COO-C ! -4 a!kyl.
- R 3 is independently selected from the group comprising H, halogen, C ] -4 -alkyl 5 benzyl, d-4-haloalkyl, Ci -4 -haloalkoxy, OH, Q -4 -alkoxy, -CN, phenyl, cyclopropyl, cyclobutyl, eyclopentyl, cyclohexyl. -S-Cj . 4 alkyl, -SO-C 1 -4 alkyl, nitro.
- R 3 is independently selected from the group comprising H, halogen, Ci -4 -alkyl, 4 -haloalkoxy, OH. C
- R 3 is independently selected from the group comprising H, halogen, C ]. -alkyl, C]. 4 -haloalkyl, Ci -4 -haloalkoxy, OH, C
- R 3 is independently selected from the group comprising H, fluorine, chlorine, bromine, Ci.?alkyl. trifluoromethyl, difluoromethyl. trifluoromethoxy, OH. Ci. ? -alkoxy, -CN. nitro, -NH 2 , -N(C
- R 3 Is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl. trifluoromethyl. trifluoromethoxy, OH, methoxy, etlioxy, -CN, nitro. -NH 2 , -N ( methyl):. -NH-methyl. -NHCO-methyl, -CONH 2 , -CONH-methyl, acetyl, -COO-methyl, and -COOH.
- R 3 is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, OH, and methoxy.
- P. 3 is independently selected from the group comprising H, fluorine, chlorine, methyl, trifluoromethyl, trifluoromethoxy, OH, and methoxy.
- R 3 is independently H.
- R 4 is independently selected from the group comprising H, Ci-4-alkyl, benzyl, OH, C
- R 4 is independently selected from the group comprising H, C
- R 4 is independently selected from the group comprising H, Ci -3 -alkyl, C 1 -4 -haloalkyl, OH, -CONH 2 , -CONH-C i -3 -alkyl, -C -C
- R 4 is independently selected from the group comprising H, methyl, ethyl, OH. -CONH 2 , -CONH-mcthyl, and -COO-methyl.
- R 4 is independently selected from the group comprising H, and methyl. Most particularly, R 4 is independently H.
- X 1 is O or S. In more specific embodiments, X 1 is S,
- R" is independently selected from the group comprising H, Ci-4-alkyl, benzyl, Q-4-haloalkyl, Ci -4 -haloalkoxy, OH, Cj -4 -alkoxy, phenyl, naphthyl, pyridyl, pyrrolyl, furanyl, thienyl, thlazolyl, oxazolyl, pyrazolyl, cyclopropyl, cyclobutyl, cyc!opcntyl, cyclohexyl, cyc!ohcptyl, decalinyl, tetrahydrofuryl, tetrahydropyrany!
- R n is independently selected from the group comprising H, C] _4-alkyl, benzyl, C 1-4 -haloalkyl, C )-4 -haloalkoxy, OH, C 1-4 -alkoxy, phenyl, -CONH 2 , -CONH-C -alkyl, -CO-C -alkyl, -COO-C,. 4 -alkyl, and -S0 2 -C l -4 -alkyl.
- R n is independently selected from the group comprising H, Ci. 3 -alkyl, C -haloalkyl, OH, -CON3 ⁇ 4, -CONH-C
- R" is independently selected from the group comprising II, methyl, ethyl, OH, -CONH 2 , -CO H-methyl, and -COO-methyl.
- R" is independently selected from the group comprising 11, and methyl. Most particularly, R" is independently H.
- A is a monocyclic or bicyclic heteroaromatic ring system consisting of 5 to 9 ring atoms, at least one of which is an N atom, wherein optionally one or two further ring atoms are heteroatoms independently selected from the group comprising O, S and N, particularly , and wherein the remaining ring atoms are carbon atoms.
- A is a monocyclic heteroaromatic ring system consisting of
- ring atoms 5 or 6 ring atoms, or a bicyclic heteroaromatic ring system consisting of 9 ring atoms, wherein at least one of the ring atoms is an N atom, wherein optionally one or two further ring atoms arc heteroatoms independently selected from the group comprising O, S and N and wherein the remaining ring atoms are carbon atoms.
- A is a 5-membered monocyclic heteroaromatic ring which is optionally fused to a phenyl ring, wherein at least one of the ring atoms is an N atom, wherein optionally one or two further ring atoms are N atoms and wherein the remaining ring atoms are carbon atoms.
- A is a 5-membered monocyclic heteroaromatic ring which is optionally fused to a phenyl ring, wherein at least one of the ring atoms is an N atom, wherein optionally one further ring atom is an N atom and/or one further ring atom is an O or
- A is a monocyclic heteroaromatic ring system consisting of 5 or 6 ring atoms, or a bi cyclic heteroaromatic ring system consisting f 9 ring atoms, wherein at least one of the ring atoms is an N atom, wherein optionally one or two further ring atoms are N atoms and wherein the remaining ring atoms are carbon atoms.
- A is a monocyclic heteroaromatic ring system consisting of 5 or 6 ring atoms, or a bicyclic heteroaromatic ring system consisting of 9 ring atoms, wherein at least one of the ring atoms is an N atom, wherein optionally one or two further ring atoms are N ato s,
- one further ring atom is an O or S atom
- one further ring atom is an N atom and one ring atom is an O or S atom,
- A is independently selected from the group comprising thiazole, oxazole, pyrazole, pyrrole, benzoxazole, benzothiazole, benzimidazole, imidazole, triazole, pyrazine. triazinc, pyrimidinc and pyridine, even more particularly thiazol-2-yl, oxazol-2-yl, pyrazol-2-yl, pyrrol-2-yl, bcnzoxazol-2-yl, benzothiazol-2-yl, benzimidazol-2-yl. imidazol-2-yl, triazol-5-yl. pyrazin-2-yl. triazin-2-yl, pyrimidin-2-yl and pyridin-2-yl.
- A is independently selected from the group comprising thiazole, oxazole. pyrazole, pyrrole, benzoxazole, benzothiazole, benzimidazole, imidazole, triazole, pyrazine. triazinc, pyrimidine, thiadiazole, oxadiazole, and pyridine, even more particularly thiazoi-2-yl, oxazol-2-yl, pyrazol-2-yl.
- pyrrol-2-yl benzoxazol-2-yl, ben/.othi a/.ol -2-yl , ben/.imidazol-2-yl, imidazol-2-yl, triazol-5-yl.
- pyrazin-2-yl triazin-2-y
- pyrimidin-2-yl thiadiazol-2-yl, thiadiazol-3-yl, thiadiazol-5-yl, oxadiazol-2-yi, oxadiazol-3- yl, oxadiazol-5-yl, and pyridin-2-yL
- A is independently selected from the group comprising imidazolyl, triazolyl, benzoimidazol and pyridinyl, In other yet even more particular embodiments, A is independently selected from the group comprising imidazolyl, triazolyl, bcnzoimidazolyl. benzothiazolyl, thiadiazolyl, pyrazolyl, thiazolyl, oxazolyh oxadiazolyl and pyridinyl.
- A is independently selected from the group comprising l//-imidazol-2-yL 1 //- 1 ,2,4-triazol-5-yI, l / -benzofi ]imidazol-2-yl and pyridin-2- yi
- A is independently selected from the group comprising lH-imidazol-2-yl, 1 //- 1 ,2,4-triazol-5-yl.
- A is independently selected from the group comprising benzimidazol-2-yl and imidazol-2-yl.
- A is independently selected from the group comprising benzimidazol-2-yl, imidazol-2-y], 1 ,3,4-thiadiazol-2-y!, lH-pyrazol-3-yl, 1 ,3- thiazol-2-yl, and 1 ,2,4-thiadiazol-3-yl. Most particularly, A is independently benzimidazol-2-yl.
- A is independently independently selected from the group comprising benzimidazol-2-yl, 1 ,3.4-thiadiazol-2-yl, lH-pyrazol-3-yl, and 1 ,3-thiazol-
- A may be substituted, where appropriate and chemically feasible, with 0 to 4, particularly, 0 to 2, more particularly 0 to 2, even more particularly 1 or 2 substituents R A , wherein R A is independently selected as detailed in the embodiments as described herein.
- the thiazole, oxazole, pyrazole, pyrrole, or imidazole group A is particularly optionally substituted with one R A substituent in position 4, the triazole group A is optionally substituted with R A in position 3, the pyrazine.
- triazine, pyri idine or pyridine group A is optionally substituted with R A in position 5, and the benzoxazole, benzothiazole, or benzimidazole group A is optionally substituted with R A in position 5 and/or 6, even more particularly optionally substituted with R A in position 5 and further optionally substituted in position 6 with a group selected from the group comprising halogen, methyl, ethyl, CF 3 , CN, N0 2 , COOH, OH, NH 2 , NMe 2 , and COOMe, more particularly selected from the group comprising halogen, methyl, CF 3 , CN, and OH, even more particularly selected from the group comprising fluorine, chlorine, bromine, CF 3 , CN and OH, yet even more particularly selected from the group comprising fluorine and chlorine, most particularly chlorine.
- the thiazole, oxazole, pyrazole, pyrrole, or imidazole group A is particularly optionally substituted with one R A substituent in position 4 or 5
- the triazole group A is optionally substituted with R A in position 3
- the pyrazine, triazine, pyrimidine or pyridine group A is optionally substituted with R A in position 5
- the benzoxazole, benzothiazole, or benzimidazole group A is optionally substituted with R A in position 5 and/or 6, or alternatively in position 1 , and further optionally substituted in position 5 or 6 (whichever one is available) with a group selected from the group comprising halogen, methyl, ethyl, CF 3 , CN, N0 2 , COOH, OH, NH 2 , NMe 2 , and COOMe, more particularly selected from the group comprising halogen, methyl, CF 3 , CN, and OH, even more particularly selected from
- A is a group of formula (la) (la), wherein
- X 2 is a group selected from the group comprising N and ethenylene, which may optionally be substituted by one or two R A :
- X 3 is an atom selected from the group comprising C and N which may optionally be substituted by R A ;
- R 5 is a substituent group selected from the groups as defined herein for R A , or R 5 , together with X 3 forms a monocyclic 5- or 6 membered aryl or heteroaryl ring, particularly a benzene ring, which may optionally be substituted by one or more R ' ⁇
- A is an aromatic group of formula (la)
- X 2 is selected from the group comprising N, S, O, NH, CI I, CR A and ethenylene optionally substituted by one or two R " ⁇ particularly selected from the group comprising N, S, O, NH, CH and CR A ;
- X 3 is selected from the group comprising N, S, NH, CH and CR A ;
- X 6 is selected from the group comprising N, S, O, NH, CH and CR 5 , wherein R 5 is a substituent group selected from the groups as defined herein for R , or R , together with X ' ' forms a monocyclic 5- or 6 membered aryl or heteroaryl ring, particularly a benzene ring, which may optionally be substituted by one or more R A , particularly in positon 5 or 6 of a resulting benzazole derivative, wherein particularly said group A comprises not more than one atom selected from O and S and not more than three heteroatoms in total. other more
- X 4 is selected from the group comprising CH and NH; X 4 is selected from the group comprising CH and a single bond; X 3 is an atom selected from the group comprising C and N which may optionally be substituted by R A ; R 5 is a substitucnt group selected from the groups as defined herein for R ' ⁇ or R ⁇ together with X 3 forms a monocyclic 5- or 6 membered aryl or heteroaryl ring, particularly a benzene ring, which may optionally be substituted by more R A .
- A is an aromatic group of formula (la)
- X 4 is selected from the group comprising N, S, O. NH. CH and CR A ;
- X 5 is selected from the group comprising CH and a single bond, particularly a single bond:
- X 3 is selected from the group comprising N. S, NH, CH and CR A ;
- X 6 is selected from the group comprising N, S, O,
- R 5 is a substituent group selected from the groups as defined herein for R ' ⁇ or R
- X 3 forms a monocyclic 5- or 6 membered aryl or heteroaryl ring, particularly a benzene ring, which may optionally be substituted by one or more R A , particularly in positon 5 or 6 of a resulting benzazole derivative, wherein particularly said group A comprises not more than one atom selected from O and S and not more than three heteroatoms in total.
- R 5 together with X 3 forms a monocyclic 5- or 6 membered aryl or heteroaryl ring, particularly a benzene ring, which may optionally be substituted by one or more R A , particularly in positon 5 or 6 of a resulting benzazole derivative
- said positon 5 or 6 of a resulting benzazole derivative is as shown in the below structure:
- R A is independently selected from the group comprising H, CN, NO:, halogen OH, alkoxy, haloalkyl. alky], haloalkoxy, -COOH, -COO-alkyl, aralkyl, aryl, -CO-N(alkyl) 2 , -CONH-(alkyl), -CONH-alkyl-alkoxy.
- R A is independently selected from the group comprising H, CN, N0 2 , halogen OH, alkoxy, haloalkyl. alkyl, haloalkoxy. -COOH, -COO-alkyl. aralkyl. aryl, -CO-N(alkyl) 2 , -CON H -(alkyl), -CONH-alkyl-alkoxy, -CONH-cycloalkyl. -CO H-alkyl- heterocycloalkyl, -NHCO-(alkyl), - NHCO-alkyl-alkoxy, - NHCO-cycloalkyl.
- R A is independently selected from the group comprising H, CN, N0 2 , halogen OH, alkoxy, haloalkyl. alkyl, haloalkoxy, -COOH. -COO-alkyl. aralkyl.
- aryl -CO- N(alkyl) 2 , -CONH-(alkyl), -CONH-alkyl-alkoxy, -CONH-cycloalkyl, -CONH-alky!- heterocycloalkyl, -CQ-heterocycloalkyl-alkyl-heteroeycloalkyl, -CO-heterocycloalkyl, -S0 2 -alkyl, -S-alkyl, and -S-aralkyl.
- R A is independently selected from the group comprising H. CN, N0 2 , halogen, OH, alkoxy, haloalkyl, alkyl, haloalkoxy. -COOH. -COO-alkyl, aralkyl, aryl. -CO-N(alkyl) 2 , -CONH-(alkyl), -CONH-alkyl-alkoxy, -CONH-cycloalkyl. -CONII- a lk yl -hct erocycl o al kyl . -CO-hctcrocycloalkyl-alkyl-heterocycloalkyl, -CO-heterocycloalkyl.
- R A is independently selected from the group comprising H, CN. N0 2 . halogen OH, alkoxy, haloalkyl, alkyl, haloalkoxy, -COOH. -COO-alkyl. aralkyl, aryl -CO-N(alkyl) 2 , -CONH-(alkyl).
- R A is independently selected from the group comprising H, CN, halogen, OH, Ci -4 -alkoxy, Ci ⁇ -alkyl, Ci -4 -haloalkyl, Ci_ 4 -haloalkoxy, - COOH, -COO-(Ci. 4 -aikyl), ben/yl, phenethyl. phenyl. -CO-N(C, -3 -alkyl) 2 .
- R A is independently selected from the group comprising H, CN, halogen OH, C ; _4-alkoxy, Ci-4-alkyl, Ci. 4 -haloalkyl, C ; favor -haloaIkoxy, - COOH, -COO-(C M -alkyl), benzyl, phenethyl, phenyl, -CO- (C 1 . 3 -alkyl) 2 , -CO H-(C ! - alkyl), -CONH-(C,. 3 -alkyl)-0(C,. 3 -alkyl), -CONH-(C 3 .
- R A is independently selected from the group comprising H, CN, F, CI, OH, C 1-2 -alkoxy, CF 3 , OCF 3 , -COOH, -COO-(Ci- 2 -alkyl), benzyl, phenethyl, phenyl, -CO-N(C i 2 -alkyl) 2 , -CONH-(C 1 -2 -alkyl), -CONH-(Ci -2 -alkyl)-0(Ci -2 - alkyl), -CONH-(C 3 - 5 -cycloalkyl), -CONH-(C,.
- R A is independently selected from the group comprising H, CN, F, CI, OH, C, 2 -alkoxy, CF 3 , OCF 3 , -COOH, -COO-(C ,.
- R n is independently selected from the group comprising I I, CN, F, CI, -S0 2 Me, -OMe, CF 3 , -CO-NMe 2 , -CO-piperazine- 1 ,4-yl-CH 2 - tetrahydrofurane-2-yl, -COO-Et, -CO-morholinc- l -yl, 3-iiietlioxyphenyl, OCF 3 , -COOMe, OH, -CONH-Me, -SMe, -CO-pwolidine-l -yl, -CONH-CH : -CH 2 -OMe, -S-iPr, -CONH- cyclopropyl, -CO-(4-methyl-piperazine- 1 -yi )-, -S-nPr, -COOH, -S-benzyl, -S-(
- R A is independently selected from the group comprising H, CN, F, CI, -S0 2 Me, -OMe, CF 3 , -CO-NMe 2 , -CO-piperazine- 1 ,4-yl-CH 2 - tetrahydrofurane-2-yl, -COO-Et, -CO-morholine- l -yl. 3-methoxyphcnyl, OCF 3 , -COOMe, OH. -CONH-Me.
- -SMe -CO-pyrroiidine- l -yl, -CQNH-CH 2 -CH 2 -OMe, -S-iPr, -CONH- cyclopropyl, -CO-(4-methyl-piperazine- 1 -yl)-, -S-nPr, -COOH, -S-benzyl, -S-(4- chlorophenylmethyl), -S-iBu, -CONH-CH 2 -tetrahydrofarane-2-yl, phenethyl, and -S-phenethyl.
- R A is independently selected from the group comprising H, - S0 2 (C M -alkyl), -CO-N(C -alkyl) ? , -CO-NH(C i -4 -alkyl), -CO-NH 2 , -CO-fC 5 6 - heterocycloalkyl)-Ci -4 -alkyl-(C 5 . 6 -heterocycloalkyl), -COO-(C i -4 -alkyl). -CO-(C 5 . 6 - hetcrocycloalkyl).
- R A is independently selected from the group comprising H, - S0 2 (Ci . 4 -alkyl). -CO-N(C , 4 -alkyl) 2 , -CO-NH(C 1-4 -alkyl), -CO-NH 2 , -CO-(C 5-6 - heterocycloalkyl)-C] - -alky]-(C . 6 -heteroeycloalkyl), -CQO-(C -alkyl). -CO-(C 5-6 - heterocycloalkyl), -CONH-C, . 4 -alkyl-0(C, .
- R A is independently selected from the group comprising H, -S0 2 (Ci -4 -alkyl), -CO-N(Ci -4 -alkyl) 2 , -CO-pipcrazinc- 1 ,4-yl-Ci-4-alkyl- tetrahydrofurane-2-yl, -COO-(Cj 4 -alkyl), -CO-morholine- 1 -yl, -CO-pyrrolidine- 1 -yl, - CONH-C I -4 -alkyl-0( C 1 -4 -alkyl ), -CONH-C , _ 4 -alkyl-ietrahydiOfurane-2-yl, halogen.
- R A is independently selected from the group comprising H, -S0 2 (Ci_ 4 -alkyl), -CO-N(Ci -4 -alkyl)2, -CO-piperazine-l,4-yl-C 1-4 -alkyl- tetrahydrofurane-2-yl , -COO-(Ci_ 4 -alkyl), -CO-morholine- 1 -yl, -CO-pyrrolidine- 1 -yl, - CONH-C , -,-alkyl-0(C , 4 -alk ), -CONH-C, -4 -alkyl-tetrahydrofurane-2-yl.
- C - haloalkyl 3-(C -alkoxy)-phenyl, C ⁇ -haloalkoxy, -CONH-(C, -4 -alkyl), -CONH-(C 3-5 - cycloalkyl), 4-(C
- R A is independently selected from the group comprising H, -S0 3 (C
- R A is independently selected from the group comprising H, -S0 2 (Ci -2 -alkyl), -CO-N(C 1-2 -alkyl) 2 , -CO-piperazine-1 ,4-yl-Ci -2 -alkyl- tetrahydrofurane-2-yl, -COO-(Ci. 2 -alkyl), -CO-morholine- 1 -yl, -CO-pyrrolidine- 1 -yl, - CONH-C 1. 2 -alkyl-0(C , - 2 -alkyl). -CONH-C , .
- R A is independently selected from the group comprising -SO . e, -CO-NMe?, -C -piperazine- 1.4-yl-CH 2 -tetrahydrofurane-2-yl, -COO- Et, -CO-morholine-l -yl, -CO-pyrrolidine- l -yl, -CONH-(CH 2 ) 2 -OMe, -CONH-CH 2 - tetrahydrofurane-2-yl, CI, CF 3 , H, 3-methoxyphenyl, OCF 3 , -CONH-Me, -CONH- cyclopropyl, 4-mcthyl-piperazine- 1 -yl, 3-pyridyl, 2-furanyl, -CO-(4-ethyl-piperazine- 1 -yl), - CO-thien-2-yl, -CO-pyrrol-2-
- R A is independently selected from the group comprising -S0 2 Me, -CO-NMe 2 , -CO-piperazine- 1.4-yl-CH 2 -tetrahydrofurane-2-yl, -COO- Et, -CO-morholine-l -yl.
- R A is independently selected from the group comprising - S0 2 (C M -alkyl), -CO-N(C 1-4 -alkyl) 2 , -CO-NH(Ci -4 -alkyl), -CO-NH 2 , -CO-(C 5 - 6 - heterocycloalkyl)-Ci_ 4 -alkyl-(C 5 -6-heterocycloaikyl), -COO-(C 1-4 -alkyl), -CO-(C 5-6 - heterocyeloalkyl), -CON1 I-C ! . 4 -alkyl-0(C i-4 -alkyl).
- R A is independently selected from the group comprising - S0 2 (C M -alkyl), -CO-N(C -alkyl) 2 , -CO-NH(C M -alkyl), -CO-NH 2 , -CO-(C 5-6 - heterocycloalkyl)-Ci -4 -alkyl-(C 5 _ 6 -heterocycloalkyl), -COO-(C, .
- R A is independently selected from the group comprising -S0 2 (Ci -4 -alkyl), -CO-N(Ci-4-alkyl) 2 , -CO-piperazine- 1 , 4-yl-Ci.
- R A is independently selected from the group comprising -S0 2 (C ] -4 -alkyl), -CO-N(C 1 -4 -alkyl)2, -CO-pipera/ine- 1 ,4-yl-C i -4 -alkyl- tetrahydrofurane-2-yl, -COO-(C i -4 -alkyl), -CO-morholine-l -yl. -CO-pyrrolidine-l -yl, - CO H-C ,_4-alkyl-0(C , -4 -alkyl ), and -CONH-C , . 4 -alkyl-tetrahydro turane-2-yl .
- R A is independently selected from the group comprising -S0 2 (Ci -2 -alkyl), -CO-N(C i . 2 -alkyl) 2 . -CO-pipera/ine- 1 ,4-yl-C , . 2 -alkyl- tetrahydrofurane-2-y , -COO-(C] -2 -alkyl), -CO-morholine-l -yl, -CO-pyrrolidine- 1 -yl, - CONH-Ci -2 -alkyl-0(Ci -2 -alkyl), -CONH-Ci.
- R A is independently selected from the group comprising -S0 2 (C, -2 -alkyl), -CO-N(C, . 2 -alkyl) 2 , -CO-piperiizine- 1 ,4-yl-C i . 2 -alkyl- tetrahydrofurane-2-yl, -COO-(Ci.
- R A is independently selected from the group comprising -S0 2 Me, -CO- Me 2 , -CO-piperazinc- 1 ,4-yl-CH -tetrahydrofuraiie-2-y1 , -COO- Et, -CO-morholine- l -yl, -CO-pyrrolidine-l-yl, -CONH-(CI l 2 ) 2 -O e, -CONH-CH 2 - tetrahydrofurane-2-yl, H, -CO-thicn-2-yl, -CO-pyrrol-2-yl, -CO-m holin-4-yl. piperidin- 1 - yi- 4-ethoxycarbonyl-piperidin- 1 -yl, and methyl.
- R A is independently selected from the group comprising -S0 2 Me, -CO-NMe 2 , -CO-pipcrazinc- l ,4-yl-CH2-tetrahydrofurane-2-y , -COO- Et, -CO-morholine- l -yl.
- R' is independently selected from the group comprising H, Ci -6 - alkyl, Ci. 6 -haloalkyl, phenyl, naphthyl. C 5 .6-heteroaryl, C3_7-cycloalkyl and C 4 7 - heterocycloalkyl. In certain embodiments, R' is independently selected from the group comprising H, C 1-6 - alkyl, Ci_ 6 -haloalkyl, phenyl, naphthyl, C -6-heteroaryl, C .7-eycloalkyl and C 4-7 - heterocycloalkyl.
- R' is Independently selected from the group comprising I I, C
- 7- heteroeyeloalkyl comprising 1 or 2 heteroatoms independently selected from the group comprising N, O and S.
- R' is independently selected from the group comprising H, Ci _ 4 -alkyl, C i -3 -haloalkyl, phenyl, C5 -ft -heteroaryl comprising 1 or 2 heteroatoms independently selected from the group comprising N, O and S, C 3-6 -cycloalkyl and C5-6-heterocycloalkyl comprising 1 or 2 heteroatoms independently selected from the group comprising N, O and S,
- R" is independently selected from the group comprising H, methyl, ethyl, i-propyl, n-propyl. i-butyl, n-butyl, t-butyl, CF 3 , phenyl, pyridine, pyrimidine, pyrrol, furane, thiphene, oxazol, pyrazol, imidazol, isothiazol, Isoxazol, thiazol, oxazol, C 3 .6-cycloalkyl, thiomorpholine, morpholine, piperidine, piperazine, tetrahydro furane, tetrahydropyrane, pyrrolidine, pyrroline, dihydrofurane, dihydrothiphene, tetrah ydro th i phen e, dihydropyrane, pyrazoline, pyrazolidine, imidazoline, imid
- R' is independently selected from the group comprising H, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, tetrahydrofuranc, tetrahydrothiphene, phenyl, pyrrolidine, piperazine, piperidine, morpholine, cyclopropyl, cyclobutyl, cyclopentyl, CF 3 , thienyl, pyrrol and piperidine.
- R' is Independently selected from the group comprising H, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, tetrahydrofuranc. tetrahydrothiphene. phenyl, pyrrolidine, piperazine, piperidine, morpholine, cyclopropyl, cyclobutyl, cyclopentyl, and CF 3 .
- R' is independently selected from the group comprising H, methyl, ethyl, n-propyl, i-propyl, i-butyl. t et rahydrofurane, phenyl, pyrrolidine, piperazine, morpholine, cyclopropyl, CF 3 , thienyl, pyrrole and piperidine.
- R * is independently selected from the group comprising 11, methyl, ethyl, n-propyl, i-propyl, i-butyl, tetrahydrofurane, phenyl, pyrrolidine, piperazine, morpholine, cyclopropyl and CF
- any of the aforementioned alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl may independently be substituted with one or more, particularly one to three, more particularly one or two substltuents R", wherein R" is independently selected from the group comprising Ci.4-alkyl, halogen, Cj-4-haloalkyl, OH, C
- R" is independently selected from the group comprising H, Ci -3 - alkyl, chlorine, fluorine, bromine, C
- R" is independently selected from the group comprising C 1 . 3-alkyl, chlorine, fluorine, bromine.
- CF 3 OH, OMe, OEt, OCF 3 , -NH 2 , -N(Me) 2 , -N(Et) 2 , -NH-Me, -NH-Et, -NH-iPr, -NHCO-Me, -CONH 2 , -CONH-Me, -CONH-Et, -CONH-iPr, acetyl, -COO-Me, -COO-Et, -COOH and -CN.
- R" is independently selected from the group comprising methyl, chlorine, fluorine, CF , OH, OMe, OCF 3 , -NH 2 , -N(Me) 2 , -N(Et) 2 , -NHCO-Me, acetyl, -COO-Me, -COOH and -COOEt.
- R" is independently selected from the group comprising methyl, chlorine, fluorine, CF 3 , OH, OMe, OCF 3 , -NH 2 , -N(Me) 2 , -N(Et) 2 , -NHCO-Me, acetyl, -COO-Me, and -COOH.
- R" is independently selected from the group comprising chlorine, fluorine, CF 3 , OH, OMe, OCF 3 , -NH 2 , -N(Me) 2 , -NHCO-Me, acetyl, -COO-Me, -COOH, -COOEt and methyl.
- R" is independently selected from the group comprising chlorine, fluorine, CF , OH, OMe, OCF , -NH 2 , -N(Me) 2 , -NHCO-Me, acetyl, -COO-Me, and -COOH.
- R" is independently selected from the group comprising H, chlorine, fluorine, CF 3 , OH, OMe. OCF 3 , -NH 2 , -N(Me) 2 , -COOEt and methyl.
- R" is independently selected from the group comprising chlorine, fluorine, CF 3 , OH, OMe, OCF 3 , -NH 2 , and -N(Me) 2 .
- the substituent R" is not further substituted.
- the compounds of the present invention are selected from the group comprising compounds 1 to 48 as described herein in the example section.
- the compounds of the present invention are selected from the group comprising compounds 1 to 82 as described herein in the example section.
- the compounds of the present invention are selected from the group comprising compounds 1, 2, 3, 4, 5. 6, 7, 8, 9, 10, 1 1 , 14, 17, 18. 19. 21 , 22, 23, 24, 25, 26, 27. 28, 29, 30, 31 , 34, 35, 37. 38. 39, 40, 41 , 42, 44, 45, 46. 47, and 48 to 71 as described herein in above Table 1.
- the compounds of the present invention are selected from the group comprising compounds 1 , 2, 3, 4, 6, 7, 8, 9, 10, 14, 17, 18, 19, 21 , 22, 23. 24, 25, 27, 28, 30, 34, 35. 38, 39, 40, 41 , 42, 45. 46 47, and 48 to 65 as described herein in above Table 1 .
- the compounds of the present invention are selected from the group comprising compounds 1 , 3, 6, 7, 8, 9, 10, 19, 22, 23, 25, 30, 35, 38, 42, 45 47 and 48 to 51 as described herein in above Table 1.
- the compounds of the present invention are selected from the group comprising compounds 1 , 2, 3, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16. 1 8, 19, 20, 21 , 22, 23, 24, 25, 30, 31 , 33, 34, 35, 36, 37, 38, 39, 40, 41, 45, 46 and 47 as described herein in above Table 1.
- the compounds of the present invention are selected from the group comprising compounds 1. 2, 3, 5, 6. 7, 8, 9, 10, 1 1 , 12, 13, 14, 19, 22, 23, 25, 35, 41 , 45, 46 and 47 as described herein in above Table 1.
- the compounds of the present invention are selected from the group comprising compounds 3. 7, 8, 9, 10, 22, 23, 25 and 35 as described herein in above Table 1 .
- the compounds of the present invention are selected from the group comprising compounds 1 1 , 42, 45, 46, 47, 50, 54, 55 and 62 as described herein in above Table 1.
- the compounds of the present Invention are selected from the group comprising compounds 1 , 2, 3, 5, 6, 7, 8, 9, 1 0. 1 1 , 14. 17, 1 8, 19, 21 , 22, 23, 24, 25, 26, 27. 28. 29, 30, 3 1 , 34, 35, 37, 38, 39, 40, 41 , 42, 44, 45, 46, and 47 as described herein in above Table 1 .
- the compounds of the present invention are selected from the group comprising compounds I , 2, 3, 6, 7, 8, 9, 10, 14, 17, 18, 19, 21 , 22, 23, 24, 25, 27, 28, 30, 34, 35, 38, 39, 40, 41 , 42, 45, 46 and 47 as described herein in above Table 1.
- the compounds of the present invention are selected from the group comprising compounds 1 , 3, 6, 7, 8, 9, 10, 19, 22, 23, 25, 30, 35, 38, 42, 45 and 47 as described herein in above Table 1.
- the compounds of the present invention are selected from the group comprising compounds 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 22, 23, 24, 25, 30, 31, 33, 34, 35, 36, 37, 38, 39, 40, 41, 45, 46 and 47 as described herein in above Table 1.
- the compounds of the present invention are selected from the group comprising compounds 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 19, 22, 23, 25,
- the compounds of the present invention are selected from the group comprising compounds 3, 7, 8, 9, 10, 22, 23, 25 and 35 as described herein in above Table 1.
- the compounds of the present invention are selected from the group comprising compounds 9, 23 and 25 as described herein in above Table 1, yet. even more specifically compound 23.
- the compounds of the present invention are selected from the group comprising compounds 5, 9, 23 and 25 as described herein in above Table 1.
- the compound of the present invention is compound 5 in above Table 1.
- alkyl encompasses a linear or branched Ci-C 6 alkanyl, C 2 - C(, alkenyl, C2-C 6 alkynyl; the total number of ring atoms in the aryl group is 6 to 14;
- cycloalkyl comprises 3 to 10 carbon atoms;
- heterocycloalkyl is a 5- to 10-membered mono- or polyeyclic ring system; haloalky!
- alkyl group denotes an alkyl group wherein one or more of the hydrogen atoms on the hydrocarbon chain are replaced by halogen atoms; alkoxy denotes an O-alkyl group, the alkyl group being as defined above; alkyl thio denotes an -S-alkyl group, the alkyl group being as defined above; haloalkoxy denotes an O-haloalkyl group, haloalkyl group being as defined above; alkylamino denotes a NH-alkyl or N-di alkyl group, the alkyl group being as defined above; and said alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl are optionally substituted by one or more suhstituents R".
- a pharmaceutical composition comprising a compound according to the present invention, in particular according to any of the above items 1 to 13 or a physiologically functional derivative, solvate or salt thereof and one or more pharmaceutically acceptable excipients for the use in the treatment or prevention of a disease or medical condition caused by a viral infection.
- the present invention relates to a method of treatment or prevention of the medical conditions specified herein, which comprises the administration of an effective amount of a compound according to the present invention, or a physiologically functional derivative, solvate or salt thereof to a subject in need thereof.
- the present invention relates to the use of a compound according to the present invention, or a physiologically functional derivative, solvate or salt thereof in the treatment or prevention of the medical conditions specified herein.
- the present invention relates to the use of a compound according to the present invention, or a physiologically functional derivative, solvate or salt thereof for the manufacture of a medicament for use in the treatment or prevention of the medical conditions specified herein.
- a method of treatment or prevention of a medical condition caused by a viral infection which comprises the administration of an effective amount of a compound according to the present invention, in particular according to any of the above items 1 to 13, or a physiologically functional derivative, solvate or salt thereof to a subject in need thereof.
- HSV is selected from the group comprising HSV- 1 and HSV-2.
- ring atom represents an atom which is part of the cyclic structure of a ring or ring system, wherein this definition does not include hydrogen atoms or substituents bound to the ring or ring system.
- a pyridine group comprises 6 ring atoms, i.e.
- suffix "' - ⁇ is in many cases omitted, which is not to be understood to delimit chemical names comprising said suffix from chemical names not comprising said suffix; for example "furyl”, “furanyl” and “furane” are meant to be used interchangeably.
- X'-azol moiety refers to the below chemical entity, which is part of formular (I) according to the present invention:
- an alkyl group particularly encompasses alkanyl, alkenyl, alkynyl, wherein alkanyl means a completely saturated hydrocarbon chain, alkenyl means a hydrocarbon chain comprising at least one carbon-carbon double bond, alkynyl means a hydrocarbon chain comprising at least one carbon-carbon triple bond (including a hydrocarbon chain comprising one or more carbon-carbon double bonds and at least one carbon-carbon triple bond).
- an alkanyl group if not stated otherwise, particularly denotes a linear or branched Ci-CValkanyl, more particularly a linear or branched Ci-C 5 -aikanyi, even more particularly a linear or branched Ci-C 4 -alkanyl;
- an alkenyl group if not stated otherwise, particularly denotes a linear or branched CVCValkenyl, more particularly a linear or branched CVCValkenyl, even more particularly ethenyl;
- an alkynyl group if not stated otherwise, particularly denotes a linear or branched CVCValkynyl group, more particularly a linear or branched CVCValkynyl, even more particularly ethynyl.
- the alky! group is selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tcrt-butyl. pentyl, hexyl, ethenyl, ethynyl, propen-l -yl. propen-2-yl, propen-3-yl. -C ⁇ C-CH 3 , and -CH 2 -C ⁇ CH.
- the alkyl, alkanyl, alkenyl, and alkynyl groups as defined above, including the groups enumerated as examples and particular or otherwise farther defined embodiments thereof, are optionally substituted by one or more substituents R".
- aryl particularly denotes an aromatic mono-or polycyclic hydrocarbon ring system, which may optionally be fused to one or more cycloalkyl or heterocycloalkyl rings, and wherein the total number of ring atoms in the aryl group is 6 to 14, particularly 6 to 10, more particularly 6.
- the point of attachment of said aryl group to the central moiety may be located on the aromatic mono-or polycyclic hydrocarbon ring system r on the optionally fused cycloalkyl or heterocycloalkyl ring.
- aryl group examples include phenyl, naphthyl, indenyl, azulenyl, fluorenyl, 1 ,2-dihydronaphthyl. 1,2,3,4- tetrahydronaphthyl , 2,3-dihydroindenyl, 1 ,5-dihydro-s-indacenyl, 1,6-dihydro-as-indacenyl, 1 H-cyclopenta[a]naphthyl and 1 H -cyclo penta j b j naphthyl , phenalenyl, phenanthrenyl anthracenyl, 1.6-dihydropentalcnyl, 1 ,6a-dihydropentalenyl, 1.2,3 ,4-tetrahydroanthracenyl , 1 ,2,3 ,4-tetrahydrophenanthrenyl, 2.3-di
- the aryl group is phenyl, 2,3-dihydrobenzo[b][l ,4]dioxinyl, 2.3-dihydrobenzofuranyl or benzo[d][ l,3]dioxolyl, more particularly phenyl.
- the aryl groups as defined above, including the groups enumerated as examples and particular or otherwise further defined embodiments thereof, are optionally substituted by one or more substituents R".
- halophenyf particularly denotes a phenyl group substituted with one or more halogen atoms, particularly with one halogen atom.
- heteroaryl particularly denotes an aromatic mono-or polycyclic hydrocarbon ring system wherein one or more carbon atoms are replaced by heteroatoms independently selected from the group comprising O, N and S, wherein the aromatic mono-or polycyclic hydrocarbon ring system may optionally be fused to one or more cycloalkyl or heterocycloalkyl rings, and wherein the total number of ring atoms in the heteroaryl group is 5 to 14, particularly 5 to 10, more particularly 5 or 6.
- the point of attachment of said heteroaryl group to the central moiety may be located on the mono-or polycyclic aromatic hydrocarbon ring system or on the optionally fused cycloalkyl or heterocycloalkyl ring.
- the heteroaryl group are furan-2-yl. furan-3-yl, thiophen-2-yl, thiophen-3-yl, thiazol-4-yl, pyrazol-3-yl, pyrazol-4-yl, oxa/ol-4-yl, oxazol-5-yl, isoxazol-4-yl. isoxazol-5-yl, pyrazin-2- yl, pyridin-2-yl.
- the heteroaryl group is selected from the group comprising furan-2- yl, thiophen-3-yl, pyiimidin-2-yl, or pyrimidin-6-yl, and pyridine-4-yl.
- the heteroaryl group is selected from the group comprising furan-2-yl, thiophen-3-yl, pyrimidin-2-yl, pyrimidin-6-yl, pyridine-4-yl, l//-imidazol-2-yl, lH- 1 ,2,4- triazol-5-yl, I H-bcnzo
- heteroaryl groups as defined above including the groups enumerated as examples and particular or otherwise further defined embodiments thereof, are optionally substituted by one or more substituents R",
- cycloalkyl particularly denotes a non-aromatic, mono- or polycyclic completely saturated or partially unsaturated hydrocarbon ring system.
- Said cycloaikyl is particularly mono- or bicyclic, more particularly monocyclic.
- Said cycloaikyl is particularly completely saturated.
- Said cycloaikyl particularly comprises 3 to 10 carbon atoms, more particularly 3 to 7, even more particularly 3 to 6 carbon atoms.
- said cycloaikyl is selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohe.xyl, eycloheptyl, 1 -norbornyl, 2-norbonryl, 7-norbornyl, 1-adamantyl, and 2-adamantyl, yet even more particularly said cycloaikyl is cyclohexyl.
- the cycloaikyl groups as defined above, including the groups enumerated as examples and particular or otherwise further defined embodiments thereof, are optionally substituted by one or more substituents R * . and 0, 1 or 2, particularly 0 or 1, more particularly 0 of the ring carbon atoms are attached to an oxygen atom via a double bond to form a carbonyl group.
- heterocyeloalkyl particularly denotes a non-aromatic mono- or polycyclic completely saturated or partially unsaturated hydrocarbon ring system, wherein one or more, particularly 1 to 3, more particularly 1 or 2 of the ring carbon atoms are replaced by a heteroatom independently selected from N, O, or S.
- Said heterocyeloalkyl is particularly mono- or bicyclic, more particularly monocyclic.
- Said heterocyeloalkyl is particularly completely saturated.
- Said heterocyeloalkyl particularly is a 5- to 10-membered mono- or polycyclic ring system, more particularly 5- to 7-membered monocyclic ring system, even more particularly 5- or 6-membered monocyclic ring system.
- Even more particularly said heterocyeloalkyl is selected from the group comprising morpholinyl, piperidinyl, pyrrolidinyl, and piperazinyl.
- heterocyeloalkyl group as defined above including the groups enumerated as examples and particular or otherwise further defined embodiments thereof, are optionally substituted by one or more substituents ' as described herein, and 0, 1 or 2, particularly 0 or 1, more particularly 0 of the ring carbon atoms are attached to an oxygen atom via a double bond to form a carbonyl group.
- haloalkyl denotes an alkyl group wherein one or more, particularly at least hall; more particularly all of the hydrogen atoms on the hydrocarbon chain are replaced by halogen atoms. .
- the haloalkyl group is particularly selected from the group comprising -C(R I0 ) 3 , -CH 2 -C(R 10 ) 3 , -C(R 10 ) 2 -CH 3 , -C(R 10 ) 2 -C(R 10 ) 3 , -C(R 10 ) 2 -CH(R 10 ) 2 , - CH 2 -CH(R ,0 ) 2 , -CH(R 10 )-C(R S0 ) 3 , -CH(R I 0 )-CH 3 , and -C 2 H 4 -C(R 10 ) 3 , more particularly -
- R 10 represents halogen, particularly F. More particular haloalkyl groups are - CF 3 , -CH2CF3, and CF 2 C1.
- alkoxy denotes an O-alkyl group, the alkyl group being defined as defined above. The alkoxy group is particularly selected from the group comprising mcthoxy and ethoxy.
- alkylthio denotes an -S-alkyl group, the alkyl group being as defined above.
- haloalkoxy denotes an O-haloalkyl group, haloalkyl group being defined as defined above.
- the haloalkoxy group is particularly selected from the group comprising -OC(R 10 ) 3 , -OCR 10 (R I 0' ) 2 , -OCH 2 -C(R 10 ) 3 , and -OC 2 H 4 -C(R 10 ) 3 , wherein R 10 , R 1 " ' represent F, CI, Br or I, particularly F.
- alkylamino denotes a NH-alkyl or N-dialkyl group, the alkyl group being as defined above.
- arylalkyl or “aralkyi” particularly denotes a linear or branched Cp
- C f C f ,-alkyl, more particularly Cj -4 -alkyl, even more particularly C].
- exemplary arylalkyl groups include styryl, benzyl, phenylethyl, particularly the arylalkyl group is styryi or benzyl, particularly optionally substituted at its phenyl part as defined above for the aryl group.
- a nitrogen heteroatom as defined herein e.g. in the context of "heteroaryl” and “heterocycle”, may include the N-oxide.
- a sulfur heteroatom as defined herein, e.g. in the context of "heteroaryl” and “heterocycle”, may include the sulfur oxide and/or the sulfur dioxide, respectively.
- morpholine-4-carbonyl is a group -CO- morpholine-4-yl.
- substituted with or ..substituted by means that one or more hydrogen atoms connected to a carbon atom or heteroatom of a chemical group or entity arc exchanged with a substituent group, respectively; e.g.
- substituted aryl comprises 4- hydroxyphenyl. wherein the H-atom in the 4-position of the phenyl group is exchanged with a hydroxy! group.
- Said hydrogen atom(s) to be replaced may be attached to a carbon atom or heteroatom, and may be expressly shown in a specific formula, such as for example in an -NH- group, or may not expressly be shown but intrinsically be present, such as for example in the typical "chain” notation which is commonly used to symbolize e.g. hydrocarbons.
- substituents or substituent patterns are excluded, which lead to compounds witch are not stable and/or not accessible via the synthesis methods known in the art.
- references to the compounds according to the present invention include the pharmaceutically acceptable derivatives, solvates or salts thereof as described herein, as well as to salts of said pharmaceutically acceptable derivatives, solvates of salts and pharmaceutically acceptable derivatives, and optionally solvates of salts of pharmaceutically acceptable derivatives.
- the term "pharmaceutically acceptable derivative " ' of a compound according to the present invention is for instance a prodrug of said compound, wherein at least one of the following groups are derivatized as specified in the following: A carboxylic acid group is derivatized into an ester, a hydroxy! group is derivatized into an ester, a carboxylic acid is derivatized into an amide, an amine is derivatized into an amide, a hydroxy! group is derivatized into a phosphate ester.
- pharmaceutically acceptable derivative is in certain embodiments analogous to the term “physiologically functional derivative " .
- tautomer used in reference to the compounds according to the present invention, in particular includes tautomers that typically form with respect to substituted benzi mid azoic groups.
- tautomers that typically form with respect to substituted benzi mid azoic groups.
- two tautomeric forms of an exemplary substituted benzimidazole moiety, as is present in the compounds according to the present invention are shown:
- the compounds according to the present invention are to be understood to comprise all tautomeric forms thereof, even if not expressly shown in the formulae described herein, including formula (I).
- formula (I) Throughout this specification, whenever a chemical formula, generic or otherwise, discloses a compound having a 4H-1 .2.4-triazole moiety that is at least partially unsubstituted, as shown on the left-hand side of the above exemplary illustration, said chemical formula it is to be understood to implicitly also relate to compounds wherein said moiety is tautomerized to form the structure as shown on the right-hand side of the above exemplary illustration.
- stereoisomer refers to a compound with at least one stereogenic centre, which may be R- or S-configured, as defined by the according IUPAC rules, and encompasses enantiomcrs and diastereomers as commonly understood by the skilled person. It has to be understood, that in compounds with more than one stereogenic centre, each of the individual stereogenic centres may independently from each other be R- or S-configured.
- stereoisomer as used herein also refers to salts of the compounds herein described with optically active acids or bases.
- the salts of the compounds according to the present invention are in particular embodiments pharmaceutically acceptable salts of the compounds according to the present invention.
- Pharmaceutically acceptable salts are such salts which are usually considered by the skilled person to be suitable for medical applications, e.g. because they are not harmful to subjects which may be treated with said salts, or which give rise to side effects which arc tolerable within the respective treatment.
- said pharmaceutically acceptable salts are such salts which are considered as acceptable by the regulatory authorities, such as the US Food and Drug Administration (FDA), the European Medicines Agency (EM A), or the Japanese Ministry of Health. Labor and Welfare Pharmaceuticals and Medical Devices Agency (PMDA).
- the present invention in principle also encompasses salts o the compounds according to the present invention which are as such not pharmaceutically acceptable, e.g. as intermediates in the production of the compounds according to the present invention or physiologically functional derivatives thereof, or as intermediates in the production pharmacologically acceptable salts of the compounds according to the present invention or physiologically functional derivatives thereof.
- a certain compound according to the present invention or pharmaceutically acceptable derivative there f can form a salt, i.e. whether said compound according to the present invention or pharmaceutically acceptable derivative or solvate thereof has a group which may carry a positive or negative charge, such as e.g. an amino group, a carboxylic acid group, etc..
- Exemplary salts of the compounds of the present invention are acid addition salts or salts with bases, particularly pharmacologically tolerable inorganic and organic acids and bases customarily used in pharmacy, which are either water insoluble or. particularly, water-soluble acid addition salts. Salts with bases may - depending on the substituents of the compounds of the present invention - also be suitable.
- Pharmacologically intolerable salts which can be obtained, for example, as process products during the preparation of the compounds according to the invention on an industrial scale, are also encompassed by the present invention and, if desired, may be converted into pharmacologically tolerable salts by processes known to the person skilled in the art.
- the compounds of the invention as well as their salts may contain, e.g. when isolated in crystalline form, varying amounts of solvents. Included within the scope of the invention are therefore solvates and in particular hydrates of the compounds of the present invention as well as solvates and in particular hydrates o the salts and/or physiologically functional derivatives of the compounds of the present invention. More particularly the invention encompasses hydrates of the compounds, salts and/or physiologically functional derivatives according to the present invention, comprising one, two or one half water molecule, with respect to their stoichiometry.
- a "solvate” is a complex formed in the crystalline state between one or more compounds according to the present invention (or pharmaceutically acceptable derivative or salt thereof) and one or more solvent molecules.
- such solvates are 1 :2, 2: 1 or 1 : 1 , more particularly 1 : 1 stoichiometric complexes.
- complexes, such solvates are formed with a solvent selected from the group comprising water, methanol, ethanol or propanol, particularly water, methanol or ethanol, more particularly water (the latter is typically also known under the term "hydrate”).
- room temperature As used herein, the term "room temperature”, “rt” or “r.t.” relates to a temperature of about 25°C, unless specified otherwise.
- stable particularly relates to a compound in which the chemical structure is not altered when the compound is stored at a temperature from about -80 °C to about +40 °C, more particularly from about -80 °C to +25 °C in the absence of light, moisture or other chemically reactive conditions for at least one week, more particularly at least one month, even more particularly at least six months, yet even more particularly, at least one year, and/or a compound which under lUPAC standard conditions and in the absence of light, moisture or other chemically reactive conditions maintains its structural integrity long enough to be useful for therapeutic or prophylactic administration to a patient, i.e. at least one week.
- Stable in this context mean that under the aforementioned conditions and time periods and compared with the the timepoint 0, i .e. when it was produced, the amount of impurities has increased by less than 2%, particularly less than 1 % more particularly less thatn 0.5%, which can e.g. be determined by analytic HPLC or LC-MS, or the like.
- Compounds which are not stable as described above are usually to be considered not encompassed by the present invention.
- such compounds which at IUPAC standard conditions spontaneously decompose within a period of less than one day are regarded as not being stable compounds.
- the skilled person will readily recognize, based on his general knowledge in his field of expertise, which compounds and which substitution patterns result in stable compounds.
- treatment includes complete or partial healing of a disease, prevention of a disease, alleviation of a disease or stop of progression of a given disease.
- prevention in particular includes that the compounds of the present invention are administered to a subject before the viral infection occurs. “Prevention” further includes that the compounds of the present invention are administered to a subject after the viral infection occurs, but before the onset of symptoms of the disease or medical condition.
- the "subject” is particularly a mammal, more particularly a human subject.
- the term “medicament” includes the compounds of the present invention, pharmacologically acceptable salts or physiologically functional derivatives thereof, which are to be administered to a subject in pure form, as well as compositions comprising at least one compound according to the present invention, a pharmacologically acceptable salt or physiologically functional derivative thereof, which is suitable for administration to a subject.
- the compounds according to the present invention and their pharmacologically acceptable salts and physiologically functional derivatives can be administered to animals, particularly to mammals, and in particular to humans as therapeutics per se, as mixtures with one another or particularly in the form of pharmaceutical preparations or compositions which allow enteral (e.g.
- compositions, medical uses and methods of treatment according to the present invention may comprise the more than one compound according to the present invention.
- compositions comprising a compound according to the present invention, or a pharmaceutically acceptable salt or physiologically functional derivative may optionally comprise one or more further therapeutically active substances which are not compounds of the present invention.
- therapeutically active substance specifies a substance which upon administration can induce a medical effect in a subject.
- Said medical effect may include the medical effect described herein for the compounds of the present invention, but may also, in the case of therapeutically active substances which are to be co- administered with the compounds according to the present invention, include other medical substances, such as for example but not exclusively adamantin, rimantadin, ose amivir, zanamivir, zidovudine, didanosine, zalcitabine, stavudine, abacavir, entecavir, apricitabine, tenofovir, adefovir, efavirenz, nevirapine, delafiridine, etravirinc.
- other medical substances such as for example but not exclusively adamantin, rimantadin, ose amivir, zanamivir, zidovudine, didanosine, zalcitabine, stavudine, abacavir, entecavir, apricitabine, tenofovir, adefovir, e
- rilpvirine and lamivudine emtricitabine, ribavirin, interferone alpha (pegylated or non-pegylated), telbivudin.
- aciclovir, valaciclovir, ganciclovir, valganciclovir, brivudin penciclovir.
- pharmaceutically acceptable is well known to the skilled person and particularly means that the respective entity is not harmful to the subject to which the entity or the composition comprising the entity is administered, that said entity is stable and that said entity is chemically compatible (i.e. non-reactive) with other ingredients of the respective pharmaceutical composition.
- Medicaments and pharmaceutical compositions according to the present invention comprising at least one compound according to the present invention or a pharmacologically acceptable salt or a physiologically functional derivative therof include those suitable for oral, rectal, bronchial, nasal, topical, buccal, sub-lingual, vaginal or parenteral (including transdermal, subcutaneous, intramuscular, intrapulmonary, intravascular, intracranial, intraperitoneal, intravenous, intraarterial, intracerebral, intraocular injection or infusion) administration, or those in a form suitable for administration by inhalation or insufflation, including powders and liquid aerosol administration, or by controlled release (e.g.
- sustained release, pH-controlled release, delayed, release, repeat action release, prolonged release, extended release) systems particularly for oral, topical or rectal administration.
- Suitable examples of controlled release systems include semipermeable matrices of solid hydrophobic polymers containing the compound of the invention, which matrices may be in form of shaped articles, e.g. films or microcapsules or colloidal drug carriers e.g. polymeric nanoparticles, or controlled release solid dosage forms, e.g. core tablets or multi-layer tablets.
- Pharmaceutically acceptable carriers used in the preparation of a pharmaceutical composition or medicament comprising a compound according to the present invention, a pharmacologically acceptable salt or physiologically functional derivative thereof can be either solid or liquid.
- Solid form pharmaceutical compositions comprising a compound according to the present invention, a pharmacological 1 y acceptable salt or physiologically functional derivative thereof include powders, tablets, pills, capsules, sachets, suppositories, and dispersible granules.
- a solid carrier may comprise one or more components, which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
- the carrier is a finely divided solid, which is in a mixture with the finely divided active component.
- the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.
- the tabletting mixture can be granulated, sieved and compressed or direct compressed.
- Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatine, tragacanth, methylcellulose, sodium carboxymcthylccllulose, a low melting wax, cocoa butter, and the like.
- preparation is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it.
- sachets and lozenges are included. Tablets, powders, capsules, pills, sachets, and lozenges can be used as solid forms suitable for oral administration.
- a low melting wax such as a mixture of fatty acid glyceride or cocoa butter
- the active component is dispersed homogeneously therein, as by stirring.
- the molten homogenous mixture is then poured into conveniently sized moulds, allowed to cool, and thereby to solidify.
- Compositions suitable for vaginal administration may be presented as peccaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
- Liquid preparations include solutions, suspensions, and emulsions, for example, water or water- propylcnc glycol solutions.
- parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution.
- the compounds according to the present invention may be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre- filled syringes, small volume infusion or in multi-dose containers with an added preservative.
- the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulation agents such as suspending, stabilizing and/or dispersing agents.
- the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for re-constitution with a suitable vehicle, e.g. sterile, pyrogen- free water, before use.
- a suitable vehicle e.g. sterile, pyrogen- free water
- Aqueous solutions suitable for oral administration can be prepared by dissolving the active component in water and adding for example suitable colorants, flavours, stabilizing and thickening agents, as desired.
- Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.
- solid form preparations which are intended to be converted, shortly before administration, to liquid form preparations for oral administration.
- liquid forms include solutions, suspensions, and emulsions.
- These preparations may contain, in addition to the active component, for example colorants, flavours, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
- the medicament is applied topically, e.g. in the form of transdermal therapeutic systems (e.g. patches) or topical formulations (e.g. liposomes, cremes, ointment, lotion, gels, dispersion, suspension, spray, solution, foam, powder).
- transdermal therapeutic systems e.g. patches
- topical formulations e.g. liposomes, cremes, ointment, lotion, gels, dispersion, suspension, spray, solution, foam, powder.
- the medicament may comprise carrier materials or excipients, including but not limited to a lipophilic phase (as for example Vaseline, paraffines, triglycerides, waxes, polyalcylsiloxanes), oils (olive oil, peanut oil.
- a lipophilic phase as for example Vaseline, paraffines, triglycerides, waxes, polyalcylsiloxanes
- oils oil, peanut oil.
- cmulsificr as for example lecithin, phosphat idylgl ycerol es, alkyl alcohols, sodium lauryl sulfate, polysorbats, Cholesterol, sorbitan fatty acid ester, polyoxyethylene fatty acid glycerol and -ester, poloxamers
- preservatives for instance benzalkonium chloride, chlorobutanol, parabene or fhiomersal
- flavouring agents for instance salts of acetic acid, citric acid, boric acid, phosphoric acid, tatric acid, trometamole or trolamine
- solvents for instance po 1 yethyi eng) ycol s, glycerol, ethanol, isopropanol or propyleneglycol
- solubilizers agents for achieving a depot effect, salts for modifying the osmotic pressure, carrier
- Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
- Lotions may be fonnulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or colouring agents.
- compositions suitable for topical administration in the mouth include lozenges comprising the active agent in a flavoured base, usually sucrose and acacia or tragacanth: pastilles comprising the active ingredient in an inert base such as gelatine and glycerine or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
- Solutions or suspensions may be applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray.
- the compositions may be provided in single or multi-dose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomizing spray pump.
- Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurized pack with a suitable propel] ant such as a chlorofluorocarbon (CFC), for example dichlorodiftuoromcthane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.
- a suitable propel] ant such as a chlorofluorocarbon (CFC), for example dichlorodiftuoromcthane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.
- CFC chlorofluorocarbon
- the aerosol may conveniently also contain a surfactant such as lecithin.
- the dose f drug may be controlled by provision of a metered valve.
- the medicament may be provided in the form of a dry powder, for example a powder mix o the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
- a powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
- PVP polyvinylpyrrolidone
- the powder carrier will form a gel in the nasal cavity.
- the powder composition may be presented in unit dose form, for example in capsules or cartridges of, e.g., gelatine, or blister packs from which the powder may be administered by means of an inhaler. in compositions for administration to the respiratory tract, including intranasal compositions.
- the compound will generally have a small particle size for example of the order of 5 microns or less. Such a particle size may be obtained by means known in the art, for example by micro
- compositions adapted to give sustained release of the active ingredient may be employed.
- the pharmaceutical preparations are particularly in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component.
- the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packaged tablets, capsules, and powders in vials or ampoules.
- the unit dosage form can be a capsule, tablet, sachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form. Tablets or capsules for oral administration and liquids for intravenous administration and continuous infusion are particular compositions.
- the compounds of the present invention may be used in combination with radiation therapy, or in combination with radiation therapy and other active compounds, already known for the treatment of the medical conditions disclosed herein, whereby a favourable additive or amplifying effect is noticed.
- pharmaceutically inert inorganic or organic excipients can be used.
- pills tablets, coated tablets and hard gelatine capsules, for example, lactose, cornstarch or derivatives thereof, talc, stearic acid or its salts, etc. can be used.
- Excipients for soft gelatine capsules and suppositories are, for example, fats, waxes, semi-solid and liquid polyols, natural or hardened oils etc.
- Suitable excipients for the production of solutions and symps are, for example, water, sucrose, invert sugar, glucose, polyols etc.
- Suitable excipients for the production of injection solutions are, for example, water, alcohols, glycerol, polyols or vegetable oils.
- the dose can vary within wide limits and is to be suited to the individual conditions in each individual case.
- the appropriate dosage will vary depending on the mode of administration, the particular condition to be treated and the effect desired, in general, however, satisfactory results are achieved at dosage rates of about 1 to 100 mg kg animal body weight particularly 1 to 50 mg/kg.
- Suitable dosage rates for larger mammals, for example humans are of the order of from about 10 mg/day to 500 mg/day, conveniently administered once, in divided doses 2 to 4 times a day, or in sustained release form.
- the compounds of the present invention are suitable for the treatment or prevention of a disease or medical condition caused by a viral infection. It is apparent that the embodiments of the present invention as described herein may be combined to form further particular embodiments of the present invention.
- HFF Human foreskin fibroblasts
- MEM minimal essential medium
- HCMV strain AD 169 was grown in HFF and quantitated for infectivity by a plaque reduction assay. Aliquots were stored at -80°C.
- HFF HFF were cultivated in 12-well plates to 90% confluency and used for infection with AD 169- GFP virus at a tissue culture infective dose of 0.5 (GFP-TCID50 0.5, referring to an MOI of 0.002 as determined by plaque assay titration).
- Virus inoculation was performed as described above. Then infected cell layers were incubated with 2.5 ml of MEM containing 5% (vol/vol) fetal calf serum with or without the respective test compound. Infected cells were incubated at 37°C under a 5% CO: atmosphere for 7 days.
- lysis buffer 25 mM Tris [pH 7.8], 2 mM dithiothreitol [DTT], 2 mM trans- 1,2-di minocyclohexane-N,N,N9,N9- tetraacetic acid, 1% Triton X-100, 10% glycerol
- lysis buffer 25 mM Tris [pH 7.8], 2 mM dithiothreitol [DTT], 2 mM trans- 1,2-di minocyclohexane-N,N,N9,N9- tetraacetic acid, 1% Triton X-100, 10% glycerol
- HFF lactate dehydrogenase
- Neutralizing activities of the antiviral compound were determined by endpoint dilution assay as described previously (Krawczyk A. et al., J Virol. 201 1 ;85(4): 1793-803). Briefly, one day before infection. Vcro cells (2 x 10 4 per well) were seeded into a culture plate in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated FBS, 100 U/rnl penicillin and 100 ⁇ streptomycin.
- DMEM Dulbecco's modified Eagle's medium
- virus without Aciclovir/compound 5 or Aciclovir/compound 5 alone, respectively were used to induce maximal CPE and no CPE, respectively.
- HSV-1 F Herpes simplex virus type 1
- strain F Aciclovir-sensitive wild-type lab strain.
- HSV-1 RIO Herpes simplex virus type 1, clinical isolate: shows resistance to Aciclovir,
- HSV-2 G Herpes simplex virus type 2, strain G: Aciclovir-sensitive wilde-type lab strain.
- HSV-2 R6 Herpes simplex virus type 2 clinical isolate: Aciclovir-resistant.
- Table 3b HSV-2 G vs. Cpd. 5
- Table 4a HSV-2 R6 vs. Aciclovir
- compound 5 is able to neutralize Aciclovir-resistant HSV-1 and HSV-2 strains.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to medical applications of compounds of the general formula (I) or a physiologically functional derivative, solvate or salt thereof for the treatment or prevention of a disease or medical condition caused by a viral infection, wherein the X1-azol moiety is attached at the 5- or 6- position of the 2,3-dihydrobenzofuran moiety, X1 is independently selected from the group comprising NRn, O or S; A is a monocyclic or bicyclic heteroaromatic ring system consisting of 5 to 10 ring atoms, at least one of which is an N atom, wherein optionally one to three further ring atoms are heteroatoms independently selected from the group comprising O, S and N and wherein the remaining ring atoms are carbon atoms; n is an integer from 0 to 2; m is an integer from 0 to 3; p is an integer from 0 to 4; and R1, R2, R3 R4, Rn, and RA are described further herein.
Description
Treatment and prevention of viral diseases with 2,3-dihydrobenzofuran-5-yl compounds BACKGROUND OF THE INVENTION
Viral infections are usually treated with substances targeting viral proteins. For example, influenza is treated with M2-membrane protein inhibitors (adamantin and rimantadin) or neuraminidase inhibitors (oseltamivir and zanamivir). HIV is treated with HIV protease inhibitors, reverse transcriptase inhibitors (nucleoside and non-nuc!eoside analoga), fusion inhibitors (blocking the viral transmembrane protein gp41 ) or cell entry inhibitors. HCV is usually treated by a combination of ribavirin and interferone alpha, where ribavirin as a nucleoside analogue inhibits the viral polymerase and interferone alpha activates the host immune system; also viral protease inhibitors and viral RNA polymerase inhibitors have been recently approved for treatment. HBV is treated with pegylated interferone alpha and/or nucleoside or nucleotide analoga. Herpes and human cytomegalovirus infections are treated with ganciclovir or structurally related substances like acyclovir and penciclovir, respectively, which also are analogs of the nuclein base guanine. However, these approaches to the treatment of viral diseases are not satisfactory due to the high mutation rate of viruses and the thus resulting lack of efficacy of presently known medications. Moreover, severe side effects caused by interaction with host factors or by incompatibility of treatments for patients who are infected with two or several different viruses occur regularly. In view of rising numbers of infections, especially with opportunistic viruses like HSV and HCMV in the background of immunocompromised patients (e.g organ transplant recipients or HIV infected persons) and taking into account the viruses' abilities to quickly adapt to new selection pressures caused by substances targeting viral proteins, new treatment options for viral diseases are urgently required. A rarely used approach to circumvent the selection pressure on viruses and thus avoid the generation of resistences is the targeting of host cell factors vital for the viral replication cycle. An example for inhibition of host: targets constitutes the small molecule CLK inhibitor TG003 ((Z)-l -(3-Ethyl-5-methoxy-2,3- dihydrobenzothiazol-2-ylidene)propan-2-one). TG003 has been tested against influenza viruses i in vitro assays and its activity was attributed to its interference with the splicing of viral M2 messanger RNA (Karlas A et al. (2010) Nature 463, 818-822). In this way, the
cellular machinery required for production of virus progeny is inhibited and thus can be exploited to suppress the replication of certain viruses. However, Karlas A et al (Nature (2010) 463, 818-822) tested TG003 in a viral model and found that TG003 inhibited viral replication by about only one order of magnitude at a concentration of about 50μΜ, thus rendering this compound unsuitable for effectively treating subjects suffering from viral infections. Even a complete knockdown of CLK1 did not stop viral replication entirely. These results indicate that inhibition of CI.K 1 alone is insufficient to inhibit viral replication.
WO 2014/202638 Al describes certain compounds of the present Formula. (I) and that they interact with DYRK kinase, suggesting their applicability in prevention and/or therapy o medical conditions wherein the function o DYRK kinase plays a role.
BRIEF SUMMARY OF THE INVENTION
It has now been found that the compounds of below Formula (I) surprisingly also display activity against certain viruses. Moreover, said compounds show inhibition of viral replication, although the entire mechnism by which said inhibition is achieved is currently not known.
In one aspect, the present invention therefore provides methods for the treatment or prevention of medical conditions involving viral infections, the method comprising the administration of compounds of Formula (I), physiologically functional derivatives or salts thereof, to a subject in need thereof, as detailed further herein below.
In another aspect, the present invention provides the use of compounds of Formula (I), physiologically functional derivatives or salts thereof, in the manufacture of a medicament for the treatment or prevention of medical conditions involving viral infections, as detailed further herein below. In another aspect, the present invention provides compounds of Formula (I), physiologically functional derivatives or salts thereof, for use in the treatment or prevention of medical conditions involving viral infections, as detailed further herein below.
Said compounds are particularly advantageous for the treatment or prevention of diseases caused by viral infections, more particularly herpes viridae, even more particularly by one of the following viruses: Human Cytomegalo Virus (HCMV) and Herpes Simplex Virus (HSV).
In another aspect, the present invention provides phannaceutical compositions comprising compounds of Formula (I), physiologically functional derivatives or salts thereof and one or more pharmaceutically acceptable excipients for the above medicinal purposes.
Said compounds of Formula (I) arc shown below, and the groups R1, R\ R\ R4, RA, X1 and A, as well as the integers n, m and p are detailed further herein below.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 shows the impact of DYRK. activity on HCMV replication. Compounds were analyzed by a GFP-based replication assay using HCMV AD169-GFP for the infection of HFFs (MOI of 0.01 , uninfected control, Mock). Antiviral compounds were added immediately post-infection at the concentrations indicated (reference drug ganciclovir - GCV, 20 μΜ). Cells were lysed seven days post-infection to perform quantitative GFP fluorometry (n = 4, mean SD).
DETAILED DESCRIPTION OF THE INVENTION
Embodiments of the present invention are enumerated in the following items:
1. A compound of the general formula (I) or a physiologically functional derivative, solvate or salt thereof for the use in the treatment or prevention of a disease or medical condition caused by a viral infection,
wherein the X'-azol moiety is attached at the 5- or 6- position of the 2,3- dihydrobenzofuran mioety. n is an integer from 0 to 2;
m is an integer from 0 to 3;
p is an integer from 0 to 4;
R1 is independently selected from the group comprising H, halogen, alkyl, aralkyl, haloalkyl, haloalkoxy, OH, alkoxy. -CN, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, -S-R-, -SO-R", nitro, -NH2. -N(R*)2, -NH(R'), -NHCO(R'), -CONH2, -CONH(R'), -CO(R'), -COH, -COO(R'), -COOH, -S02NH2, -S02NH(R"), -S02(R"). -NH-S02(R" ) and -NHCOOR":
R2 is independently selected from the group comprising H, halogen, alkyl, aralkyl, haloalkyl, haloalkoxy, OH, alkoxy, -CN, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, -S-R\ -SO-R-, nitro, -NH , -N(R')2, -NH(R'), -NHCO(R'), -CONH2, -CONH(R ) -CO(R'), -COH, -COO(R'), -COOH, -S02NH2, -S02NH(R"). -S02(R'). -NH-S02(R') and -NHCOOR';
R3 is independently selected from the group comprising H. halogen, alkyl, aralkyl, haloalkyl haloalkoxy, OH, alkoxy, -CN, aryl, heteroaryl, cycloalkyl. heterocycloalkyl, -S-R\ -SO-R', nitro. -N¾, -N(R')2, -NH(R'), -NHCO(R'), -CONH2, -CONH(R'), -CO(R'), -COH, -COO(R'), -COOH, -S02NH2, -S03NH(R"), -S02(R\). -NH-S02(R") and -NHCOOR';
R4 is independently selected from the group comprising 11, alkyl, aralkyl, haloalkyl, haloalkoxy, OH, alkoxy, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, -CONH2s -CONH(R'), -CO(R'), -COO(R'), and -S02(R\);
1 is independently selected from the group comprising NR", O or S;
Rn is independently selected from the group comprising H, alkyl, aralkyl, haloalkyl. haloalkoxy. OH, alkoxy, aryl, heteroaryl, cycloalkyl. heterocycloalkyl, -CONH2, -CONH(R'), -CO(R'), -COO(R'), and -S02(R');
A is a monocyclic or bi cyclic heteroaromatic ring system consisting of 5 to 10 ring atoms, at least one of which is an N atom, wherein optionally one to three further ring atoms are heteroatoms independently selected from the group comprising O, S and N and wherein the remaining ring atoms are carbon atoms;
RA is independently selected from the group comprising H, halogen, CN, N02, alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, -OR*. -CO-R*. -COO-R*. -CONH-R', -NHCO-R", -CON(R')2, -NR'CO-R', -NR'-CONR*. -NR'-COOR', -S-R\ -SO-R', -S02-R\ -NHSO2-R*, -S02NH-R\ -O-CO-NHR', -O-CO-R", -R'-O-R*. -R'-CO-R', -R'-NH-R', -R'-CONH-R', -R'-NHCO-R', -CONH-alkyl-O-R*. -CQNH- alkyl-R', -NHCO-alkyl-O-R", -NHCO-alkyl-R', -CO-R'-alkyl-R', -CO-R'-alkyl, -S-alkyl-R' and lkyl-R" ; or in an alternative embodiment of item 1 , RA is independently selected from the group comprising H, halogen. CN, N02, alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, -OR5, -CO-R', -COO-R", -CONH-R', -NHCO-R', -CON(R )2. -NR'CO-R', -NR'-CONR', -NR'-COOR', -S-R\ -SO-R". -S02-R\ -NHS02-R".
-SO2NH-R', -O-CO-N H R*. -O-CO-R". -R'-O-R', -R'-CO-R', -R'-NH-R', -R'-CONH- R', -R'-NHCO-R', -CONH-alkyl-O-R', -CONH-alkyl-R', -NHCO-alkyl-O-R', -NHCO-alkyl-R'. -CO-R'-alkyl-R', -CO-R'-alkyl, N(R')2, -KHR", NH2, -S-R', -S- alkyi-R' and alkyl-R';
R' is independently selected from the group comprising H. alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl;
wherein any of the aforementioned alkyl. aryl. heteroaryl, cycloalkyl and heterocycloalkyl may independently be substituted with one or more, particularly one to three, more particularly one or two substituents R", wherein R" independently selected from the group comprising Ci_4-alkyl halogen, Ci ^-haloalkyl. OH, Ci-4-
alkoxy, C,.4-haloalkoxy, itro, -NH2, -N(C -alkyl)2, -NH(C |.4-alkyl). -NHCO(Ci_4- alkyl). -CONH2, -CONH(C1-4-alkyl), -CO(C1 -4-alkyl), -COH, -COO(C -alkyl). -COOH and - CN.
The compound for the use according to above item 1 or a physiologically functional derivative, solvate or salt thereof, wherein
R1 is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, triiluoromethoxy, OH, methoxy, ethoxy, -CN, nitro, -NH2, -N(methyl)2, -NH-methyl, -NHCO-methyl. -CO I K -CONH-methyl, acetyl. -COO-mcthyl. and COOH; and
R2 is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, triiluoromethoxy, OH, methoxy, ethoxy, -CN, nitro, -NH2, -N(methyl)2, -NH-methyl, -NHCO-methyl, -CO H2. -CONH-methyl, acetyl, -COO-methyl, and COOH.
The compound for the use according to the present invention, in particular according to above item I or 2 or a physiologically functional derivative, solvate or salt thereof, wherein n is 0 and m is 0.
The compound for the use according to the present invention, in particular according to any of the above items 1 to 3 or a physiologically functional derivative, solvate or salt thereof, wherein
R3 is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, -OCF3, OH, methoxy, ethoxy, -CN, nitro, -NH2, -N(methyi)2, -NH-methyl, -NHCO-methyl, -CONH2, -CONH-methyl, acetyl, -COO-methyl, and -COOH.
The compound for the use according to the present invention, in particular according to any o the above items 1 to 4 or a physiologically functional derivative, solvate or salt thereof, wherein R3 is I I.
The compound for the use according to the present invention, in particular according to any of the above items 1 to 5 or a physiologically functional derivative, solvate or salt thereo , wherein
R4 is independently selected from the group comprising I I, Ci-3-alkyl. Ci-4-haloalky], OIL -CONH2, -CONH-C ,.3-alkyi, -CO-C^-alkyl, and -COO-C1-3-alkyl.
The compound for the use according to the present invention, in particular according to any of the above items 1 to 6 or a physiologically functional derivative, solvate or salt thereof, wherein R4 is 11.
The compound for the use according to any of the above items 1 to 7 or a physiologically functional derivative, solvate or salt thereof, wherein
A is a monocyclic heteroaromatic ring system consisting o 5 or 6 ring atoms, or a bicyclic heteroaromatic ring system consisting of 9 ring atoms, wherein at least one of the ring atoms is an N atom, wherein optionally one or two further ring atoms are N atoms and wherein the remaining ring atoms are carbon atoms,
or in an alternative embodiment of item 8, A is a monocyclic heteroaromatic ring system consisting of 5 or 6 ring atoms, or a bicyclic heteroaromatic ring system consisting of 9 ring atoms, wherein at least one of the ring atoms is an N atom, wherein optionally one or two further ring atoms are N atoms,
or one further ring atom is an O or S atom, or one further ring atom is an N atom and one ring atom is an O or S atom, and wherein the remaining ring atoms are carbon atoms; wherein A is optionally substituted with one or two substituents RA selected from the group comprising H, CN, NC½, halogen Oi l, alkoxy, haloalkyL alkyl, haloalkoxy, -COOH, -COO-alkyl, aralkyl, aryi, -CO-N(alkyl)2, -CONH-(alkyl), -CONH-alkyl- alkoxy, -CONH-cycloalkyl, -C NH-alk yl -heterocycl oalk yl , -CO-heterocycloalkyl- alkyl-heterocycloalkyl, -CO-heterocycloalkyl, -S02-alkyl, -S-alkyl, and -S-aralkyl, or in an alternative embodiment of item 8, A is optionally substituted with one or two substituents RA selected from the group comprising H, CN, N02, NH2, N(alkyl)2, halogen OH, alkoxy, haloalkyl, alkyl, haloalkoxy, alkoxyalkyl, heterocycloalkyl, -
heterocycloalkyl-alkyl, -heterocycloalkyl-COO-alkyl, heteroaryl, -COOH, -COO- alkyl, aralkyl, aryl. -aryl-halogen. -CO-N(alkyl)2, -CONH-(aikyl), -CONH-alkyl- alkoxy, -CONH-cycloalkyl, -CONH-alkyl-heteroeycloalkyl, -CO-heterocycloalkyl- alkyl-heteroeycloalkyl, -CO-heterocycloalkyl, -CO-heteroaryl, -CO-aryl, -CO- alkyl, -S02-alkyl, -S-alkyl, -S-alkyl-COO-alkyl. and -S-aralkyl.
The compound for the use according to any of the above items 1 to 8 or a physiologicall functional derivative, solvate or salt thereof, wherein
A is a monocyclic or bicyclic heteroaromatic ring system selected from the group comprising thiazole, oxazole, pyrazole, pyrrole, benzoxazole, benzothiazole, benzimidazole, imidazole, triazole, pyrazine, triazine, pyiimidine and pyridine, or in an alternative embodiment of item 9, A is a monocyclic or bicyclic heteroaromatic ring system selected from the group comprising thiazole. oxazole, pyrazole, pyrrole, benzoxazole, benzothiazole, benzimidazole, imidazole, triazole. pyrazine, triazine, pyrimidinc, pyridine, thiadiazole, and oxadiazole, wherein A is optionally substituted with a substituent RA selected from the group comprising H, CN, F, CI, OH, C|.2-alkoxy. CF3, OCF3, -COOH, -COO-(C|.2-alkyl), benzyl, phenethyl, phenyl. -CO-N(C,-2-alkyl)2, -CONH-(C,.2-alkyl), -CO H-(Ci 2- alkyl)-0(Ci.2-alkyl), -CONH-(C3-5-cycloalkyl), -CONH-(C , .2-alkyl-tetrahydrofuryl), -CO-piperazinyl-(Ci.2-alkyl)-tetrahydrofurany , -C -morholinyl. -CO-pyrrolidinyl, -CO-(methy] -pi peraziny )-. -S02(Ci.2-alkyl), -S-(Ci ,,-alkyl), -S-benzyl, -S-(chlorophenylmethyl), and -S-phenethyl, or in an alternative embodiment of item 9, A is optionally substituted with a substituent RA selected from the group comprising H, CN, F, CI, Br, OH. Cj 2-alkyl, C, .2-alkoxy. CF3, OCF3, -COOH, -COO-(Ci.2-alkyl), benzyl, phenethyl, phenyl, fluorophenyl, -CO-N(Ci_2-alkyl)2, -CONH-(C,-2-alkyl), -CONH-(C , -2-alkyl)-0(C , .2- alkyl), -CONH-(C3-5-cycloalkyl), -CONH-(C,-2-alkyl-tctrahydrofuryl), -CO- pipcrazinyl-(C i .2-alkyl)-tctrahydrofuranyl. -CO-morholinyl, -CO-pyrrolidinyl, -CO- (methyl-piperazinyl)-. -S02(Ci-2-alkyl), -S-(Ci-4-alkyl), -S-benzyl, -S- (chlorophenylmethyl), -S-phenethyl, -CO-thienyl, -CO-pyrrolyl, -CO-piperidinyl, -CO-piperidinyl-COO-(Ci.?-alkyl), morpholinyl, C i -2-alkylpipera/.inyl , C]-2-
alkylthiazolyl, pyridyl, -CO-phenyl, -S-(C1-2-alkyl)-COO-(Ci-2-alkyl), H2, N(C,.2- alkyl)2, -CO-C, .2-alkyl. -(C] -2-alkyl)-0(Ci-2-alkyl) and wherein, when A is benzoxazole, benzothiazole or benzimidazole, A may optionally further be substituted with a halogen atom, or in an alternative embodiment of item 9, when A is benzoxazole, benzothiazole or benzimidazole, A may optionally further be substituted with a halogen atom, and wherein, when A is thi azoic, A may optionally further be substituted with a methyl group. The compound for the use according to any of the above items 1 to 9 or a physiologically functional derivative, solvate or salt thereof, wherein the X1 -a/.ol moiety is attached at the 5- position of the 2,3-dihydrobenzofuran mioety. The compound for the use according to above item 1 or a physiologically functional derivative, solvate or salt thereof, wherein the X 1 -azol moiety i s attached at the 5- position of the 2,3-dihydrobenzofuran mioety;
1 is 0 or 1 ;
m is 0 or 1 ;
X1 is independently selected from the group comprising NRn, O or S;
R" is independently selected from the group comprising I I, methyl, ethyl, OH, - CONH2, -CO H-methyl, and -COO-methyl;
R' is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, tri iluoromethyl, trifluoromethoxy, OH, methoxy, cthoxy, -CN, nitro, -NH2, -N(methyl)2, -NH-methyl, -NHCO-methyl, -CONH2, -CONH-methyl, acetyl, -COO-methyl, and COOH;
R2 is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, triiluoromethyl. trifluoromethoxy, OH, methoxy, ethoxy, -CN. nitro, -NH2, -N(methyl)2, -NH-methyl, -NHC O-methyl, -CONH2. -CONH-methyl, acetyl, -COO-methyl, and -COOH;
R3 is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, OH, methoxy, ethoxy, -CN, nitro, -NH2, -N(methyl)2. -NH-methyl, -NHCO-methyl, -CONH2. -CONH-methyl, acetyl, -COO-methyl, and -COOH;
R4 is independently selected from the group comprising H, Ci-3-alkyl, Ci .4-haloalkyl, OH, -CONH2, -CO H-C i .3-alkyl, -CO-Ci-3-alkyl, and -COO-d .3-alkyl;
A is independently selected from the group comprising thiazole, oxazole, pyrazol c. pyrrole, benzoxazole, benzothiazole, benzimidazole. imidazole, triazole, pyrazine, triazine, pyrimidine and pyridine; or in an alternative embodiment of item 1 1 , A is independently selected from the group comprising thiazole, oxazole, pyrazol e. pyrrole, benzoxazole, benzothiazole, benzimidazole, imidazole, triazole, pyrazine. triazine, pyrimidine, pyridine, thiadiazole, and oxadiazole: wherein A is optionally substituted with a substituent RA selected from the group comprising H, CN, F, CI, Oi l, C | .2-alkoxy. CF3, OCF3. -COOH, -COO-(C1 -2-alkyl), benzyl, phenethyl, phenyl, -CO-N(C1-2-alkyl)2, -CONH-(C1 -2-alkyl), -CONH-(C| .2- a]kyl}-0(C,.2-alkyl), -CONH-(C3-5-cycloalkyl), -CONH-(C,-2-alkyl etrahydrofuryl), -CO-piperazinyl-(Ci -2-alkyl)-tetrahydrofuranyl, -CO-morholinyl, -CO-pyrrolidinyl, -CO-(methyl-piperazinyl)-. -S02(C i-2-alkyl), -S-(C -alky]). -S-benzyl, -S-(c lorophenylrncthyl), and -S-phenethyl; or in an alternative embodiment of item 1 1 , A is optionally substituted with a substituent RA selected from the group comprising H, CN, F, CI, Br, OH, C| .2-alkyl, C,.2-alkoxy, CF3, OCF3, -COOH. -COO-(C i.2-alkyl), benzyl, phenethyl, phenyl, fluorophenyl, -CO-N(C, -2-alkyl)2, -CONH-(Ci .2-alkyl), -CONH-(C , -2-alkyl )-0( C , -2- alkyl). -CONl I-(C3.5-cycloalkyl), -CONH-(C , .2-alkyl-tetrahydrofuryl ), -CO- piperazinyl-(C 1.2-alkyl )-tetrahydrofuranyl . -CO-morholinyl, -CO-pyrrolidinyl, -CO- (methyl-piperazinyl)-, -S02(C, .2-alkyl). -S-(Ci.4-alkyl), -S-benzyl, -S- ( chl oropheny 1 m ethyl ) . -S-phenethyl. -CO-thienyi, -CO-pyrrolyl, -CO-piperidinyl, -CO-piperidinyl-COO-(Ci„2-alkyl), morpholinyl. Ci-2-alkylpiperazinyl, Ci_2- alkylthiazoiyi, pyriciyl, -CO-phenyi, -S-(Cj.2-aIkyl)-COO-(C1-2-aikyl), NH2, (C , .2- alkyl)2, -CO-Ci-2-alkyl, and -(C1-2-alkyl)-0(C,-2-alkyl);
and wherein, when A is benzoxazole, benzothiazole or benzimidazole, A may optionally further be substituted with a halogen atom, or in an alternative embodiment of item 1 1 , when A is benzoxazole, benzothiazole or benzimidazole, A may optionally further be substituted with a halogen atom, and wherein, when A is thiazole, A may optionally further be substituted with a methyl group. The compound for the use according to above item 1 or a physiologically functional derivative, solvate or salt thereof, wherein the X' -azol moiety is attached at the 5- position of the 2,3-dihydrobenzofuran mioety, n is 0; m is 0; X1 is S, R3 is H; R4 is H;
A is a monocyclic or bicyclic hetcroaromatic ring system selected from the group comprising lH-irnidazol-2-yl, 1 //- 1 ,2,4-triazol-5-yl, 1 H-benzo [c ] i midazol -2-yl and pyridin-2-yl; or in an alternative embodiment of item 12. A is a monocyclic or bicyclic hetcroaromatic ring system selected from the group comprising l//-imidazol-2-yl, 1 //- 1.2,4-triazol-5-yl, l/J-benzo[«i]imidazol-2-yi, pyridin-2-yl, 1 ,3,4-thiadiazol-2-yl, 1 H- pyrazol-3-yl, l ,3-thiazol-2-yl, and 1 ,2,4-thiadiazol-3-yl; wherein A is optionally substituted with a substituent RA selected from the group comprising F, CL CN, -S02-Me, O e. CF3, -CO-N(Me)2, -CO-N(Me)2, 5-(4- ((tetrahydrofuran-2-yl)methyl)piperazine- 1 -carbonyl, -COO-Et, morpholine-4- carbonyl, OCF3, -COO-Me, OH, -CO-NHMe, -S-Me, pyrrolidin-1 -carbonyl, -CO-NH- C2H4-OMe, -S-iPr, cyclopropyiearbamoyl, 4-methylpiperazine- 1 -carbonyl. -S-nPr, COOH, -S -benzyl, -S-(4-chlorobenzyl), -S-iBu, ((tetrahydrofuran-2- y 1 )m et h y 1 ) carb am o y 1 , phenethyl and -S-phencthyl; or in an alternative embodiment of item 12, A is optionally substituted with a substituent RA selected from the group comprising F, CI, Br. CN, methyl, -S02-Me, OMe. CF3, -CO-N(Me)2, -CO-N(Me)2, 5-(4-((tetrahydrofuran-2-yl)methyl)piperazine- 1 -carbonyl -COO-Et, morpholine-4-carbonyl, OCF3, -COO-Me, OH, -CO-NHMe, -S- Me, pyrrolidin-1 -carbonyl, -CO-N H-C2i Lj-OMe, -S-iPr, cyclopropyiearbamoyl, 4-
methylpiperazine- 1 -earbonyl, -S-nPr, COOH, -S-bcnzyl, -S-(4-chlorobenzyl), -S-iBu, ((tetrahydrofuran-2-yl)methyl)carbamoyl, phenethyl, -S-phenethyl, -CO-thien-2-yl, -CO-pyrrol-2-yl, -CO-pipcridin- 1 -yl, -CQ-(4ethoxycarbonyl-piperidin-l -yl), morpholm-4-yl. 4-methyl-piperazin- 1 -yl, 5 -methyl -thi azo 1 -2 -y 1. pyridin-4-y1, -CO- phenyl -S-(CH2)-COO e, NH2, -CO-Ci-2-alkyl. 3 -fluorophenyl, acetyl, -methylthio, and m ethoxym ethyl ; and wherein, when A is l //-benzo[r/|inndazol-2-yl, A may optionally further be substituted with a chlorine atom, or in an alternative embodiment of item 12, when A is 1 // -benzol c/j i midazo 1-2-yl, A may optionally further be substituted with a chlorine atom, and when A is 1.3-thiazol-
2-yl, A may optionally further be substituted with a methyl group.
The compound for the use according to above item 1 or a physiologically functional derivative, solvate or salt thereof, wherein said compound is selected from the group comprising the compounds 1 to 47, or in an alternative embodiment of item 13 compounds 1 to 82, as shown below in the Table 1 .
Table 1 : Specific compounds of the present invention (the production thereof is described in
WO 2014/202638 Al :
In certain embodiments, m is an integer from 0 to 2, more particularly 0 to 1 , even more particularly 0.
In certain embodiments, p is an integer from 0 to 3, more particularly 0 to 2, even more particularly 0 to 1 , yet even more particularly 1 ,
In certain embodiments, R 1 is independently selected from the group comprising H, halogen, Ci-4-aIkyl, benzyl, C\ 4-haloalkyl, Ci-4-haloalkoxy, OH, C1.4-alko.xy, -CN, phenyl, naphthyl, pyridyl, pyrrolyl, furanyl, tliienyl, thiazolyl, oxazolyl, pyrazolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohcxyl, cycloheptyl. decalinyl, tetrahydrofuryl, tetrahydropyranyl. tetrahydrothienyl, piperidyl, piperazinyl, morpholinyl, pyrrolidinyl,
-S-C,_4alkyl, -SO-C] -4alkyl, nitro, -NH2, -N(C1-4alkyl)2, -NH-C, .4alkyl. -NHCO-C1 -4alkyl, -CONH2, -CONH-C,-4alkyl, -CO-C alkyl, -COH. -COO-Cl -4alkyl.
-COOH, -SO2NH2, -S02NH-Ci-4alkyl, -S02-C1.4alkyl -NH-S02-C1 -4alkyl and -NHCOC-CV
4alkyl.
In more particular embodiments, Rl is independently selected from the group comprising H, halogen, C^-alky!, benzyl, Ci-4-haloalkyl, C i -4-haloalkoxy, OH, Ci-4-alkoxy, -CN, phenyl, cyclopropyl, cyclobutyl. cyclopentyl, cyclohexyl, -S-C i.4alkyl, -SO-C i-4alkyl. nitro, - H2, -N(Ci_4alkyl)25 -NH-C ,_4alkyl, -NHCO-C i 4alkyl, -CONH2, -CONH-Ci ^aikyl, -CO-C, 4alkyl, -COO-C i-4alkyl. -COOH. -S02NH2, -S02NH-CMalkyL -S02-Cl -4alkyl, -NH-S02-C ,.4alkyl and -NHCOO-Ci-4alkyl.
In even more particular embodiments, R1 is independently selected from the group comprising H, halogen, C| .4-alkyl, C| .4-haloalkyl. CVi-haloalkoxy, OH, C i_4-alkoxy, -CN, cyclopropyl, cyclobutyl, nitro, -NH2, -N(C] -4alkyl)2, -NH-C1-4alkyl, -NHCO-Ci- alkyl, - CONH2,
-CONH-C| .4alkyl, -CO-C,-4alkyl, -COO-C,.4alkyl, and -COOH.
In yet even more particular embodiments, R 1 is independently selected from the group comprising H, halogen, Ci-4-alkyl, Ci-4-haloalkyl, d-4-haloalkoxy, OH, C | 4-alkoxy, -CN,
nitro. -NH2, -N(Ci-2alkyl)2, -NH-CV2a]kyl, -NHCO-C^alkyl, -CONH2, -CONH-C1-2alkyl, -CO-C,.2alkyl, ~COO-C,-2aikyl, and -COOH.
In yet even more particular embodiments, R1 is independently selected from the group comprising 11, fluorine, chlorine, bromine,
trifluoromethyl, difluoromethyl, trifluoromethoxy, OH, Ci.3-alkoxy. -CN, nitro, -NH2, -N(C, .2alkyl)2. -NH-C,.2alkyl, -NHCO-Ci 2alkyl, -CONH2, -CONH-Ci 2alkyl, -CO-C,_2alkyl, -COO-C1 2alkyl and -COOH. In yet even more particular embodiments, P.1 is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, OH, methoxy, ethoxy, -CN. nitro, -NH2. -N(methyl)2, -NH-methyl, -NHCO-methyl, -CONH2. -CONH-methyl, acetyl, -COO-methyl, and -COOH.
In yet even more particular embodiments, R! is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, OH, and methoxy.
In yet even more particular embodiments, R1 is independently selected from the group comprising H, fluorine, chlorine, metliyl, trifluoromethyl. trifluoromethoxy, OH, and methoxy.
Most particularly, R l is independently H.
In certain embodiments, R2 is independently selected from the group comprising H, halogen, Ci-4-alkyl, benzyl, Q-4-haloalkyl, Ci-4-haloalkoxy, OH, Ci-4-alkoxy, -CN. phenyl, naphthyl, pyridyl, pyrrol yl. furanyl, thienyl, thiazolyl, oxa/olyl. pyrazolyl, cyclopropyl, cyclobutyl. cyclopentyl, cyclohexyl, cycl heptyl, decalinyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothienyl, piperidyl, piperazinyL morpholinyl, pyrrolidinyl,
-SO-C,.4alkyl, nitro, -NH2. -N(Ci.4alkyl)2, -NH-C1-4alkyl, -NHCO-Ci.4alkyl, -CONH2, -CONH-C|_4alkyl, -CO-C|-4alkyl, -COH. -COO-C alkyl, -COOH, -S02NH2, -S02NH-C alkyl, -S02-C1-4alkyl, -NH-S02-Ci.4alkyl and -NHCOO-C! -4alkyl.
In more specific embodiments, R2 is independently selected from the group comprising H, halogen, C1-4-alkyl, benzyl, C! -4-haloalkyl, Cj.4-haloalkoxy, OH, C)-4-alkoxy, -CN, phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -S-Ci_4alkyl, -SO-Ci. alkyl, nitro, -NH2,
-N(C1-4alkyl)2, -NH-C,-4alkyl, -NHCO-C^alkyl, -CONH2, -CONIi-C alkyl, -CO-Ci-4alkyl, -COO-C | . alkyl, -COOH. -S02NH2, -S02NH-C| .4alkyl, -S02-Ci.4alkyl, -NH-S02-C ,-4alkyl and -NHCOO-C i -4alkyl. In even more particular embodiments, R2 is independently selected from the group comprising H, halogen, d . -alkyl, C] -4-haloalkyl, Ci .4-haloalkoxy, OI L C |.4-alkoxy, -CN, cyelopropy], cyelobutyl, nitro, -NH2, -N(C alkyl)2, -NH-C,-4alkyl, -NHCQ-Ci .4alkyl. -
CONH2,
-CONH-C | .4alkyl, -CO-C alkyl, -COO-C1 -4alkyl and -COOH.
In yet even more particular embodiments, R2 is independently selected from the group comprising H, halogen, Ci-4-alkyl, C|-4-haloalkyl, C i-4-haloalkoxy, OH, Ci-4-alkoxy, -CN, nitro, -NH2, -N(Cl -2alkyl)2, -NH-C,.2alkyl. -NHCO-C, .2alkyl, -CO H2, -CONH-C1-2alkyl, -CO-Ci-2alkyl, -COO-C, -2alkyL and -COOH.
In yet even more particular embodiments, R2 is independently selected from the group comprising H, fluorine, chlorine, bromine, Chalky!, trifluoromethyl, dilluoromethyl, trifluoromethoxy, OH, C1-3-alkoxy, -CN, nitro, -NH2, -N(C] -2alkyl)2, -NH-C, -2alkyl. -NHCO-C| .2alkyl, -CONH2, -CONH-C|.2alkyl -CO-C,.2alkyl, -COO-C1 -2alkyl. and -COOH.
In yet even more particular embodiments, R2 is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, Oi l. methoxy, ethoxy, -CN, nitro, -NH2, -N(methyl)2, -NH-methyl. -NHCO-methyl, -CONH2, -CONH-methyl, acetyl, -COO-methyl, and -COOH.
In yet even more particular embodiments, R2 is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, OH, and methoxy. In yet even more particular embodiments, R2 is independently selected from the group comprising H, fluorine, chlorine, methyl, trifluoromcthyl, tri fl uorom ethox y, OH, and methoxy.
Most particularly, R is independently 11.
In certain embodiments, R3 is independently selected from the group comprising H, halogen, Ci-4-alkyl, benzyl, C i-4-haloalkyl, Ci_4-haloalkoxy, OH, Ci - -alkoxy, -CN, phenyl, naphthyl, pyridyl, pyrro!yl, furanyl, thienyl, thiazolyl, oxazolyl, pyrazolyl, cyclopropyl, cyclobutyl, eyclopentyl, cyclohexyl, cycloheptyl. dccalinyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydro thienyl, piperidyi, piperazinyl, morpholinyl, pyrrolidinyl, ~S-C,_4alkyL -SO-C alkyl, nitro, -NH2. -N(C1-4alkyl)2, -NH-C1-4alkyl, -NHCO-C! -4alkyl. -CONH2. -CONH-C1 -4a!ky!, -CO-C;.4alkyL -COH, -COO-C! -4a!kyl. -COOH, -S02N¾, -S02NH-C,.4alkyl, -S02-CMaIkyl, -NH-S02-Ci .4alkyl and -NHCOO-C1 -4alkyl.
In more particular embodiments, R3 is independently selected from the group comprising H, halogen, C] -4-alkyl5 benzyl, d-4-haloalkyl, Ci-4-haloalkoxy, OH, Q-4-alkoxy, -CN, phenyl, cyclopropyl, cyclobutyl, eyclopentyl, cyclohexyl. -S-Cj .4alkyl, -SO-C1 -4alkyl, nitro. -NH2, -N(Ci 4alkyl}2, -NH-C1 -4alkyl, -NHCO-Ci-4alkyl, -CONH2, -CONH-C, .4alkyl, -CO-C, .4alkyl. -COO-C,.4alkyl, -COOH, -S02NH2, -S02NH-C,.4alkyl, -S02-C1 -4alkyl. -NH-S02-C1-4alkyl and -NHCOO-C,-4alkyl.
In even more particular embodiments, R3 is independently selected from the group comprising H, halogen, Ci-4-alkyl, 4-haloalkoxy, OH. C| 4-alkoxy. -CN, cyclopropyl, cyclobutyl, nitro, -N
-NH-C,.4alkyl, -NHCO-Ci-4alkyl, - CONH2, -CONH-C,-4alkyl. -CO-C,-4alkyl, -COO-C,.4alkyl, and -COOH.
In yet even more particular embodiments, R3 is independently selected from the group comprising H, halogen, C ]. -alkyl, C].4-haloalkyl, Ci-4-haloalkoxy, OH, C | . -alkoxy, -CN, nitro, -NH2, -N(C l -2alkyl)2, -NH-C| .2alkyl, -NHCO-C,.2alkyl, -CONH2. -CONH-C] -2alkyl, -CO-C i .2alkyl, -COO-C1 -2alkyl, and -COOH.
In yet even more particular embodiments, R3 is independently selected from the group comprising H, fluorine, chlorine, bromine, Ci.?alkyl. trifluoromethyl, difluoromethyl. trifluoromethoxy, OH. Ci.?-alkoxy, -CN. nitro, -NH2, -N(C| .2alkyl)2, -NH-C,-2alkyl, -NHCO-Ci.2alkyl, -CONH2, -CONH-C, 2alkyl. -CO-C).2alkyl, -COO-C,.2alkyl, and -COOH.
In yet even more particular embodiments, R3 Is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl. trifluoromethyl. trifluoromethoxy,
OH, methoxy, etlioxy, -CN, nitro. -NH2, -N ( methyl):. -NH-methyl. -NHCO-methyl, -CONH2, -CONH-methyl, acetyl, -COO-methyl, and -COOH.
In yet even more particular embodiments, R3 is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, OH, and methoxy.
In yet even more particular embodiments, P.3 is independently selected from the group comprising H, fluorine, chlorine, methyl, trifluoromethyl, trifluoromethoxy, OH, and methoxy.
Most particularly, R3 is independently H.
In certain embodiments, R4 is independently selected from the group comprising H, Ci-4-alkyl, benzyl,
OH, C | .4-alkoxy, phenyl, naphthyl, pyridyl, pyrrolyl, furanyl, thienyl, thiazolyl, oxazolyl, pyrazolyl. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, decalinyl, tetrahydrofuryl. tetrahydropyranyl, tetraliydrothicnyl. piperidyl, piperazinyl, mo holinyl, pyrrolidinyl, -CONH2, -CONH-C , .4-alkyl. -CO-C,-4-alkyl, -COO-C! -4-alkyl, and -S02-C! -4-alkyl.
In more particular embodiments, R4 is independently selected from the group comprising H, C| -alkyL benzyl, Ci- -haloalkyb Ci 4-haloalkoxy, OH, C| 4-alkoxy, phenyl, -CONH2, -CONH-C |-4-alkyl, -CO-C,-4-alkyl, -COO-C, .,-alkyh and -S02-C, .4-alkyl. In more particular embodiments, R4 is independently selected from the group comprising H, Ci-3-alkyl, C1 -4-haloalkyl, OH, -CONH2, -CONH-C i -3-alkyl, -C -C|_j-alkyl, and
-COO-C, .3-alkyl.
In even more particular embodiments. R4 is independently selected from the group comprising H, methyl, ethyl, OH. -CONH2, -CONH-mcthyl, and -COO-methyl.
In yet even more particular embodiments, R4 is independently selected from the group comprising H, and methyl.
Most particularly, R4 is independently H.
In certain embodiments, X1 is O or S. In more specific embodiments, X1 is S, In certain embodiments, R" is independently selected from the group comprising H, Ci-4-alkyl, benzyl, Q-4-haloalkyl, Ci-4-haloalkoxy, OH, Cj-4-alkoxy, phenyl, naphthyl, pyridyl, pyrrolyl, furanyl, thienyl, thlazolyl, oxazolyl, pyrazolyl, cyclopropyl, cyclobutyl, cyc!opcntyl, cyclohexyl, cyc!ohcptyl, decalinyl, tetrahydrofuryl, tetrahydropyrany! , tetrahydrothienyi, piperidyi piperazinyl, morpholinyl, pyrrolidinyl, -CON¾, -CONH-C1 4-alkyl. -CO-C1-4-alkyl, -COO-C|.4-alkyl, and -S02-Ci 4-alkyl.
In more particular embodiments, Rn is independently selected from the group comprising H, C] _4-alkyl, benzyl, C1-4-haloalkyl, C)-4-haloalkoxy, OH, C1-4-alkoxy, phenyl, -CONH2, -CONH-C -alkyl, -CO-C -alkyl, -COO-C,.4-alkyl, and -S02-Cl -4-alkyl.
In more particular embodiments, Rn is independently selected from the group comprising H, Ci.3-alkyl, C -haloalkyl, OH, -CON¾, -CONH-C|.?-alkyl, -CO-Cj.3-alkyl, and -COO-Cralkyl. In even more particular embodiments, R" is independently selected from the group comprising II, methyl, ethyl, OH, -CONH2, -CO H-methyl, and -COO-methyl.
In yet even more particular embodiments, R" is independently selected from the group comprising 11, and methyl. Most particularly, R" is independently H.
In certain embodiments, A is a monocyclic or bicyclic heteroaromatic ring system consisting of 5 to 9 ring atoms, at least one of which is an N atom, wherein optionally one or two further ring atoms are heteroatoms independently selected from the group comprising O, S and N, particularly , and wherein the remaining ring atoms are carbon atoms.
In more particular embodiments, A is a monocyclic heteroaromatic ring system consisting of
5 or 6 ring atoms, or a bicyclic heteroaromatic ring system consisting of 9 ring atoms, wherein at least one of the ring atoms is an N atom, wherein optionally one or two further ring atoms
arc heteroatoms independently selected from the group comprising O, S and N and wherein the remaining ring atoms are carbon atoms.
In other more particular embodiments, A is a 5-membered monocyclic heteroaromatic ring which is optionally fused to a phenyl ring, wherein at least one of the ring atoms is an N atom, wherein optionally one or two further ring atoms are N atoms and wherein the remaining ring atoms are carbon atoms.
In other more particular embodiments, A is a 5-membered monocyclic heteroaromatic ring which is optionally fused to a phenyl ring, wherein at least one of the ring atoms is an N atom, wherein optionally one further ring atom is an N atom and/or one further ring atom is an O or
S atom, and wherein the remaining ring atoms are carbon atoms.
In even more particular embodiments, A is a monocyclic heteroaromatic ring system consisting of 5 or 6 ring atoms, or a bi cyclic heteroaromatic ring system consisting f 9 ring atoms, wherein at least one of the ring atoms is an N atom, wherein optionally one or two further ring atoms are N atoms and wherein the remaining ring atoms are carbon atoms.
In other even more particular embodiments, A is a monocyclic heteroaromatic ring system consisting of 5 or 6 ring atoms, or a bicyclic heteroaromatic ring system consisting of 9 ring atoms, wherein at least one of the ring atoms is an N atom, wherein optionally one or two further ring atoms are N ato s,
or one further ring atom is an O or S atom,
or one further ring atom is an N atom and one ring atom is an O or S atom,
and wherein the remaining ring atoms are carbon atoms
In other more particular embodiments, A is independently selected from the group comprising thiazole, oxazole, pyrazole, pyrrole, benzoxazole, benzothiazole, benzimidazole, imidazole, triazole, pyrazine. triazinc, pyrimidinc and pyridine, even more particularly thiazol-2-yl, oxazol-2-yl, pyrazol-2-yl, pyrrol-2-yl, bcnzoxazol-2-yl, benzothiazol-2-yl, benzimidazol-2-yl. imidazol-2-yl, triazol-5-yl. pyrazin-2-yl. triazin-2-yl, pyrimidin-2-yl and pyridin-2-yl.
In other more particular embodiments, A is independently selected from the group comprising thiazole, oxazole. pyrazole, pyrrole, benzoxazole, benzothiazole, benzimidazole, imidazole,
triazole, pyrazine. triazinc, pyrimidine, thiadiazole, oxadiazole, and pyridine, even more particularly thiazoi-2-yl, oxazol-2-yl, pyrazol-2-yl. pyrrol-2-yl, benzoxazol-2-yl, ben/.othi a/.ol -2-yl , ben/.imidazol-2-yl, imidazol-2-yl, triazol-5-yl. pyrazin-2-yl, triazin-2-y , pyrimidin-2-yl, thiadiazol-2-yl, thiadiazol-3-yl, thiadiazol-5-yl, oxadiazol-2-yi, oxadiazol-3- yl, oxadiazol-5-yl, and pyridin-2-yL
In yet even more particular embodiments, A is independently selected from the group comprising imidazolyl, triazolyl, benzoimidazol and pyridinyl, In other yet even more particular embodiments, A is independently selected from the group comprising imidazolyl, triazolyl, bcnzoimidazolyl. benzothiazolyl, thiadiazolyl, pyrazolyl, thiazolyl, oxazolyh oxadiazolyl and pyridinyl.
In yet even more particular embodiments, A is independently selected from the group comprising l//-imidazol-2-yL 1 //- 1 ,2,4-triazol-5-yI, l / -benzofi ]imidazol-2-yl and pyridin-2- yi
In other yet even more particular embodiments, A is independently selected from the group comprising lH-imidazol-2-yl, 1 //- 1 ,2,4-triazol-5-yl. l //-benzo[i/jimidazol-2-yl, pyridin-2-yl, l ,3.4-thiadiazol-2-yl, lH-pyrazol-3-yi, l ,3-thiazol-2-yh l ,2,4-thiadiazol-3-yl. 1 ,3,4- thiadiazol-2-yl, J .2,4-thiadiazol-5-yl. l ,3-oxazol-2-yl and l ,2,4-oxadia/.ol-3-yl.
In yet even more particular embodiments, A is independently selected from the group comprising benzimidazol-2-yl and imidazol-2-yl.
In other yet: even more particular embodiments, A is independently selected from the group comprising benzimidazol-2-yl, imidazol-2-y], 1 ,3,4-thiadiazol-2-y!, lH-pyrazol-3-yl, 1 ,3- thiazol-2-yl, and 1 ,2,4-thiadiazol-3-yl. Most particularly, A is independently benzimidazol-2-yl.
In other embodiments, most particularly, A is independently independently selected from the group comprising benzimidazol-2-yl, 1 ,3.4-thiadiazol-2-yl, lH-pyrazol-3-yl, and 1 ,3-thiazol-
2-yl.
In all embodiments described herein, A may be substituted, where appropriate and chemically feasible, with 0 to 4, particularly, 0 to 2, more particularly 0 to 2, even more particularly 1 or 2 substituents RA, wherein RA is independently selected as detailed in the embodiments as described herein. In certain particular embodiments, the thiazole, oxazole, pyrazole, pyrrole, or imidazole group A is particularly optionally substituted with one RA substituent in position 4, the triazole group A is optionally substituted with RA in position 3, the pyrazine. triazine, pyri idine or pyridine group A is optionally substituted with RA in position 5, and the benzoxazole, benzothiazole, or benzimidazole group A is optionally substituted with RA in position 5 and/or 6, even more particularly optionally substituted with RA in position 5 and further optionally substituted in position 6 with a group selected from the group comprising halogen, methyl, ethyl, CF3, CN, N02, COOH, OH, NH2, NMe2, and COOMe, more particularly selected from the group comprising halogen, methyl, CF3, CN, and OH, even more particularly selected from the group comprising fluorine, chlorine, bromine, CF3, CN and OH, yet even more particularly selected from the group comprising fluorine and chlorine, most particularly chlorine.
In other certain particular embodiments, the thiazole, oxazole, pyrazole, pyrrole, or imidazole group A is particularly optionally substituted with one RA substituent in position 4 or 5, the triazole group A is optionally substituted with RA in position 3, the pyrazine, triazine, pyrimidine or pyridine group A is optionally substituted with RA in position 5, and the benzoxazole, benzothiazole, or benzimidazole group A is optionally substituted with RA in position 5 and/or 6, or alternatively in position 1 , and further optionally substituted in position 5 or 6 (whichever one is available) with a group selected from the group comprising halogen, methyl, ethyl, CF3, CN, N02, COOH, OH, NH2, NMe2, and COOMe, more particularly selected from the group comprising halogen, methyl, CF3, CN, and OH, even more particularly selected from the group comprising fluorine, chlorine, bromine, CF3, CN and OH, yet even more particularly selected from the group comprising fluorine and chlorine, most particularly chlorine. For sake of completeness, it is mentioned that thiadiazolc and oxadiazole groups are optionally substituted at the ring carbon atom available for binding.
X2 is a group selected from the group comprising N and ethenylene, which may optionally be substituted by one or two RA: X3 is an atom selected from the group comprising C and N which may optionally be substituted by RA; R5 is a substituent group selected from the groups as defined herein for RA, or R5, together with X3 forms a monocyclic 5- or 6 membered aryl or heteroaryl ring, particularly a benzene ring, which may optionally be substituted by one or more R '\
In other more particular embodiments, A is an aromatic group of formula (la)
X2 is selected from the group comprising N, S, O, NH, CI I, CRA and ethenylene optionally substituted by one or two R"\ particularly selected from the group comprising N, S, O, NH, CH and CRA; X3 is selected from the group comprising N, S, NH, CH and CRA; X6 is selected from the group comprising N, S, O, NH, CH and CR5, wherein R5 is a substituent group selected from the groups as defined herein for R , or R , together with X'' forms a monocyclic 5- or 6 membered aryl or heteroaryl ring, particularly a benzene ring, which may optionally be substituted by one or more RA, particularly in positon 5 or 6 of a resulting benzazole derivative, wherein particularly said group A comprises not more than one atom selected from O and S and not more than three heteroatoms in total. other more particular embodiments, A is a group of formula (lb)
X4 is selected from the group comprising CH and NH; X4 is selected from the group comprising CH and a single bond; X3 is an atom selected from the group comprising C and N
which may optionally be substituted by RA; R5 is a substitucnt group selected from the groups as defined herein for R '\ or R\ together with X3 forms a monocyclic 5- or 6 membered aryl or heteroaryl ring, particularly a benzene ring, which may optionally be substituted by more RA.
In et other more particular embodiments, A is an aromatic group of formula (la)
X4 is selected from the group comprising N, S, O. NH. CH and CRA; X5 is selected from the group comprising CH and a single bond, particularly a single bond: X3 is selected from the group comprising N. S, NH, CH and CRA; X6 is selected from the group comprising N, S, O,
NH, CH and CR5, wherein R5 is a substituent group selected from the groups as defined herein for R '\ or R , together with X3 forms a monocyclic 5- or 6 membered aryl or heteroaryl ring, particularly a benzene ring, which may optionally be substituted by one or more RA, particularly in positon 5 or 6 of a resulting benzazole derivative, wherein particularly said group A comprises not more than one atom selected from O and S and not more than three heteroatoms in total.
For explanation, when R5, together with X3 forms a monocyclic 5- or 6 membered aryl or heteroaryl ring, particularly a benzene ring, which may optionally be substituted by one or more RA, particularly in positon 5 or 6 of a resulting benzazole derivative, said positon 5 or 6 of a resulting benzazole derivative is as shown in the below structure:
In certain embodiments, RA is independently selected from the group comprising H, CN, NO:, halogen OH, alkoxy, haloalkyl. alky], haloalkoxy, -COOH, -COO-alkyl, aralkyl, aryl, -CO-N(alkyl)2, -CONH-(alkyl), -CONH-alkyl-alkoxy. -CO H-cycloalkyl, -CONH-alkyl- heterocycloalkyl, -NHCO-(alkyl), - NHCO-alkyl-alkoxy. - NHCO-cycloalkyl. - NHCO-alkyl- hctcrocycloalkyl. -CO-hcterocycloalkyl-alkyl-heterocycloalkyl, -CO-heterocycloalkyl. -S02- alkyl. -S-alkyL -S-aralkyl, -CO-heteroaryl, heteroaryl. -heterocycloalkyl-alkoxycarbonyl. -
CO-aryl, -S-alkyl-COO-alkyl, halophenyl, NH2, NH(alkyl), N(alkyl), -CO-alkyl. and -alkyl- O-alkyL
In certain embodiments, RA is independently selected from the group comprising H, CN, N02, halogen OH, alkoxy, haloalkyl. alkyl, haloalkoxy. -COOH, -COO-alkyl. aralkyl. aryl, -CO-N(alkyl)2, -CON H -(alkyl), -CONH-alkyl-alkoxy, -CONH-cycloalkyl. -CO H-alkyl- heterocycloalkyl, -NHCO-(alkyl), - NHCO-alkyl-alkoxy, - NHCO-cycloalkyl. - NHCO-alkyl- heterocycloalky!, -CO-heterocycloalkyl-alkyi-heterocycloalkyl, -CO-heterocycloalkyl, -S02~ alkyl, -S-alkyl, and -S-aralkyl.
In further embodiments, RA is independently selected from the group comprising H, CN, N02, halogen OH, alkoxy, haloalkyl. alkyl, haloalkoxy, -COOH. -COO-alkyl. aralkyl. aryl, -CO- N(alkyl)2, -CONH-(alkyl), -CONH-alkyl-alkoxy, -CONH-cycloalkyl, -CONH-alky!- heterocycloalkyl, -CQ-heterocycloalkyl-alkyl-heteroeycloalkyl, -CO-heterocycloalkyl, -S02-alkyl, -S-alkyl, and -S-aralkyl.
In more particular embodiments, RA is independently selected from the group comprising H. CN, N02, halogen, OH, alkoxy, haloalkyl, alkyl, haloalkoxy. -COOH. -COO-alkyl, aralkyl, aryl. -CO-N(alkyl)2, -CONH-(alkyl), -CONH-alkyl-alkoxy, -CONH-cycloalkyl. -CONII- a lk yl -hct erocycl o al kyl . -CO-hctcrocycloalkyl-alkyl-heterocycloalkyl, -CO-heterocycloalkyl.
-S02-alkyl, -S-alkyl, -S-aralkyl, -CO-heteroaryl, heteroaryl. -heterocycloalkyl- alkoxycarbonyl, -CO-aryl, -S-alkyl-COO-alkyl, halophenyl, N¾ NH(alkyl), N(alkyl), -CO- alkyl, and -alkyl-O-alkyl.
In more particular embodiments, RA is independently selected from the group comprising H, CN. N02. halogen OH, alkoxy, haloalkyl, alkyl, haloalkoxy, -COOH. -COO-alkyl. aralkyl, aryl -CO-N(alkyl)2, -CONH-(alkyl). -CONH-alkyl-alkoxy, -CONH-cycloalkyl, -CONH- alkyl-heterocycloalkyl, -CO-heterocycloalkyl-alkyl-heterocycloalkyl, -CO-heterocycloalkyl, -S02-alkyl, -S-alkyl. and -S-aralkyl.
In even more particular embodiments. RA is independently selected from the group comprising H, CN, halogen, OH, Ci-4-alkoxy, Ci^-alkyl, Ci-4-haloalkyl, Ci_4-haloalkoxy, - COOH, -COO-(Ci.4-aikyl), ben/yl, phenethyl. phenyl. -CO-N(C,-3-alkyl)2. -CON H -(Chalky!), -CONH -(C i -a!kyl )-0( C , 3-alkyl), -CONH-(C3-5-cycloalkyl), -CONH-(C ralkyl)-(CV
6-heterocycloaikyl), -CO-(C5-6-heterocycloalkyl)-(Ci.3-alkyl)-(C5-6-heterocycloalkyl), -CO- (C5-6-heterocycloalkyl), -S02(Ci.4-alkyl), -S-(C -alkyl), -S-benzyl, -S-(chlorophenylmethyl), -S-phenethyl, -CO-(C5-6-heteroaryl), C5-6-heteroaryl, -C5-6-heterocycloalkyI-(C1-4- alkoxycarbonyl), -CO-phenyl, -S-(C , -4-alkyl )-COO-(C , alkyl), halophenyl, NH2, NH(C - alkyl), N(C,-4-alkyl)2, -CO-(C -a1ky1), and -(C , _ -alkyl)-0-(C , -4-alkyl).
In even more particular embodiments, RA is independently selected from the group comprising H, CN, halogen OH, C ;_4-alkoxy, Ci-4-alkyl, Ci.4-haloalkyl, C ;„ -haloaIkoxy, - COOH, -COO-(CM-alkyl), benzyl, phenethyl, phenyl, -CO- (C1.3-alkyl)2, -CO H-(C ! - alkyl), -CONH-(C,.3-alkyl)-0(C,.3-alkyl), -CONH-(C3.5-cycloalkyl), -CONH-(Ci .ralkyl)-(C5- 6-hctcrocycloalkyl ), -CO-(C5-6-heterocycloalkyl)-(Ci-3-alkyl)-(C5-6-heterocycloalkyl), -CO- (C5.6-heterocycloalkyl), -S02(C1 -4-alkyl), -S-(C1-4-alkyl), -S-benzyl, -S-(chlorophenylniethyl), and -S-phenethyl,
In yet even more particular embodiments, RA is independently selected from the group comprising H, CN, F, CI, OH, C1-2-alkoxy, CF3, OCF3, -COOH, -COO-(Ci-2-alkyl), benzyl, phenethyl, phenyl, -CO-N(Ci 2-alkyl)2, -CONH-(C1 -2-alkyl), -CONH-(Ci-2-alkyl)-0(Ci-2- alkyl), -CONH-(C3-5-cycloalkyl), -CONH-(C,.2-alkyl4etrahydrofuryl), -CO-piperazinyl-id 2- alkyl)-tctrahydrofuranyl, -CO-morholinyl, -CO-pyrrolidinyl, -CO-(methyl-piperazinyl)-, -S02(Ci-2-alkyl). -S-(CM- alkyl), -S-benzyl, -S-(chiorophenylmethyl). -S-phenethyl, -CO- thien-2-yl, -CO-pyrrol-2-yl, -CO-morphol in-4-yl , piperidin- l -yl-, 4-(C 1.2-alkoxycarbonyl)- piperidin-l -yl, C] 2-alky1, C ^-alkoxycarbonyl, moi holin-4-yl, 4-pyridyl, -CO-phenyl, -S- (Ci_2-alkyl)-COO-(Ci-2-alkyl), Br, 3 -fluorophenyl, NH2, -CO-(C1-2-alkyl), -S-(Ci -2-alkyl), and -(C|-2-alkyl)-0-(C,-2-a]kyl).
In yet even more particular embodiments, RA is independently selected from the group comprising H, CN, F, CI, OH, C, 2-alkoxy, CF3, OCF3, -COOH, -COO-(C ,.2-alkyl), benzyl, phenethyl, phenyl -CO-N(C1 2-alkyl )2, -CONH-(C,-2-alkyl), -CONH-(C1-2-alkyl)-0(Ci_2- alkyi), -CONH-(C3-5-cycloalkyl),
-CO-piperazinyl-(C1-2- alkyl)-tetrahydrofuranyl, -CO-morholinyl, -CO-pyrrolidinyl, -CO-(methyl-piperazinyl)-, -S02(Ci.2-alkyl). -S-(Ci.4-alkyl), -S-benzyl. -S-(chlorophenylmethyl), and -S-phenethyl.
In yet even more particular embodiments, Rn is independently selected from the group comprising I I, CN, F, CI, -S02Me, -OMe, CF3, -CO-NMe2, -CO-piperazine- 1 ,4-yl-CH2-
tetrahydrofurane-2-yl, -COO-Et, -CO-morholinc- l -yl, 3-iiietlioxyphenyl, OCF3, -COOMe, OH, -CONH-Me, -SMe, -CO-pwolidine-l -yl, -CONH-CH:-CH2-OMe, -S-iPr, -CONH- cyclopropyl, -CO-(4-methyl-piperazine- 1 -yi )-, -S-nPr, -COOH, -S-benzyl, -S-(4- chloroplienylmethyl), -S-iBu. -CONH-CH2-tetrahydroiuranc-2-yl, phenethyl, -S-phenethyl, - CO-thien-2-yl, -CO-pyrrol-2-yl, -CO-morpholin-4-yl, piperidin- l -yl-, 4-ethoxycarbonyi - piperidin- l -yl, methyl, ethoxycarbonyl, morpholin-4-yl. 4-pyridyl, -CO-phenyl, -S~CH2~ COO-Et, Br. 3 -fluorophenyl, NH2, acetyl, -S-Me, and -Clb-OMe.
In yet even more particular embodiments, RA is independently selected from the group comprising H, CN, F, CI, -S02Me, -OMe, CF3, -CO-NMe2, -CO-piperazine- 1 ,4-yl-CH2- tetrahydrofurane-2-yl, -COO-Et, -CO-morholine- l -yl. 3-methoxyphcnyl, OCF3, -COOMe, OH. -CONH-Me. -SMe, -CO-pyrroiidine- l -yl, -CQNH-CH2-CH2-OMe, -S-iPr, -CONH- cyclopropyl, -CO-(4-methyl-piperazine- 1 -yl)-, -S-nPr, -COOH, -S-benzyl, -S-(4- chlorophenylmethyl), -S-iBu, -CONH-CH2-tetrahydrofarane-2-yl, phenethyl, and -S-phenethyl.
In other particular embodiments, RA is independently selected from the group comprising H, - S02(CM-alkyl), -CO-N(C -alkyl)?, -CO-NH(C i -4-alkyl), -CO-NH2, -CO-fC5 6- heterocycloalkyl)-Ci-4-alkyl-(C5.6-heterocycloalkyl), -COO-(C i-4-alkyl). -CO-(C5.6- hetcrocycloalkyl). -CONH-C , -4-alkyl-0(C , -4-aikyl ), -CONH-C i -4-alkyl -(C5.6-heteroaryl ), halogen, C,.4-haloalkyl, 3-(C, 4-alkoxy)-aryl C -haloalkoxy, -CONH-(CM-alkyl). -CONH-
(C3_5-cycloalkyl), -(C5-6-heterocycloalkyl)-(Ci-4-alkyl), C5-6-heteroaryl, and -CO-(Ci.4-alkyi)- ( C j-6-heterocycl oal k y! ), -CO-(C5.6-heteroaryl), -CO-(C5-6-heterocycloalkyl), -(C5-6- heterocycloalkyl)-(Ci-4-alkoxycarbonyl), Ci-4-alkyl, C] -4-alkoxycarbonyl, -CO-phenyl, -S-(C | 4-alkylene)-COO-(Ci .4-alkyl). and C ! -4-alkoxy.
In other particular embodiments, RA is independently selected from the group comprising H, - S02(Ci .4-alkyl). -CO-N(C , 4-alkyl)2, -CO-NH(C1-4-alkyl), -CO-NH2, -CO-(C5-6- heterocycloalkyl)-C] - -alky]-(C .6-heteroeycloalkyl), -CQO-(C -alkyl). -CO-(C5-6- heterocycloalkyl), -CONH-C, .4-alkyl-0(C, .4-alkyl), -CONH-Ci-4-alkyl-(C5-6-heteroaryl), halogen, C1 -4-haloalkyl, 3-(C -alkoxy)-aryl, C1-4-haloalkoxy, -CO H-(C -alkyl), -CONH- (Cv5-cycloalkyl), (C5-6-heterocycloalkyl)-(C i- -alkyl), C5.6-heteroaryl, and -CO-(C-4-alkyl)- (C5_6-heterocycloalkyl).
In other more particular embodiments, RA is independently selected from the group comprising H, -S02(Ci-4-alkyl), -CO-N(Ci-4-alkyl)2, -CO-pipcrazinc- 1 ,4-yl-Ci-4-alkyl- tetrahydrofurane-2-yl, -COO-(Cj 4-alkyl), -CO-morholine- 1 -yl, -CO-pyrrolidine- 1 -yl, - CONH-C I -4-alkyl-0( C 1 -4-alkyl ), -CONH-C , _4-alkyl-ietrahydiOfurane-2-yl, halogen. C1-4- haloalkyl, 3-(C i.4-alkoxy)-phenyl, C | .4-haloalkoxy. -CONH-(C, .4-alkyl), -CONH-(C3-5- cycloalkyl), 4-(C 1 -4-alkyl)-piperazine- 1 -yl, 3-pyxidyl, 2-furanyl, -CO-(4-[C |-4-alkyl]- pipera/.ine-l -yl), -CO-thien-2-yl. -CO-pyrrol-2-yl. -CO-morpholin-4-yl, piperidin- 1 -yl-, 4-C|. -a!koxycarbony!-pipcridin- ! -yl, C1-4-alkyl, C , .4-alkoxycarbony! , mo holin- -y!. 4-pyridyi, - CO-phenyl. -S-(C , -4-alkyl ene)-COO-(C , .4-alky1 ). and C1-4-alkoxy.
In other more particular embodiments, RA is independently selected from the group comprising H, -S02(Ci_4-alkyl), -CO-N(Ci-4-alkyl)2, -CO-piperazine-l,4-yl-C1-4-alkyl- tetrahydrofurane-2-yl , -COO-(Ci_4-alkyl), -CO-morholine- 1 -yl, -CO-pyrrolidine- 1 -yl, - CONH-C , -,-alkyl-0(C , 4-alk ), -CONH-C, -4-alkyl-tetrahydrofurane-2-yl. halogen. C - haloalkyl. 3-(C -alkoxy)-phenyl, C^-haloalkoxy, -CONH-(C,-4-alkyl), -CONH-(C3-5- cycloalkyl), 4-(C|-4-alkyl)-piperazine- 1 -yl, 3-pyridyl, 2-furanyl and »CO-(4-[C1-4-alkyI]- piperazine-l -yl).
In other even more particular embodiments, RA is independently selected from the group comprising H, -S03(C |.2-alkyl), -CO-N(Ci.2-alkyl)2, -CO-pipera/.ine- l ,4-yl-Ci ..-..-alkyl- tetrahydroiurane-2-yl. -COO-(C'! .2-alkyl), -CO-morholine- 1-yl, -CO-pyrrolidine- 1 -yl, - CONH-Ci.2-alkyl-0(C|-2-alkyl), -CONH-C -2-alkyl-tetrahydrofurane-2-yl, halogen, C,.2- haloalkyl, 3-(C! -2-alkoxy)-phenyl, C ,-4-haloalkoxy, -CONH-(C i .4-alkyl). -CONH-(C3- - cycloaJkyl). 4-(Ci-4-alkyl)-piperazine- 1 -yl. 3-pyridyl, 2-furanyl, -CO-(4-[Ci.4-alkyl]- pipera/.ine- l -y ), -CO-thien-2-yl. -CO-pyrrol-2-yl, -CO-moipholin-4-yl, piperidin- 1-yl-, 4-C]. 2-alkoxycarbonyl -piperidin- 1-yl, C] .2-alkyl, C 1.2-a]koxycarbonyl , morpholin-4-yl, 4-pyridyl, - CO-phenyl, -S-(C| .2-alkylene)-COO-(C, .2-alkyl), and C,-2-alkoxy.
In other even more particular embodiments, RA is independently selected from the group comprising H, -S02(Ci-2-alkyl), -CO-N(C1-2-alkyl)2, -CO-piperazine-1 ,4-yl-Ci-2-alkyl- tetrahydrofurane-2-yl, -COO-(Ci.2-alkyl), -CO-morholine- 1 -yl, -CO-pyrrolidine- 1 -yl, - CONH-C 1.2-alkyl-0(C , -2-alkyl). -CONH-C , .2-alkyl-tetrahydrofurane-2-yl, halogen, C1 -2- haloalkyl, 3-(C | .2-alkoxy)-phenyl, C, .4-haloalkoxy, -CONH-(C| .4-alkyl), -CONH-(C3-5-
cycloalkyl), 4-(Ci-4-alkyl)-piperazine-l-yl, 3-pyridyl, 2-furanyl and -CO-(4- [C i-alk yl ] - piperazinc-l-yl).
In other yet even more particular embodiments, RA is independently selected from the group comprising -SO . e, -CO-NMe?, -C -piperazine- 1.4-yl-CH2-tetrahydrofurane-2-yl, -COO- Et, -CO-morholine-l -yl, -CO-pyrrolidine- l -yl, -CONH-(CH2)2-OMe, -CONH-CH2- tetrahydrofurane-2-yl, CI, CF3, H, 3-methoxyphenyl, OCF3, -CONH-Me, -CONH- cyclopropyl, 4-mcthyl-piperazine- 1 -yl, 3-pyridyl, 2-furanyl, -CO-(4-ethyl-piperazine- 1 -yl), - CO-thien-2-yl, -CO-pyrrol-2-yl. -CO-morphoiin-4-yl, piperidin- 1 -yl-, 4 elho ycarbony! - piperidin- 1 -yl, methyl, ethoxycarbonyl, morpholin-4-yl, 4-pyridyl, -CO-phenyl, -S-CH2- COO-Et, and methoxy.
In other yet even more particular embodiments, RA is independently selected from the group comprising -S02Me, -CO-NMe2, -CO-piperazine- 1.4-yl-CH2-tetrahydrofurane-2-yl, -COO- Et, -CO-morholine-l -yl. -CO-pyrrolidine-l-yl, -CONH-(CH2)2-OMe, -CONH-CH2- tetrahydrofurane-2-yl, CI, CF3, H, 3-methoxyphenyl. OCF3, -CONH-Me, -CONH- cyclopropyl, 4-methyl-piperazine- 1 -yl. 3-pyridyl, 2-furanyl and -CO-(4-ethyl-piperazine- 1 - yl).
In other particular embodiments, RA is independently selected from the group comprising - S02(CM-alkyl), -CO-N(C1-4-alkyl)2, -CO-NH(Ci-4-alkyl), -CO-NH2, -CO-(C5-6- heterocycloalkyl)-Ci_4-alkyl-(C5-6-heterocycloaikyl), -COO-(C1-4-alkyl), -CO-(C5-6- heterocyeloalkyl), -CON1 I-C ! .4-alkyl-0(C i-4-alkyl). ~CQNH-Ci.4-alkyI-(C5-6-heteroaryf)5 H, - CO-(C5-6-heteroaryi), -(Cs-g-heterocycloalkyl), C -alkyloxycarbonyl-substituted C5-6- heterocycloalkyl, and Q .4-alkyl.
In other particular embodiments. RA is independently selected from the group comprising - S02(CM-alkyl), -CO-N(C -alkyl)2, -CO-NH(CM-alkyl), -CO-NH2, -CO-(C5-6- heterocycloalkyl)-Ci-4-alkyl-(C5_6-heterocycloalkyl), -COO-(C, .4-alkyl), -CO-(C5-6- heterocycloalkyl), -CON H-C i .4 -al k yl -0( C 1 -4-alkyl ), and -CON H -C , .4-alkyl -(C5-6-heteiOaryl) .
In other more particular embodiments, RA is independently selected from the group comprising -S02(Ci-4-alkyl), -CO-N(Ci-4-alkyl)2, -CO-piperazine- 1 , 4-yl-Ci.4-alkyl- tetrahydrofurane-2-yl, -COO-(C1-4-alkyl), -CO-morholine-l-yl, -CO-pyrrolidinc- 1 -yl, - CONH-C 1-4-alkyl-0(C 1 -4-alkyl), -CONH-C, 4-alkyl-tetrahydrofuranc-2-yL B, -CO-thicn-2-yl,
-CO-pyrrol-2-yl, -CO-morpholin-4-yl, piperidin- l -yl- 4-C -alkyloxycarbonyl-piperidin- 1 -yl. and Ci^-alkyl.
In other more particular embodiments, RA is independently selected from the group comprising -S02(C] -4-alkyl), -CO-N(C1 -4-alkyl)2, -CO-pipera/ine- 1 ,4-yl-C i -4-alkyl- tetrahydrofurane-2-yl, -COO-(Ci -4-alkyl), -CO-morholine-l -yl. -CO-pyrrolidine-l -yl, - CO H-C ,_4-alkyl-0(C , -4-alkyl ), and -CONH-C , .4-alkyl-tetrahydro turane-2-yl .
In other even more particular embodiments, RA is independently selected from the group comprising -S02(Ci-2-alkyl), -CO-N(C i .2-alkyl)2. -CO-pipera/ine- 1 ,4-yl-C , .2-alkyl- tetrahydrofurane-2-y , -COO-(C]-2-alkyl), -CO-morholine-l -yl, -CO-pyrrolidine- 1 -yl, - CONH-Ci-2-alkyl-0(Ci-2-alkyl), -CONH-Ci.2-alkyl-tetrahydrofurane-2-yl. H, -CO-thien-2-yl, -CO-pyrrol-2-yl, -CO-morpholin-4-yl, piperidin- l -yl- 4-C i-?-alkyloxycarbonyl-piperidin- 1 -yl, and Ci-2-alkyl.
In other even more particular embodiments, RA is independently selected from the group comprising -S02(C,-2-alkyl), -CO-N(C, .2-alkyl)2, -CO-piperiizine- 1 ,4-yl-C i .2-alkyl- tetrahydrofurane-2-yl, -COO-(Ci.2-alkyl), -CO-morholine- 1 -yl, -CO-pyrrolidine- 1 -yl, - CONH-C , ,2-alkyl-0(C , 2-alkyl), and -CON I i-C i -2-alkyl-tetrahydroi urane-2-yl .
In other yet even more particular embodiments, RA is independently selected from the group comprising -S02Me, -CO- Me2, -CO-piperazinc- 1 ,4-yl-CH -tetrahydrofuraiie-2-y1 , -COO- Et, -CO-morholine- l -yl, -CO-pyrrolidine-l-yl, -CONH-(CI l2)2-O e, -CONH-CH2- tetrahydrofurane-2-yl, H, -CO-thicn-2-yl, -CO-pyrrol-2-yl, -CO-m holin-4-yl. piperidin- 1 - yi- 4-ethoxycarbonyl-piperidin- 1 -yl, and methyl.
In other yet even more particular embodiments, RA is independently selected from the group comprising -S02Me, -CO-NMe2, -CO-pipcrazinc- l ,4-yl-CH2-tetrahydrofurane-2-y , -COO- Et, -CO-morholine- l -yl. -CO-pyrrolidine-l-yl, -CONH-(CH2)2-OMe, and -CONH-CH2- tctrahydrofurane-2-yl .
In certain embodiments, R' is independently selected from the group comprising H, Ci-6- alkyl, Ci.6-haloalkyl, phenyl, naphthyl. C5.6-heteroaryl, C3_7-cycloalkyl and C4 7- heterocycloalkyl.
In certain embodiments, R' is independently selected from the group comprising H, C1-6- alkyl, Ci_6-haloalkyl, phenyl, naphthyl, C -6-heteroaryl, C .7-eycloalkyl and C4-7- heterocycloalkyl.
In more particular embodiments, R' is Independently selected from the group comprising I I, C| _4-alkyi.
phenyl, C5-6-heteroaryl comprising 1 to 3 heteroatoms independently selected from the group comprising N, O and S, C3_7-cycioalkyl and C4. 7- heteroeyeloalkyl comprising 1 or 2 heteroatoms independently selected from the group comprising N, O and S.
In even more particular embodiments, R' is independently selected from the group comprising H, Ci _4-alkyl, C i-3-haloalkyl, phenyl, C5-ft-heteroaryl comprising 1 or 2 heteroatoms independently selected from the group comprising N, O and S, C3-6-cycloalkyl and C5-6-heterocycloalkyl comprising 1 or 2 heteroatoms independently selected from the group comprising N, O and S,
In even more particular embodiments, R" is independently selected from the group comprising H, methyl, ethyl, i-propyl, n-propyl. i-butyl, n-butyl, t-butyl, CF3, phenyl, pyridine, pyrimidine, pyrrol, furane, thiphene, oxazol, pyrazol, imidazol, isothiazol, Isoxazol, thiazol, oxazol, C3.6-cycloalkyl, thiomorpholine, morpholine, piperidine, piperazine, tetrahydro furane, tetrahydropyrane, pyrrolidine, pyrroline, dihydrofurane, dihydrothiphene, tetrah ydro th i phen e, dihydropyrane, pyrazoline, pyrazolidine, imidazoline, imidazolidine, isothiazoline, isothiazolidine, isoxazoline, isoxazol idine, thiazoline, thiazolidine, oxazoline, oxazoline, and oxazol idine.
In yet even more particular embodiments, R' is independently selected from the group comprising H, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, tetrahydrofuranc, tetrahydrothiphene, phenyl, pyrrolidine, piperazine, piperidine, morpholine, cyclopropyl, cyclobutyl, cyclopentyl, CF3, thienyl, pyrrol and piperidine.
In yet even more particular embodiments, R' is Independently selected from the group comprising H, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, tetrahydrofuranc.
tetrahydrothiphene. phenyl, pyrrolidine, piperazine, piperidine, morpholine, cyclopropyl, cyclobutyl, cyclopentyl, and CF3.
In yet even more particular embodiments, R' is independently selected from the group comprising H, methyl, ethyl, n-propyl, i-propyl, i-butyl. t et rahydrofurane, phenyl, pyrrolidine, piperazine, morpholine, cyclopropyl, CF3, thienyl, pyrrole and piperidine.
In yet even more particular embodiments, R* is independently selected from the group comprising 11, methyl, ethyl, n-propyl, i-propyl, i-butyl, tetrahydrofurane, phenyl, pyrrolidine, piperazine, morpholine, cyclopropyl and CF
Any of the aforementioned alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl, including any particular or otherwise further specified embodiments thereof (e.g. for alkyl: Ci -6-aIkyl, isopropyl, methyl etc.), may independently be substituted with one or more, particularly one to three, more particularly one or two substltuents R", wherein R" is independently selected from the group comprising Ci.4-alkyl, halogen, Cj-4-haloalkyl, OH, C|..i-alkoxy, Ci_4- haloalkoxy, -N02, -CN, -Nib, -N(C1-4-alkyl)2, -NH(C,-4-alkyl), -NHCO(C]-4-alkyl), -CONH2, -CONH(C,.4-alkyl), -CO(C,_4-alkyl), -COH, -COO(Ci.4-alkyl), -COOH and -CN. In certain embodiments, R" is independently selected from the group comprising H, Ci-3- alkyl, chlorine, fluorine, bromine, C|.3-haloalkyl, OH. Ci-3-alkoxy, Ci-3-haloalkoxy, -NH2, -N(Ci_3-alkyl)2, -NH(C,-3-alkyl), -NHCO(C1-3-alkyl), -CONH2, -CONH(C, -alkyl), -CO(Cr 3- alkyl), -COH, -COO(Ci-3-alkyl), -COOH and -CN. In more particular embodiments, R" is independently selected from the group comprising C 1 . 3-alkyl, chlorine, fluorine, bromine. CF3, OH, OMe, OEt, OCF3, -NH2, -N(Me)2, -N(Et)2, -NH-Me, -NH-Et, -NH-iPr, -NHCO-Me, -CONH2, -CONH-Me, -CONH-Et, -CONH-iPr, acetyl, -COO-Me, -COO-Et, -COOH and -CN. In even more particular embodiments, R" is independently selected from the group comprising methyl, chlorine, fluorine, CF , OH, OMe, OCF3, -NH2, -N(Me)2, -N(Et)2, -NHCO-Me, acetyl, -COO-Me, -COOH and -COOEt.
In even more particular embodiments, R" is independently selected from the group comprising methyl, chlorine, fluorine, CF3, OH, OMe, OCF3, -NH2, -N(Me)2, -N(Et)2, -NHCO-Me, acetyl, -COO-Me, and -COOH. In yet even more particular embodiments, R" is independently selected from the group comprising chlorine, fluorine, CF3, OH, OMe, OCF3, -NH2, -N(Me)2, -NHCO-Me, acetyl, -COO-Me, -COOH, -COOEt and methyl.
In yet even more particular embodiments, R" is independently selected from the group comprising chlorine, fluorine, CF , OH, OMe, OCF , -NH2, -N(Me)2, -NHCO-Me, acetyl, -COO-Me, and -COOH.
In yet even more particular embodiments, R" is independently selected from the group comprising H, chlorine, fluorine, CF3, OH, OMe. OCF3, -NH2, -N(Me)2, -COOEt and methyl.
In yet even more particular embodiments, R" is independently selected from the group comprising chlorine, fluorine, CF3, OH, OMe, OCF3, -NH2, and -N(Me)2.
Particularly, the substituent R" is not further substituted.
In a specific embodiment, the compounds of the present invention are selected from the group comprising compounds 1 to 48 as described herein in the example section.
In a specific embodiment, the compounds of the present invention are selected from the group comprising compounds 1 to 82 as described herein in the example section.
In a specific embodiment, the compounds of the present invention are selected from the group comprising compounds 1, 2, 3, 4, 5. 6, 7, 8, 9, 10, 1 1 , 14, 17, 18. 19. 21 , 22, 23, 24, 25, 26, 27. 28, 29, 30, 31 , 34, 35, 37. 38. 39, 40, 41 , 42, 44, 45, 46. 47, and 48 to 71 as described herein in above Table 1.
In a more specific embodiment, the compounds of the present invention are selected from the group comprising compounds 1 , 2, 3, 4, 6, 7, 8, 9, 10, 14, 17, 18, 19, 21 , 22, 23. 24, 25, 27,
28, 30, 34, 35. 38, 39, 40, 41 , 42, 45. 46 47, and 48 to 65 as described herein in above Table 1 .
In an even more specific embodiment, the compounds of the present invention are selected from the group comprising compounds 1 , 3, 6, 7, 8, 9, 10, 19, 22, 23, 25, 30, 35, 38, 42, 45 47 and 48 to 51 as described herein in above Table 1.
In another specific embodiment, the compounds of the present invention are selected from the group comprising compounds 1 , 2, 3, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16. 1 8, 19, 20, 21 , 22, 23, 24, 25, 30, 31 , 33, 34, 35, 36, 37, 38, 39, 40, 41, 45, 46 and 47 as described herein in above Table 1.
In another more specific embodiment, the compounds of the present invention are selected from the group comprising compounds 1. 2, 3, 5, 6. 7, 8, 9, 10, 1 1 , 12, 13, 14, 19, 22, 23, 25, 35, 41 , 45, 46 and 47 as described herein in above Table 1.
In another even more specific embodiment, the compounds of the present invention are selected from the group comprising compounds 3. 7, 8, 9, 10, 22, 23, 25 and 35 as described herein in above Table 1 .
In another yet even more specific embodiment, the compounds of the present invention are selected from the group comprising compounds 1 1 , 42, 45, 46, 47, 50, 54, 55 and 62 as described herein in above Table 1. In a specific embodiment, the compounds of the present Invention are selected from the group comprising compounds 1 , 2, 3, 5, 6, 7, 8, 9, 1 0. 1 1 , 14. 17, 1 8, 19, 21 , 22, 23, 24, 25, 26, 27. 28. 29, 30, 3 1 , 34, 35, 37, 38, 39, 40, 41 , 42, 44, 45, 46, and 47 as described herein in above Table 1 . In a more specific embodiment, the compounds of the present invention are selected from the group comprising compounds I , 2, 3, 6, 7, 8, 9, 10, 14, 17, 18, 19, 21 , 22, 23, 24, 25, 27, 28, 30, 34, 35, 38, 39, 40, 41 , 42, 45, 46 and 47 as described herein in above Table 1.
In an eve more specific embodiment, the compounds of the present invention are selected from the group comprising compounds 1 , 3, 6, 7, 8, 9, 10, 19, 22, 23, 25, 30, 35, 38, 42, 45 and 47 as described herein in above Table 1. In another specific embodiment, the compounds of the present invention are selected from the group comprising compounds 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 22, 23, 24, 25, 30, 31, 33, 34, 35, 36, 37, 38, 39, 40, 41, 45, 46 and 47 as described herein in above Table 1. In another more specific embodiment, the compounds of the present invention are selected from the group comprising compounds 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 19, 22, 23, 25,
35, 41, 45, 46 and. 47 as described herein in above Table 1.
In another even more specific embodiment, the compounds of the present invention are selected from the group comprising compounds 3, 7, 8, 9, 10, 22, 23, 25 and 35 as described herein in above Table 1.
In another yet even more specific embodiment, the compounds of the present invention are selected from the group comprising compounds 9, 23 and 25 as described herein in above Table 1, yet. even more specifically compound 23.
In another yet even more specific embodiment, the compounds of the present invention are selected from the group comprising compounds 5, 9, 23 and 25 as described herein in above Table 1.
In another yet even more specific embodiment, the compound of the present invention is compound 5 in above Table 1.
In certain embodiments, the following compounds are excluded:
2-(2,3-dihydro- 1 -benzofuran-5-yl)-N-[3-(piperazin- 1 -yl)pyridin-2-yl]- 1 ,3-thiazole-4- carboxamide;
tert-butyl 4- {2-[2-(2,3-dihydro- 1 -bcn/.ofuran-5-yl)- 1 ,3-thiazole-4-amido]pyridin-3-yl } piperazine- 1 -carboxylate; and
2-(2,3-dihydro- l -benzofuran-5-yl)-N-ethyl-N-(2- {[(l S)- l -phenyl ethyl] amino } pyrimidin-4- yl)- 1 ,3-thiazole-4-carboxamide.
In certain particular embodiments alkyl encompasses a linear or branched Ci-C6 alkanyl, C2- C(, alkenyl, C2-C6 alkynyl; the total number of ring atoms in the aryl group is 6 to 14;
the total number of ring atoms in the heteroaryl group is 5 to 1 4; cycloalkyl comprises 3 to 10 carbon atoms; heterocycloalkyl is a 5- to 10-membered mono- or polyeyclic ring system; haloalky! denotes an alkyl group wherein one or more of the hydrogen atoms on the hydrocarbon chain are replaced by halogen atoms; alkoxy denotes an O-alkyl group, the alkyl group being as defined above; alkyl thio denotes an -S-alkyl group, the alkyl group being as defined above; haloalkoxy denotes an O-haloalkyl group, haloalkyl group being as defined above; alkylamino denotes a NH-alkyl or N-di alkyl group, the alkyl group being as defined above; and said alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl are optionally substituted by one or more suhstituents R". 14. A pharmaceutical composition comprising a compound according to the present invention, in particular according to any of the above items 1 to 13 or a physiologically functional derivative, solvate or salt thereof and one or more pharmaceutically acceptable excipients for the use in the treatment or prevention of a disease or medical condition caused by a viral infection. Furthermore, the present invention relates to a method of treatment or prevention of the medical conditions specified herein, which comprises the administration of an effective amount of a compound according to the present invention, or a physiologically functional derivative, solvate or salt thereof to a subject in need thereof.
Furthermore, the present invention relates to the use of a compound according to the present invention, or a physiologically functional derivative, solvate or salt thereof in the treatment or prevention of the medical conditions specified herein.
Furthermore, the present invention relates to the use of a compound according to the present invention, or a physiologically functional derivative, solvate or salt thereof for the manufacture of a medicament for use in the treatment or prevention of the medical conditions specified herein.
15. A method of treatment or prevention of a medical condition caused by a viral infection, which comprises the administration of an effective amount of a compound according to the present invention, in particular according to any of the above items 1 to 13, or a physiologically functional derivative, solvate or salt thereof to a subject in need thereof. 16. Use of a compound according to the present invention, in particular according to any of the above items 1 to 13, or a physiologically functional derivative, solvate or salt thereof in the manufacture of a medicament for the treatment or prevention of a medical condition caused by a viral infection.
17. Use of a compound according to the present invention, in particular according to any of the above items 1 to 13, or a physiologically functional derivative, solvate or salt thereof for the treatment or prevention of a medical condition caused by a viral infection.
18. The compound for the use, the pharmaceutical composition, the method, the use of said compound for treatment or the use of said compound for the manufacture of a medicament according to the present invention, in particular according to any of the above items 1 to 17, wherein said medical condition caused by a viral infection is caused by an infection with a virus from the family of herpesviridae. more particularly a virus selected from the group consisting of HCMV and HSV, even more particularly HCMV, and in another embodiment even more particularly HSV,
Particularly in the context of the present invention, HSV is selected from the group comprising HSV- 1 and HSV-2.
19. The compound for the use, the pharmaceutical composition, the method, the use of said compound for treatment or the use of said compound for the manufacture of a medicament according to the present invention, in particular according to any of the above items 1 to 1 7, wherein said medical condition caused by a viral infection ith HSV or HCMV.
The following definitions are meant to further define certain terms used in the context of the present invention. If a particular term used herein is not specifically defined, the term should not be considered to be indefinite. Rather, such terms are to be construed in accordance with
their meaning as regularly understood by the skilled artisan in the field of art to which the invention is directed, particularly in the field of organic chemistry, pharmaceutical sciences and medicine. As used herein, a "ring atom" represents an atom which is part of the cyclic structure of a ring or ring system, wherein this definition does not include hydrogen atoms or substituents bound to the ring or ring system. For example, a pyridine group comprises 6 ring atoms, i.e. one N atom and five C atoms; In the context of the present invention, and for reasons of legibility, chemical group names such as "aikyF, "aryl", "phenyl", "heteroaryl", "cycloalkyi", "heterocyclyl", etc., depending on the respective particular context, are meant to include terminal groups and connecting groups which are often referred to as "...ene" groups, such as for example "alkylene", "arylene", etc. Moreover, in the context of the present invention, the suffix "'-νΓ is in many cases omitted, which is not to be understood to delimit chemical names comprising said suffix from chemical names not comprising said suffix; for example "furyl", "furanyl" and "furane" are meant to be used interchangeably.
As used herein, the term "X'-azol moiety" refers to the below chemical entity, which is part of formular (I) according to the present invention:
As used herein, an alkyl group particularly encompasses alkanyl, alkenyl, alkynyl, wherein alkanyl means a completely saturated hydrocarbon chain, alkenyl means a hydrocarbon chain comprising at least one carbon-carbon double bond, alkynyl means a hydrocarbon chain comprising at least one carbon-carbon triple bond (including a hydrocarbon chain comprising one or more carbon-carbon double bonds and at least one carbon-carbon triple bond). In the context of the present invention, an alkanyl group, if not stated otherwise, particularly denotes a linear or branched Ci-CValkanyl, more particularly a linear or branched Ci-C5-aikanyi, even more particularly a linear or branched Ci-C4-alkanyl; an alkenyl group, if not stated
otherwise, particularly denotes a linear or branched CVCValkenyl, more particularly a linear or branched CVCValkenyl, even more particularly ethenyl; and an alkynyl group, if not stated otherwise, particularly denotes a linear or branched CVCValkynyl group, more particularly a linear or branched CVCValkynyl, even more particularly ethynyl. In certain particular embodiments the alky! group is selected from the group comprising methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tcrt-butyl. pentyl, hexyl, ethenyl, ethynyl, propen-l -yl. propen-2-yl, propen-3-yl. -C≡C-CH3, and -CH2-C≡CH. The alkyl, alkanyl, alkenyl, and alkynyl groups as defined above, including the groups enumerated as examples and particular or otherwise farther defined embodiments thereof, are optionally substituted by one or more substituents R".
As used herein, the term "aryl" particularly denotes an aromatic mono-or polycyclic hydrocarbon ring system, which may optionally be fused to one or more cycloalkyl or heterocycloalkyl rings, and wherein the total number of ring atoms in the aryl group is 6 to 14, particularly 6 to 10, more particularly 6. The point of attachment of said aryl group to the central moiety may be located on the aromatic mono-or polycyclic hydrocarbon ring system r on the optionally fused cycloalkyl or heterocycloalkyl ring. Examples of the aryl group are phenyl, naphthyl, indenyl, azulenyl, fluorenyl, 1 ,2-dihydronaphthyl. 1,2,3,4- tetrahydronaphthyl , 2,3-dihydroindenyl, 1 ,5-dihydro-s-indacenyl, 1,6-dihydro-as-indacenyl, 1 H-cyclopenta[a]naphthyl and 1 H -cyclo penta j b j naphthyl , phenalenyl, phenanthrenyl anthracenyl, 1.6-dihydropentalcnyl, 1 ,6a-dihydropentalenyl, 1.2,3 ,4-tetrahydroanthracenyl , 1 ,2,3 ,4-tetrahydrophenanthrenyl, 2.3-dihydro-l H-cyclopenta[a]naphthalenyl, 2,3-dihydro- l H- cyclopenta[b]naphthalenyl, 2,3-dihydro- 1 H -phenalenyl, 2,3 -dihydrobenzo[b]thiophcnyl- 1.1 - dioxide, 1.2,3.4-tetrahydroisoquinolinyl. 1 ,2,3,4-tetrahydroquinolinyl, 2,3- dihydrobcnzo[b][ 1 ,4]dioxinyl, 2,3-dihydrobcnzo[b]thiophenyl, 2,3 -dihydrobenzofuranyl , benzo[d][ 1.3]dioxolyl, chromanyl, indazolinyl and indolinyi. In particular embodiments, the aryl group is phenyl, 2,3-dihydrobenzo[b][l ,4]dioxinyl, 2.3-dihydrobenzofuranyl or benzo[d][ l,3]dioxolyl, more particularly phenyl. The aryl groups as defined above, including the groups enumerated as examples and particular or otherwise further defined embodiments thereof, are optionally substituted by one or more substituents R".
As used herein, the term "halophenyf ' particularly denotes a phenyl group substituted with one or more halogen atoms, particularly with one halogen atom.
As used herein, the term "heteroaryl" particularly denotes an aromatic mono-or polycyclic hydrocarbon ring system wherein one or more carbon atoms are replaced by heteroatoms independently selected from the group comprising O, N and S, wherein the aromatic mono-or polycyclic hydrocarbon ring system may optionally be fused to one or more cycloalkyl or heterocycloalkyl rings, and wherein the total number of ring atoms in the heteroaryl group is 5 to 14, particularly 5 to 10, more particularly 5 or 6. The point of attachment of said heteroaryl group to the central moiety may be located on the mono-or polycyclic aromatic hydrocarbon ring system or on the optionally fused cycloalkyl or heterocycloalkyl ring. Examples of the heteroaryl group are furan-2-yl. furan-3-yl, thiophen-2-yl, thiophen-3-yl, thiazol-4-yl, pyrazol-3-yl, pyrazol-4-yl, oxa/ol-4-yl, oxazol-5-yl, isoxazol-4-yl. isoxazol-5-yl, pyrazin-2- yl, pyridin-2-yl. pyridin-3-yl, pyridin-4-yl, pyrrol -2-yl. 1 ,2.3-thiadiazol-5-yl, 1 ,2,4-thiadiazol- 3-yl, benzothiophen-3-yl, l ,2,3-triazol-4-yl, l ,2,4-triazol-5-yl, quinolin-2-yl, , thiazol-2-yl, thiazol-5-yl, isothiazol-3-yl. isothiazol-4-yl, isothiazol-5-yl, oxazol-2-yl, isoxazol-3-yl, 1 ,2,4- oxadiazol-3-yl, l ,2,4-oxadiazol-5-yl, 1 ,2,5-oxadiazol-3-yl. 1 ,2,5-oxadiaz.ol-4-yl, 1.2,3- oxadiazol-4-yl, l ,2,3-oxadiazol-5-yl, 1 ,3,4-oxadiazol-2-yl, 1 ,2,4-thiadiazol-5-yl, 1 ,2,5- thiadiazol-3-yl, l ,2,5-thiadiazol-4-yl, 1 ,3.4-thiadiazol-2-yl, l ,2,3-thiadiazol-4-yl, pyrrol- 1 -yl, pyrrol-3-yl, pyrazol-l -yl, purin-2-yl , purin-6-yl, purin-8-yl, purin- -yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrimidin-6-yl, imidazol- l -yl, imidazol-2-yl, imidazol-4-yl, l ,2,3-triazol-5-yl, l ,2,4-triazol-3-yl, furan-2-yl, benzo[b]furanyl, quinolinyl, isoquinolinyl, indol-2-yl, indol-3-yl, isoindol- l -yl, isoindol-3-yl, indol-2-yi.indol-3-yl, purin-2-yl. In particular embodiments, the heteroaryl group is selected from the group comprising furan-2- yl, thiophen-3-yl, pyiimidin-2-yl, or pyrimidin-6-yl, and pyridine-4-yl. In other particular embodiments, the heteroaryl group is selected from the group comprising furan-2-yl, thiophen-3-yl, pyrimidin-2-yl, pyrimidin-6-yl, pyridine-4-yl, l//-imidazol-2-yl, lH- 1 ,2,4- triazol-5-yl, I H-bcnzo | r/j imidazol-2-yl , pyridin-2-yl, lH-imidazol-2-yl, 1 ,3,4-thiadiazol-2-yl, lH-pyrazol-3-yl, l ,3-thiazol-2-yl, 1 ,2,4-thiadiazol-3-yl, l,3,4-thiadiazol~2-yl, 1 ,2,4- thiadiazol-5-yl, 1.3-oxazol-2-yl and l ,2.4-oxadiazol-3-yl.
The heteroaryl groups as defined above, including the groups enumerated as examples and particular or otherwise further defined embodiments thereof, are optionally substituted by one or more substituents R",
As used herein, the term "cycloalkyl" particularly denotes a non-aromatic, mono- or polycyclic completely saturated or partially unsaturated hydrocarbon ring system. Said
cycloaikyl is particularly mono- or bicyclic, more particularly monocyclic. Said cycloaikyl is particularly completely saturated. Said cycloaikyl particularly comprises 3 to 10 carbon atoms, more particularly 3 to 7, even more particularly 3 to 6 carbon atoms. Even more particularly, said cycloaikyl is selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohe.xyl, eycloheptyl, 1 -norbornyl, 2-norbonryl, 7-norbornyl, 1-adamantyl, and 2-adamantyl, yet even more particularly said cycloaikyl is cyclohexyl. The cycloaikyl groups as defined above, including the groups enumerated as examples and particular or otherwise further defined embodiments thereof, are optionally substituted by one or more substituents R*. and 0, 1 or 2, particularly 0 or 1, more particularly 0 of the ring carbon atoms are attached to an oxygen atom via a double bond to form a carbonyl group.
As used herein, the term "heterocyeloalkyl" particularly denotes a non-aromatic mono- or polycyclic completely saturated or partially unsaturated hydrocarbon ring system, wherein one or more, particularly 1 to 3, more particularly 1 or 2 of the ring carbon atoms are replaced by a heteroatom independently selected from N, O, or S. Said heterocyeloalkyl is particularly mono- or bicyclic, more particularly monocyclic. Said heterocyeloalkyl is particularly completely saturated. Said heterocyeloalkyl particularly is a 5- to 10-membered mono- or polycyclic ring system, more particularly 5- to 7-membered monocyclic ring system, even more particularly 5- or 6-membered monocyclic ring system. Even more particularly said heterocyeloalkyl is selected from the group comprising morpholinyl, piperidinyl, pyrrolidinyl, and piperazinyl. The heterocyeloalkyl group as defined above, including the groups enumerated as examples and particular or otherwise further defined embodiments thereof, are optionally substituted by one or more substituents ' as described herein, and 0, 1 or 2, particularly 0 or 1, more particularly 0 of the ring carbon atoms are attached to an oxygen atom via a double bond to form a carbonyl group.
As used herein, the term "halo" or "halogen" particularly independently denotes fluorine, chlorine, bromine or iodine, more particularly bromine, chlorine or fluorine, even more particularly chlorine or fluorine.
As used herein, the term "haloalkyl" denotes an alkyl group wherein one or more, particularly at least hall; more particularly all of the hydrogen atoms on the hydrocarbon chain are replaced by halogen atoms. . The haloalkyl group is particularly selected from the group comprising -C(RI0)3, -CH2-C(R10)3, -C(R10)2-CH3, -C(R10)2-C(R10)3, -C(R10)2-CH(R10)2, -
CH2-CH(R,0)2, -CH(R10)-C(RS0)3, -CH(R I 0)-CH3, and -C2H4-C(R10)3, more particularly -
C(R"')3. wherein R10 represents halogen, particularly F. More particular haloalkyl groups are - CF3, -CH2CF3, and CF2C1. As used herein, the term "alkoxy" denotes an O-alkyl group, the alkyl group being defined as defined above. The alkoxy group is particularly selected from the group comprising mcthoxy and ethoxy.
As used herein, the term "alkylthio" denotes an -S-alkyl group, the alkyl group being as defined above.
As used herein, the term "haloalkoxy" denotes an O-haloalkyl group, haloalkyl group being defined as defined above. The haloalkoxy group is particularly selected from the group comprising -OC(R10)3, -OCR10(RI 0')2, -OCH2-C(R10)3, and -OC2H4-C(R10)3, wherein R10, R 1 "' represent F, CI, Br or I, particularly F.
As used herein, the term "alkylamino" denotes a NH-alkyl or N-dialkyl group, the alkyl group being as defined above. As used herein, the term "arylalkyl" or "aralkyi" particularly denotes a linear or branched Cp
Cf,-alkyl, more particularly Cj-4-alkyl, even more particularly C].2-alkyl, yet even more particularly methyl, wherein "alkyl" is as defined herein, substituted with at least one, particularly exactly one, aryl group as defined herein. Exemplary arylalkyl groups include styryl, benzyl, phenylethyl, particularly the arylalkyl group is styryi or benzyl, particularly optionally substituted at its phenyl part as defined above for the aryl group.
Where chemically feasible from the viewpoint of molecule stability and/or chemical valence rules, a nitrogen heteroatom as defined herein, e.g. in the context of "heteroaryl" and "heterocycle", may include the N-oxide.
Where chemically feasible from the viewpoint of molecule stability under physiological conditions and/or chemical valence rales, the definition of a sulfur heteroatom as defined herein, e.g. in the context of "heteroaryl" and "heterocycle", may include the sulfur oxide and/or the sulfur dioxide, respectively.
For sake of completeness, it is mentioned that "morpholine-4-carbonyl" is a group -CO- morpholine-4-yl. As used herein the term "substituted with" or ..substituted by" means that one or more hydrogen atoms connected to a carbon atom or heteroatom of a chemical group or entity arc exchanged with a substituent group, respectively; e.g. substituted aryl comprises 4- hydroxyphenyl. wherein the H-atom in the 4-position of the phenyl group is exchanged with a hydroxy! group. Said hydrogen atom(s) to be replaced may be attached to a carbon atom or heteroatom, and may be expressly shown in a specific formula, such as for example in an -NH- group, or may not expressly be shown but intrinsically be present, such as for example in the typical "chain" notation which is commonly used to symbolize e.g. hydrocarbons. The skilled person will readily understand that particularly such substituents or substituent patterns are excluded, which lead to compounds witch are not stable and/or not accessible via the synthesis methods known in the art.
Unless specified otherwise, references to the compounds according to the present invention include the pharmaceutically acceptable derivatives, solvates or salts thereof as described herein, as well as to salts of said pharmaceutically acceptable derivatives, solvates of salts and pharmaceutically acceptable derivatives, and optionally solvates of salts of pharmaceutically acceptable derivatives.
As used herein, the term "pharmaceutically acceptable derivative"' of a compound according to the present invention is for instance a prodrug of said compound, wherein at least one of the following groups are derivatized as specified in the following: A carboxylic acid group is derivatized into an ester, a hydroxy! group is derivatized into an ester, a carboxylic acid is derivatized into an amide, an amine is derivatized into an amide, a hydroxy! group is derivatized into a phosphate ester. To clarify, the term "pharmaceutically acceptable derivative" is in certain embodiments analogous to the term "physiologically functional derivative".
As used herein, the term "tautomer" used in reference to the compounds according to the present invention, in particular includes tautomers that typically form with respect to substituted benzi mid azoic groups. As an illustration two tautomeric forms of an exemplary
substituted benzimidazole moiety, as is present in the compounds according to the present invention, are shown:
The compounds according to the present invention are to be understood to comprise all tautomeric forms thereof, even if not expressly shown in the formulae described herein, including formula (I). Throughout this specification, whenever a chemical formula, generic or otherwise, discloses a compound having a 4H-1 .2.4-triazole moiety that is at least partially unsubstituted, as shown on the left-hand side of the above exemplary illustration, said chemical formula it is to be understood to implicitly also relate to compounds wherein said moiety is tautomerized to form the structure as shown on the right-hand side of the above exemplary illustration.
The compounds of formula (I) as defined herein are to be understood to encompass, where applicable, all stereoisomers of said compounds, unless specified otherwise. The term "stereoisomer" as used herein refers to a compound with at least one stereogenic centre, which may be R- or S-configured, as defined by the according IUPAC rules, and encompasses enantiomcrs and diastereomers as commonly understood by the skilled person. It has to be understood, that in compounds with more than one stereogenic centre, each of the individual stereogenic centres may independently from each other be R- or S-configured. The term "stereoisomer" as used herein also refers to salts of the compounds herein described with optically active acids or bases.
In the present invention, the salts of the compounds according to the present invention are in particular embodiments pharmaceutically acceptable salts of the compounds according to the present invention. Pharmaceutically acceptable salts are such salts which are usually considered by the skilled person to be suitable for medical applications, e.g. because they are not harmful to subjects which may be treated with said salts, or which give rise to side effects
which arc tolerable within the respective treatment. Usually, said pharmaceutically acceptable salts are such salts which are considered as acceptable by the regulatory authorities, such as the US Food and Drug Administration (FDA), the European Medicines Agency (EM A), or the Japanese Ministry of Health. Labor and Welfare Pharmaceuticals and Medical Devices Agency (PMDA). However, the present invention in principle also encompasses salts o the compounds according to the present invention which are as such not pharmaceutically acceptable, e.g. as intermediates in the production of the compounds according to the present invention or physiologically functional derivatives thereof, or as intermediates in the production pharmacologically acceptable salts of the compounds according to the present invention or physiologically functional derivatives thereof.
In each case, the skilled person can readily determine whether a certain compound according to the present invention or pharmaceutically acceptable derivative there f can form a salt, i.e. whether said compound according to the present invention or pharmaceutically acceptable derivative or solvate thereof has a group which may carry a positive or negative charge, such as e.g. an amino group, a carboxylic acid group, etc..
Exemplary salts of the compounds of the present invention are acid addition salts or salts with bases, particularly pharmacologically tolerable inorganic and organic acids and bases customarily used in pharmacy, which are either water insoluble or. particularly, water-soluble acid addition salts. Salts with bases may - depending on the substituents of the compounds of the present invention - also be suitable.
Pharmacologically intolerable salts, which can be obtained, for example, as process products during the preparation of the compounds according to the invention on an industrial scale, are also encompassed by the present invention and, if desired, may be converted into pharmacologically tolerable salts by processes known to the person skilled in the art.
According to expert's knowledge the compounds of the invention as well as their salts may contain, e.g. when isolated in crystalline form, varying amounts of solvents. Included within the scope of the invention are therefore solvates and in particular hydrates of the compounds of the present invention as well as solvates and in particular hydrates o the salts and/or physiologically functional derivatives of the compounds of the present invention. More particularly the invention encompasses hydrates of the compounds, salts and/or physiologically functional derivatives according to the present invention, comprising one, two or one half water molecule, with respect to their stoichiometry.
As used herein, a "solvate" is a complex formed in the crystalline state between one or more compounds according to the present invention (or pharmaceutically acceptable derivative or salt thereof) and one or more solvent molecules. In certain embodiments, such solvates are 1 :2, 2: 1 or 1 : 1 , more particularly 1 : 1 stoichiometric complexes. Furthermore, in certain embodiments, complexes, such solvates are formed with a solvent selected from the group comprising water, methanol, ethanol or propanol, particularly water, methanol or ethanol, more particularly water (the latter is typically also known under the term "hydrate").
As used herein, the term "room temperature", "rt" or "r.t." relates to a temperature of about 25°C, unless specified otherwise.
As used herein, the term "stable" particularly relates to a compound in which the chemical structure is not altered when the compound is stored at a temperature from about -80 °C to about +40 °C, more particularly from about -80 °C to +25 °C in the absence of light, moisture or other chemically reactive conditions for at least one week, more particularly at least one month, even more particularly at least six months, yet even more particularly, at least one year, and/or a compound which under lUPAC standard conditions and in the absence of light, moisture or other chemically reactive conditions maintains its structural integrity long enough to be useful for therapeutic or prophylactic administration to a patient, i.e. at least one week. Stable in this context mean that under the aforementioned conditions and time periods and compared with the the timepoint 0, i .e. when it was produced, the amount of impurities has increased by less than 2%, particularly less than 1 % more particularly less thatn 0.5%, which can e.g. be determined by analytic HPLC or LC-MS, or the like. Compounds which are not stable as described above are usually to be considered not encompassed by the present invention. In particular, such compounds which at IUPAC standard conditions spontaneously decompose within a period of less than one day are regarded as not being stable compounds. The skilled person will readily recognize, based on his general knowledge in his field of expertise, which compounds and which substitution patterns result in stable compounds.
As used herein, the term "treatment" of a disease or medical condition includes complete or partial healing of a disease, prevention of a disease, alleviation of a disease or stop of progression of a given disease.
"Prevention" in particular includes that the compounds of the present invention are administered to a subject before the viral infection occurs. "Prevention" further includes that
the compounds of the present invention are administered to a subject after the viral infection occurs, but before the onset of symptoms of the disease or medical condition.
In the context of the present invention, the "subject" is particularly a mammal, more particularly a human subject. As used herein, the term "medicament" includes the compounds of the present invention, pharmacologically acceptable salts or physiologically functional derivatives thereof, which are to be administered to a subject in pure form, as well as compositions comprising at least one compound according to the present invention, a pharmacologically acceptable salt or physiologically functional derivative thereof, which is suitable for administration to a subject. The compounds according to the present invention and their pharmacologically acceptable salts and physiologically functional derivatives can be administered to animals, particularly to mammals, and in particular to humans as therapeutics per se, as mixtures with one another or particularly in the form of pharmaceutical preparations or compositions which allow enteral (e.g. oral) or parenteral administration and which comprise as active constituent a therapeutically effective amount of at least one compound according to the present invention, or a salt or physiologically functional derivative thereof, in addition to e.g. one or more components selected from the group comprising customary adjuvants, pharmaceutically innocuous excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries. The pharmaceutical compositions, medical uses and methods of treatment according to the present invention may comprise the more than one compound according to the present invention.
Pharmaceutical compositions comprising a compound according to the present invention, or a pharmaceutically acceptable salt or physiologically functional derivative may optionally comprise one or more further therapeutically active substances which are not compounds of the present invention. As used herein, the term "therapeutically active substance" specifies a substance which upon administration can induce a medical effect in a subject. Said medical effect may include the medical effect described herein for the compounds of the present invention, but may also, in the case of therapeutically active substances which are to be co- administered with the compounds according to the present invention, include other medical substances, such as for example but not exclusively adamantin, rimantadin, ose amivir,
zanamivir, zidovudine, didanosine, zalcitabine, stavudine, abacavir, entecavir, apricitabine, tenofovir, adefovir, efavirenz, nevirapine, delafiridine, etravirinc. rilpvirine and lamivudine, emtricitabine, ribavirin, interferone alpha (pegylated or non-pegylated), telbivudin. aciclovir, valaciclovir, ganciclovir, valganciclovir, brivudin, penciclovir. The term "pharmaceutically acceptable" is well known to the skilled person and particularly means that the respective entity is not harmful to the subject to which the entity or the composition comprising the entity is administered, that said entity is stable and that said entity is chemically compatible (i.e. non-reactive) with other ingredients of the respective pharmaceutical composition. Medicaments and pharmaceutical compositions according to the present invention, comprising at least one compound according to the present invention or a pharmacologically acceptable salt or a physiologically functional derivative therof include those suitable for oral, rectal, bronchial, nasal, topical, buccal, sub-lingual, vaginal or parenteral (including transdermal, subcutaneous, intramuscular, intrapulmonary, intravascular, intracranial, intraperitoneal, intravenous, intraarterial, intracerebral, intraocular injection or infusion) administration, or those in a form suitable for administration by inhalation or insufflation, including powders and liquid aerosol administration, or by controlled release (e.g. sustained release, pH-controlled release, delayed, release, repeat action release, prolonged release, extended release) systems, particularly for oral, topical or rectal administration. Suitable examples of controlled release systems include semipermeable matrices of solid hydrophobic polymers containing the compound of the invention, which matrices may be in form of shaped articles, e.g. films or microcapsules or colloidal drug carriers e.g. polymeric nanoparticles, or controlled release solid dosage forms, e.g. core tablets or multi-layer tablets.
The production of medicaments or pharmaceutical compositions comprising the compounds according to the present invention and their application can be performed according to methods which are well-known to the medical practitioner.
Pharmaceutically acceptable carriers used in the preparation of a pharmaceutical composition or medicament comprising a compound according to the present invention, a pharmacologically acceptable salt or physiologically functional derivative thereof, can be either solid or liquid. Solid form pharmaceutical compositions comprising a compound according to the present invention, a pharmacological 1 y acceptable salt or physiologically functional derivative thereof, include powders, tablets, pills, capsules, sachets, suppositories,
and dispersible granules. A solid carrier may comprise one or more components, which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired. The tabletting mixture can be granulated, sieved and compressed or direct compressed. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatine, tragacanth, methylcellulose, sodium carboxymcthylccllulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it. Similarly, sachets and lozenges are included. Tablets, powders, capsules, pills, sachets, and lozenges can be used as solid forms suitable for oral administration.
For preparing suppositories, a low melting wax, such as a mixture of fatty acid glyceride or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into conveniently sized moulds, allowed to cool, and thereby to solidify. Compositions suitable for vaginal administration may be presented as peccaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate. Liquid preparations include solutions, suspensions, and emulsions, for example, water or water- propylcnc glycol solutions. For example, parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution. The compounds according to the present invention may be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre- filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulation agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for re-constitution with a suitable vehicle, e.g. sterile, pyrogen- free water, before use.
Aqueous solutions suitable for oral administration can be prepared by dissolving the active component in water and adding for example suitable colorants, flavours, stabilizing and thickening agents, as desired. Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.
Also included are solid form preparations, which are intended to be converted, shortly before administration, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, for example colorants, flavours, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
In an embodiment f the present invention the medicament is applied topically, e.g. in the form of transdermal therapeutic systems (e.g. patches) or topical formulations (e.g. liposomes, cremes, ointment, lotion, gels, dispersion, suspension, spray, solution, foam, powder). This may be suitable to reduce possible side effects and. where appropriate, limit the necessary treatment to those areas affected.
Particularly the medicament may comprise carrier materials or excipients, including but not limited to a lipophilic phase (as for example Vaseline, paraffines, triglycerides, waxes, polyalcylsiloxanes), oils (olive oil, peanut oil. castor oil, triglyceride oil), cmulsificr (as for example lecithin, phosphat idylgl ycerol es, alkyl alcohols, sodium lauryl sulfate, polysorbats, Cholesterol, sorbitan fatty acid ester, polyoxyethylene fatty acid glycerol and -ester, poloxamers), preservatives (for instance benzalkonium chloride, chlorobutanol, parabene or fhiomersal), flavouring agents, buffer substances (for example salts of acetic acid, citric acid, boric acid, phosphoric acid, tatric acid, trometamole or trolamine), solvents (for instance po 1 yethyi eng) ycol s, glycerol, ethanol, isopropanol or propyleneglycol) or solubilizers, agents for achieving a depot effect, salts for modifying the osmotic pressure, carrier materials for patches (for instance polypropylene, ethy!ene-vinylacetat-copolymer, polyacrylates, silicon) or antioxidants (for example ascorbate, tocopherol, butylhydroxyanisole, gallic acid esters or butylhydroxytoluol). Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be fonnulated with an aqueous or oily base and will in general also contain one or more emulsifying agents,
stabilizing agents, dispersing agents, suspending agents, thickening agents, or colouring agents.
Compositions suitable for topical administration in the mouth include lozenges comprising the active agent in a flavoured base, usually sucrose and acacia or tragacanth: pastilles comprising the active ingredient in an inert base such as gelatine and glycerine or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
Solutions or suspensions may be applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray. The compositions may be provided in single or multi-dose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomizing spray pump.
Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurized pack with a suitable propel] ant such as a chlorofluorocarbon (CFC), for example dichlorodiftuoromcthane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas. The aerosol may conveniently also contain a surfactant such as lecithin. The dose f drug may be controlled by provision of a metered valve.
Alternatively the medicament may be provided in the form of a dry powder, for example a powder mix o the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP). Conveniently the powder carrier will form a gel in the nasal cavity. The powder composition may be presented in unit dose form, for example in capsules or cartridges of, e.g., gelatine, or blister packs from which the powder may be administered by means of an inhaler. in compositions for administration to the respiratory tract, including intranasal compositions. the compound will generally have a small particle size for example of the order of 5 microns or less. Such a particle size may be obtained by means known in the art, for example by microni/.ation.
When desired, compositions adapted to give sustained release of the active ingredient may be employed.
The pharmaceutical preparations are particularly in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packaged tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, sachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form. Tablets or capsules for oral administration and liquids for intravenous administration and continuous infusion are particular compositions.
Further details on techniques for formulation and administration may be found in the 21st edition of Remington's Pharmaceutical Sciences (Maack Publishing Co. Easton, Pa.).
The compounds of the present invention may be used in combination with radiation therapy, or in combination with radiation therapy and other active compounds, already known for the treatment of the medical conditions disclosed herein, whereby a favourable additive or amplifying effect is noticed. To prepare the pharmaceutical preparations, pharmaceutically inert inorganic or organic excipients can be used. To prepare pills, tablets, coated tablets and hard gelatine capsules, for example, lactose, cornstarch or derivatives thereof, talc, stearic acid or its salts, etc. can be used. Excipients for soft gelatine capsules and suppositories are, for example, fats, waxes, semi-solid and liquid polyols, natural or hardened oils etc. Suitable excipients for the production of solutions and symps are, for example, water, sucrose, invert sugar, glucose, polyols etc. Suitable excipients for the production of injection solutions are, for example, water, alcohols, glycerol, polyols or vegetable oils.
The dose can vary within wide limits and is to be suited to the individual conditions in each individual case. For the above uses the appropriate dosage will vary depending on the mode of administration, the particular condition to be treated and the effect desired, in general, however, satisfactory results are achieved at dosage rates of about 1 to 100 mg kg animal body weight particularly 1 to 50 mg/kg. Suitable dosage rates for larger mammals, for example humans, are of the order of from about 10 mg/day to 500 mg/day, conveniently administered once, in divided doses 2 to 4 times a day, or in sustained release form. The compounds of the present invention are suitable for the treatment or prevention of a disease or medical condition caused by a viral infection.
It is apparent that the embodiments of the present invention as described herein may be combined to form further particular embodiments of the present invention.
Examples Methods for the synthesis of compounds of the present invention is known to the skilled person and described in WO 2014/202638 Al , as well as their potency in the inhibition of DYRK Kinase, and the hedgehog pathway.
Cell culture and virus: Primary human foreskin fibroblasts (HFF) were cultivated in minimal essential medium (MEM) containing 5% (vol/vol) fetal calf serum. Infection analysis was restricted to cell passage numbers below 20. HCMV strain AD 169 was grown in HFF and quantitated for infectivity by a plaque reduction assay. Aliquots were stored at -80°C.
GFP-based antiviral assay:
HFF were cultivated in 12-well plates to 90% confluency and used for infection with AD 169- GFP virus at a tissue culture infective dose of 0.5 (GFP-TCID50 0.5, referring to an MOI of 0.002 as determined by plaque assay titration). Virus inoculation was performed as described above. Then infected cell layers were incubated with 2.5 ml of MEM containing 5% (vol/vol) fetal calf serum with or without the respective test compound. Infected cells were incubated at 37°C under a 5% CO: atmosphere for 7 days. For lysis, 200 ml of lysis buffer (25 mM Tris [pH 7.8], 2 mM dithiothreitol [DTT], 2 mM trans- 1,2-di minocyclohexane-N,N,N9,N9- tetraacetic acid, 1% Triton X-100, 10% glycerol) was added to each well and incubated for 10 min at 37°C, followed by a 30-miii incubation at room temperature on a shaker. Lysates were eentriftiged for 5 min at 15,000 rpm in an Eppendorf centrifuge to remove cell debris. One hundred microliters of the supernatants was transferred to an opaque 96-well plate for automated measuring of GFP signals in a Victor 1420 Multilabel Counter (Wallac). The efficacy of the test compounds against virus was determined by comparing the compound- treated samples with the untreated infection control.
Cytotoxicity assay:
HFF were cultivated in 48-well plates until contluency was reached. Antiviral compounds were added and cells were incubated at 37°C for 7 days, before a measurement of the lactate dehydrogenase (LDH) activity in the residual cell layer was performed by use of the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega). For this, culture media were removed, and cells were rinsed with PBS and lysed in a concentration of the kit lysis buffer (100 ml per well). After incubation for 45 min at 37°C, the cell debris was removed by centrifugation and 10 ml of each lysate was diluted in a total of 50 ml of PBS for the determination of LDH activity. Fifty microliters of substrate mix was added to each well and incubated for 30 min at room temperature in the dark. Thereafter, 50 ml of stop buffer was added, and the color reaction was quantitated by use of an enzyme-linked immunosorbent assay (ELISA) reader (optical density [OD] at 490 nm).
11SV virus neutralization assay:
Neutralizing activities of the antiviral compound were determined by endpoint dilution assay as described previously (Krawczyk A. et al., J Virol. 201 1 ;85(4): 1793-803). Briefly, one day before infection. Vcro cells (2 x 104 per well) were seeded into a
culture plate in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated FBS, 100 U/rnl penicillin and 100 ^πιΐ streptomycin. Next day, serial dilutions of Aciclovir (Ratiopharm, Ulm, Germany) or compound 5 (3-400μΜ) in Dulbecco's modified Eagle's medium (DMEM) supplemented with 2% heat-inactivated FBS, 100 U/nil penicillin and 100 g/ml streptomycin were incubated with 100 TCID50 of HSV-1 F, HSV-2 G or an Aciclovir- resistant clinical isolate for 2 days at 37°C on Vero cell monolayers. After two days, cell cultures were screened for plaque formation. The drug concentration required for reducing virus-induced cytopathic effect (CPE) by 100% was determined as the complete
neutralization titer.
For control purposes, virus without Aciclovir/compound 5 or Aciclovir/compound 5 alone, respectively, were used to induce maximal CPE and no CPE, respectively. Virus
neutralization assays were repeated at least twice with similar results.
The following HSV-strains were used:
HSV-1 F: Herpes simplex virus type 1 , strain F: Aciclovir-sensitive wild-type lab strain. HSV-1 RIO: Herpes simplex virus type 1, clinical isolate: shows resistance to Aciclovir,
Foscarnet and Cidofovir.
HSV-2 G: Herpes simplex virus type 2, strain G: Aciclovir-sensitive wilde-type lab strain. HSV-2 R6: Herpes simplex virus type 2 clinical isolate: Aciclovir-resistant.
The results are shown in the following tables, wherein an X marks plaque format ion and thus cell lysis by viral infection, whereas an empty space indicates absence of cell lysis and thus virus neutralization :
Table l a: HSV- 1 F vs. Aciclovir
It is shown that, in addition to Aciclovir-sensitive strains, compound 5 is able to neutralize Aciclovir-resistant HSV-1 and HSV-2 strains.
Claims
1. A compound of the general formula (I) or a physiologically functional derivative, solvate or salt thereof for the use in the treatment or prevention of a disease or medical condition caused by a viral infection,
wherein the X -azol moiety is attached at the 5- or 6- position of the 2,3- dihydrobenzo furan mioety, n is an integer from 0 to 2: m is an integer from 0 to 3; p is an integer from 0 to 4;
R1 is independently selected from the group comprising H, halogen, alkyl, aralkyl. haloalkyl, haloalkoxy, OH, alkoxy, -CN, aryl, heteroaryl, cycloalkyi, heterocycloalkyl, -S-R\ -SO-R', nitro, -NH2, -N(R')2, -NH(R'), -NHCO(R'), -CON¾, -CONH(R'), -CO(R'), -COM, -COO(R'), -COOH, -S02NH2, -S02NH(R'), -S02(R\), -NH-S02(R') and -NHCOOR* ;
R2 is independently selected from the group comprising H, halogen, alkyl, aralkyl, haloalkyl, haloalkoxy, OH. alkoxy, -CN, aryl, heteroaryl, cycloalkyi, heterocycloalkyl, -S-R\ -SO-R", nitro, -NH2, -N(R')2, -NH(R'), -NHCO(R'), -CONH2, -CO H(R'), -C (R '). -COH, -COO(R'), -COOH, -S02N¾, -S02NH(R'), -S02(R'), -NH-S02(R') and -NHCOOR';
R3 is independently selected from the group comprising H, halogen, alkyl, aralkyl, haloalkyl, haloalkoxy, OH, alkoxy, -CN, aryl, heteroaryl, cycloalkyl. heterocycloalkyl, -S-R\ -SO-R', nitro, -NH2, -N(R' )2, -NH(R'), -NHCO(R'), -CONH2, -CONH(R'), -C()( R" ). -COH, -COO(R'), -COOH, -SQ2NH2. -S02NI I(R" ), -S02(R'), -NH-S02(R' ) and -NHCOOR';
R4 is independently selected from the group comprising H, alkyl, aralkyl, haloalkyl, haloalkoxy, OH, alkoxy, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, -CONH2, -CONH(R'), -CO(R'), -COO(R'), and -S02( R");
X 1 is independently selected from the group comprising NR.", O or S;
Rn is independently selected from the group comprising H, alkyl, aralkyl, haloalkyl, haloalkoxy, OH, alkoxy, aryl. heteroaryl, cycloalkyl, heterocycloalkyl, -CONH2,
-CO H(R'), -CO(R'), -COO(R'), and -S02(R" );
A is a monocyclic or bicyclic heteroaromatic ring system consisting of 5 to 10 ring atoms, at least one of which is an N atom, wherein optionally one to three further ring atoms are heteroatoms independently selected from the group comprising O, S and N and wherein the remaining ring atoms are carbon atoms;
RA is independently selected from the group comprising H, halogen, CN, N02, alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, -OR", -CO-R', -COO-R", -CONH-R", -NHCO-R\ -CON(R')2. -NR.' CO-R', -NR'-CONR', -NR'-COOR", -S-R', -SO-R", -SO2-R', -NHSO2-R', -SO:NH-R\ -O-CO-NHR*, -O-CO-R'. -R'-O-R*. -R'- CO-R", -R'-NH-R', -R'-CONH-R', -R'-NHCO-R', -CONH-alkyl-O-R", -CONH-alkyl- R\ -NHCO-alkyl-O-R', -NHCO-alkyl-R\ -CO-R'-alkyl-R', -CO-R'-alkyl, N(R')2, -NHR', NH2, -S-R', -S-alkyl-R- and alkyl-R';
R' is independently selected from the group comprising H, alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl; wherein any of the aforementioned alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl may independently be substituted with one or more, particularly one to three, more particularly one or two substituents R", wherein R" independently selected from the group comprising
halogen, Ci-4-haloalkyl, Oil. C |..i-alkoxy, C1.4-
haloalkoxy, nitro, -NH2, -N(C,.4-alkyl)2, -NH(C1-4-alkyl), -NHCO(C,-4-alkyl), -CONH2, -CONH(C,-4-alkyl), -CO(C|-4-alkyl). -COH, -COO(C -alkyl), -COOH and -CN.
A compound for the use according to claim 1 , which is a compound of the general formula (I) or a physiologically functional derivative, solvate or salt thereof, wherein
R1 is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, triiluoromethyl, trifluoromethoxy, OH, methoxy, cthoxy, -CN, nitro, -NH2, -N(methyl)2, -NH-methyl. -NHCO-methyl, -CONH2, -CONH-methyl, acetyl, -COO-methyl, and COOH; and
R2 is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, triiluoromethyl, trifluoromethoxy, OH, methoxy, ethoxy, -CN, nitro, -Ni b, -N(methyl)2, -NH-methyl, -NHCO-methyl, -CONH2, -CONH-methyl. acetyl, -COO-methyl, and COOH
The compound for the use according to claim 1 or 2 or a physiologically functional derivative, solvate or salt thereof, wherein n is 0 and m is 0.
The compound for the use according to claim 1 , 2 or 3 or a physiologically functional derivative, solvate or salt thereof, wherein
R is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, triiluoromethyl, tri l uorom etho y , OH, methoxy, ethoxy, -CN, nitro, -NH2. -N(methyl )2. -NH-methyl. -NHCO-methyl. -CONH2, -CONH-methyl, acetyl, -COO-methyl, and -COOH.
The compound for the use according to any of claims 1 to 4 or a physiologically functional derivative, solvate or salt thereof, wherein R3 is I I.
The compound for the use according to any of claims 1 to 5 or a physiologically functional derivative, solvate or salt thereof, wherein
R4 is independently selected from the group comprising H, C^-alky!, C| .4-haloalkyl, OI L -CONH2, -CONH-d.B-alkyi, -CO-C1-3-aikyl, and -COO-C,.3-alkyl.
7. The compound for the use according to any of claims 1 to 6 or a physiologically functional derivative, solvate or salt thereof, wherein R4 is H.
The compound for the use according to any of claims 1 to 7 or a physiologically functional derivative, solvate or salt thereof, wherein
A is a monocyclic heteroaromatic ring system consisting of 5 or 6 ring atoms, or a bi cyclic heteroaromatic ring system consisting of 9 ring atoms, wherein at least one of the ring atoms is an N atom, wherein optionally one or two further ring atoms are N atoms
or one further ring atom is an O or S atom,
or one further ring atom is an N atom and one ring atom is an O or S atom,
and wherein the remaining ring atoms are carbon atoms,
wherein A is optionally substituted with one or two substituents RA selected from the group comprising H, CN. N02, NH2, N(alkyl)2, halogen OH, alkoxy, haloalkyl, alkyi, haloalkoxy, alkoxyalkyl, heterocycloalkyl, -heterocycloalkyl-alkyl, -heteiocycloalky!- COO-alkyl, heteroaryl, -COOH, -COO-alkyL aralkyl, aryl, -aryl -halogen. -CO- N(alkyl)2, -CONH-(alkyl), -CONH-alkyl-alkoxy, -CONH- cycloalkyl, -CONH-alkyl-heterocycloalkyl, -CO-hetcrocycloalkyl-alkyl- heterocycloalkyl, -CO-hctcrocycloalkyl, -CO-heteroaryl, -CO-aryl, -CO-alkyl, -S02- alky!. -S-alkyl, -S-alkyl-CQO-alkyl. and -S-aralkyl.
The compound for the use according to any of claims 1 to 8 or a physiologically functional derivative, solvate or salt thereof, wherein
A is a monocyclic or bicyclic heteroaromatic ring system selected from the group comprising thia/ole, oxazole, pyrazole, pyrrole, ben/oxazole, benzothiazole, benzimidazole, imidazole, triazole, pyrazine, triazine, pyrimidine, pyridine, thiadiazole, and oxadiazole,
wherein A is optionally substituted with a substituent RA selected from the group comprising H, CN, F, CI, Br, OH, C1-2-alkyl, Ci.2-alkoxy, CF3, OCF3, -COOH, -COO- (C] -2-alkyl), benzyl, phenethyl, phenyl, fluorophenyl, -CO-N(C,-2-alkyl)2, -CONH-(C,. 2-alkyl), -CONH-(C, .2-alkyl)-0(C, 2-alkyl), -CONH-(C3-5-cycloa!kyl), -CONH-(C,-2- alkyl -tctrahydro furyl ), -CO-piperazinyl-iC) 2-alkyl)-tetrahydrofuranyk -CO- morholinyl, -CO-pyrrolidinyl, -CO-(methyl-piperazinyl)-, -S02(Ci-2-alkyl), -S-(Ci-4- alkyl), -S-benzyl, -S-(chlorophenylmethyl), -S-phenethyl, -CO-thienyl, -CO-pyrrolyl, -
CO-piperidinyl, -CO-piperidinyl-COO-(Ci-2-alkyl), morpholinyl, C i -2 -al ky 1 pi pera/.i ny 1 , C1-2-alkylthiazolyl, pyridyl, -CO-phenyl, -S-(Ci-2-alkyl)-COO-(C1-2-alkyl), NH2, N(C,.2- alkyl)2, -CQ-C, 2-alkyl, -(Ci-2-alkyl)-0(C1 -2-a1kyl), and wherein, when A is benzoxazole, benzothiazole or benzimidazole, A may optionally further be substituted with a halogen atom, and wherein, when A is thiazole, A may optionally further be substituted with a methyl group
The compound for the use according to any of claims 1 to 9 or a physiologically functional derivative, solvate or salt thereof, wherein the X!-azol moiety is attached at the 5- position of the 2,3-dihydrobenzofuran mioety.
The compound for the use according to claim 1 or a physiologically functional derivative, solvate or salt thereof, wherein the X'-azol moiety is attached at the 5- position of the 2,3-dihydrobenzofuran mioety; n is 0 or 1 ; m is 0 or 1 ;
X1 is independently selected from the group comprising NR.", O or S;
Rn is independently selected from the group comprising H, methyl, ethyl, OH, -CONH2, -CONH-methyl, and -COO-methyl;
R1 is independently selected from the group comprising I I, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, OH, methoxy, ethoxy, -CN, nitro, -NI 12, -N(methyi)2, -NH-methyl, -NHCO-methyl, -CONH2, -CONH-methyl, acetyl, -COO-methyl, and COOH:
R2 is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, OH, methoxy, ethoxy, -CN, nitro. -NI I2, -N(mcthyl)2, -NH-methyl, -NHCO-methyl, -CONH2, -CONH-methyl, acetyl, -COO-methyl. and -COOH:
R is independently selected from the group comprising H, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trifluoromethoxy, Oi l, methoxy, ethoxy, -CN, nitro, -NH2, -N(methyl)2, -NH-methyl, -NHCO-methyl, -CONH2, -CONH-methyl, acetyl, -COO-methyl, and -COOH;
R4 is independently selected from the group comprising H, Ci-3-alkyl, Ci-j-haloalkyl,
OH, -CONH2, -CONH-CJ-3-alkyL -CO-C1-3-alkyl, and -COO-C,. alkyl;
A is independently selected from the group comprising thiazoie, oxazole, pyrazole, pyrrole, benzoxazole, benzothiazole, benzimidazole, imidazole, triazoie, pyrazine, triazine, pyrimidine, pyridine, thiadiazole, and oxadiazole; wherein A is optionally substituted with a substituent RA selected from the group comprising H, CN, F, CI, Br, OH, C1-2-alkyl, CY2-alkoxy, CF3, OCF3? -COOH. -COO- (C . -alkyl). benzyl, phenethyl, phenyl, fluorophenyl. -CO-N(Ci.2-aikyl)2, -CO H-(C|. 2-alkyl), -CONH-(C , .2-alkyl)-0(C , .2-alkyl), -CONH-(C3.5-cycloalkyl), -CONH-ld - alkyl-tetrahydrofuryl), -CO-piperazinyl-(Ci.2-alkyl)-tetnihydroturanyl, -CO- morholinyl, -CO-pyrrolidinyl, -CO-(metliyl-piperazinyl)-, -S02(Ci-2-alkyl), -S-(C1-4- alkyl), -S-benzyl, -S-(chlorophenylrnethyl), -S-phenethyl. -CO-thienyl, -CO-pyrrolyl, - CO-piperidinyl, -CO-piperidinyl-COO-(Ci-2-alkyl), morpholinyl, C i .2-alkylpiperazinyl. C,-2-alkylmiazolyl, pyridyl, -CO-phenyl, -S-(C,.2-alkyl)-COO-(C, .2-alkyl) NH2, N(C,.2- alkyl)2, -CO-C,.2-alkyl, and -(C,.2-alkyl)-0(C,.2-alkyl); and wherein, when A is benzoxazole, benzothiazole or benzimidazole, A may optionally further be substituted with a halogen atom, and wherein, when A is thiazoie, A may optionally further be substituted with a methyl group.
The compound for the use according to claim 1 or a physiologically functional derivative, solvate or salt thereof, wherein the X'-azol moiety is attached at the 5- position of the 2,3 -dihydrobenzofuran mioety, n is 0; m is 0; X1 is S, R3 is H; R4 is H;
A is a monocyclic or bi cyclic heteroaromatic rin system selected from the group comprising lH-imidazol-2-yl, 1//-1 ,2„4-triazol-5-yl, l//-benzo[cT]imidazol-2-yl, pyridin- 2-yl, l,3,4-thiadiazol-2-yl, l H-pyrazol-3-yl, l ,3-thiazol-2-yl, and 1 ,2,4-thiadiazol-3-yl; wherein A is optionally substituted with a substituent RA selected from the group comprising F, CI, Br, CN, methyl, -S02-Me, OMe, CF3, -CO-N(Me)2, -CO-N(Me)2, 5- (4-((tetrahydr furan-2-yl )methyl)piperazine- 1 -carbonyl. -COO-Et, morpholine-4- carbonyl OCF3, -COO- Me, OH, -CO-NHMe, -S-Me, pyrrolidin- 1 -carbonyl, -CO-NH- C2H4-OMc, -S-iPr. cyclopropylcarbamoyl, 4-methylpipcrazinc- 1 -carbonyl, -S-nPr, COOH, -S-benzyl, -S-(4-chlorobenzyl), -S-iBu, ((tetrahydrofuran-2-
y 1 ) met h yl ) carb am o y 1 , phcnethyl, -S-phenethyl, -CO-thien-2-yl, -CO-pyrrol-2-yl, -CO- piperidin-l-yl, -CO-(4ethoxycarbonyl-piperidin- 1 -yl), morpholin-4-yl, 4-methyl- piperazin-l -yl, 5-methyl-thiazol-2-yl, pyridin-4-yL -CO-phenyl, -S-(CH2)-COOMe,
N¾, -CO-Ci-2-alkyl, 3 -fluorophenyl, acetyl, -methylthio, and methoxymethyl; and wherein, when A is l//-benzo[ii]imidazol-2-yl, A may optionally further be substituted with a chlorine atom, and when A is l ,3-tbiazol-2-yl, A may optionally further be substituted with a methyl group.
The compound for the use according to any of claims 1 to 12 or a physiologically functional derivative, solvate or salt thereof, wherein said compound is selected from the roup comprising the following compounds
14. A pharmaceutical composition comprising a compound according to any of claims 1 to
13 or a physiologically functional derivative, solvate or salt thereof and one or more pharmaceutically acceptable excipients for the use in the treatment or prevention of a disease or medical condition caused by a viral infection.
15. A method of treatment or prevention of a disease or medical condition caused by a viral infection, which comprises the administration of an effective amount of a compound according to any of claims 1 to 13¾ or a physiologically functional derivative, solvate or salt thereof to a subject in need thereof.
16. Use of a compound according to any of claims 1 to 13, or a physiologically functional derivative, solvate or salt thereof in the manufacture of a medicament for the treatment or prevention of a disease or medical condition caused by a viral infection.
17. The compound, pharmaceutical composition, method or use according any of claims 1 to 16, wherein said disease or medical condition is caused by an infection with a virus from the family herpesviridae selected from the group consisting of herpes simplex virus and cytomegalovirus.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15177777.8 | 2015-07-21 | ||
EP15177777 | 2015-07-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017013210A1 true WO2017013210A1 (en) | 2017-01-26 |
Family
ID=53761971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2016/067417 WO2017013210A1 (en) | 2015-07-21 | 2016-07-21 | Treatment and prevention of viral diseases with 2,3-dihydrobenzofuran-5-yl compounds |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2017013210A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005033072A2 (en) * | 2003-09-30 | 2005-04-14 | Scios Inc. | Heterocyclic amides and sulfonamides |
WO2008054702A1 (en) * | 2006-10-31 | 2008-05-08 | Schering Corporation | Anilinopiperazine derivatives and methods of use thereof |
WO2014001464A1 (en) * | 2012-06-27 | 2014-01-03 | 4Sc Discovery Gmbh | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders |
WO2014202638A1 (en) * | 2013-06-18 | 2014-12-24 | 4Sc Discovery Gmbh | 2,3-dihydrobenzofuran-5-yl compounds as dyrk kinase inhibitors |
-
2016
- 2016-07-21 WO PCT/EP2016/067417 patent/WO2017013210A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005033072A2 (en) * | 2003-09-30 | 2005-04-14 | Scios Inc. | Heterocyclic amides and sulfonamides |
WO2008054702A1 (en) * | 2006-10-31 | 2008-05-08 | Schering Corporation | Anilinopiperazine derivatives and methods of use thereof |
WO2014001464A1 (en) * | 2012-06-27 | 2014-01-03 | 4Sc Discovery Gmbh | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders |
WO2014202638A1 (en) * | 2013-06-18 | 2014-12-24 | 4Sc Discovery Gmbh | 2,3-dihydrobenzofuran-5-yl compounds as dyrk kinase inhibitors |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2998741C (en) | Hepatitis b core protein modulators | |
DK2038265T3 (en) | Inhibitors of human protein tyrosine phosphatase and methods of use | |
AU2013283318B2 (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders | |
DK3002283T3 (en) | THIAZOLE DERIVATIVES. | |
US20040077633A1 (en) | Antiviral agents | |
WO2012068546A1 (en) | Heterocycle amines and uses thereof | |
CA2915566C (en) | 2,3-dihydrobenzofuran-5-yl compounds as dyrk kinase inhibitors | |
WO2013086131A1 (en) | Inhibitors targeting drug-resistant influenza a | |
WO2007091106A2 (en) | Treatment of duchenne muscular dystrophy | |
KR20080019213A (en) | Thiazole compounds and methods of use | |
RU2005128832A (en) | NON-NUCLEOSIDE REVERTASE INHIBITORS | |
AU2012345843B2 (en) | Improved modulators of Hec1 activity and methods therefor | |
JPH11302177A (en) | Medicine for treating nephritis | |
WO2017013210A1 (en) | Treatment and prevention of viral diseases with 2,3-dihydrobenzofuran-5-yl compounds | |
US10160756B2 (en) | Antiviral compounds and methods using same | |
CN101723903B (en) | 4-carbonyl diaryl pyridine derivatives as well as preparation methods and applications thereof | |
EP2164494A1 (en) | Methods of treatment | |
AU2006265653A1 (en) | Combination of a renin inhibitor and an insulin secretion enhancer or an insulin sensitizer | |
CA2857441A1 (en) | Carboxamide-substituted heteroaryl-pyrazoles and their use | |
JPH11255669A (en) | Treating agent for hyperuricemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16750115 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 11/07/2018) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16750115 Country of ref document: EP Kind code of ref document: A1 |